- preprint:
    doi: 10.1101/2021.04.07.438649
  tweets:
    - id: 1392209505039970300
      id_str: "1392209505039970304"
      created_at: Tue May 11 20:06:26 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.07.438649v1
- preprint:
    doi: 10.1101/2020.12.08.415836
  tweets:
    - id: 1391847033548513300
      id_str: "1391847033548513280"
      created_at: Mon May 10 20:06:06 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.08.415836v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1391836736234430500
      id_str: "1391836736234430466"
      created_at: Mon May 10 19:25:11 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/703801
  tweets:
    - id: 1391484653425541000
      id_str: "1391484653425541120"
      created_at: Sun May 09 20:06:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/703801v4
- preprint:
    doi: 10.1101/2021.04.23.441101
  tweets:
    - id: 1391122233016397800
      id_str: "1391122233016397824"
      created_at: Sat May 08 20:06:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.23.441101v1
- preprint:
    doi: 10.1101/2021.03.12.435194
  tweets:
    - id: 1390759866919264300
      id_str: "1390759866919264257"
      created_at: Fri May 07 20:06:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.12.435194v1
- preprint:
    doi: 10.1101/2021.03.24.436620
  tweets:
    - id: 1390397507335774200
      id_str: "1390397507335774211"
      created_at: Thu May 06 20:06:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.24.436620v1
- preprint:
    doi: 10.1101/2020.12.04.409144
  tweets:
    - id: 1390035038566338600
      id_str: "1390035038566338569"
      created_at: Wed May 05 20:05:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.04.409144v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1387497218853294000
      id_str: "1387497218853294081"
      created_at: Wed Apr 28 20:01:30 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.04.11.439311
  tweets:
    - id: 1387134724020207600
      id_str: "1387134724020207617"
      created_at: Tue Apr 27 20:01:04 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.04.11.439311v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1386772363019268000
      id_str: "1386772363019268101"
      created_at: Mon Apr 26 20:01:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1386409953213042700
      id_str: "1386409953213042697"
      created_at: Sun Apr 25 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.03.10.432967
  tweets:
    - id: 1386047590752477200
      id_str: "1386047590752477184"
      created_at: Sat Apr 24 20:01:11 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.432967v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1385685210021441500
      id_str: "1385685210021441541"
      created_at: Fri Apr 23 20:01:13 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1385322787099775000
      id_str: "1385322787099774976"
      created_at: Thu Apr 22 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1384960464875032600
      id_str: "1384960464875032577"
      created_at: Wed Apr 21 20:01:20 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1384598026065485800
      id_str: "1384598026065485827"
      created_at: Tue Apr 20 20:01:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.03.29.437450
  tweets:
    - id: 1384235613415559200
      id_str: "1384235613415559175"
      created_at: Mon Apr 19 20:01:02 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.29.437450v1
- preprint:
    doi: 10.1101/2021.03.06.434193
  tweets:
    - id: 1383873288414191600
      id_str: "1383873288414191624"
      created_at: Sun Apr 18 20:01:17 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.06.434193v1
- preprint:
    doi: 10.1101/2020.06.29.174888
  tweets:
    - id: 1383510866650222600
      id_str: "1383510866650222594"
      created_at: Sat Apr 17 20:01:09 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.06.29.174888v1
- preprint:
    doi: 10.1101/2021.03.10.434840
  tweets:
    - id: 1383148442663411700
      id_str: "1383148442663411714"
      created_at: Fri Apr 16 20:01:01 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434840v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1382786153011642400
      id_str: "1382786153011642374"
      created_at: Thu Apr 15 20:01:24 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1382423695801647000
      id_str: "1382423695801647118"
      created_at: Wed Apr 14 20:01:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1382061355453255700
      id_str: "1382061355453255687"
      created_at: Tue Apr 13 20:01:19 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1381698970569822200
      id_str: "1381698970569822209"
      created_at: Mon Apr 12 20:01:19 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.03.18.435945
  tweets:
    - id: 1381336552777912300
      id_str: "1381336552777912320"
      created_at: Sun Apr 11 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.18.435945v1
- preprint:
    doi: 10.1101/2021.03.12.435194
  tweets:
    - id: 1380974162383151000
      id_str: "1380974162383151110"
      created_at: Sat Apr 10 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.12.435194v1
- preprint:
    doi: 10.1101/2021.03.18.436013
  tweets:
    - id: 1380611776392409000
      id_str: "1380611776392409092"
      created_at: Fri Apr 09 20:01:12 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.18.436013v1
- preprint:
    doi: 10.1101/2021.03.24.436752
  tweets:
    - id: 1380249365672034300
      id_str: "1380249365672034306"
      created_at: Thu Apr 08 20:01:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.24.436752v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1379886938673537000
      id_str: "1379886938673537026"
      created_at: Wed Apr 07 20:00:57 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.03.10.434756
  tweets:
    - id: 1379524605304582100
      id_str: "1379524605304582150"
      created_at: Tue Apr 06 20:01:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434756v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1379162184828215300
      id_str: "1379162184828215300"
      created_at: Mon Apr 05 20:01:03 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1378799859306741800
      id_str: "1378799859306741760"
      created_at: Sun Apr 04 20:01:17 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.03.10.432967
  tweets:
    - id: 1378437352503320600
      id_str: "1378437352503320579"
      created_at: Sat Apr 03 20:00:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.432967v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1378074936477106200
      id_str: "1378074936477106180"
      created_at: Fri Apr 02 20:00:42 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1377712631981744000
      id_str: "1377712631981744128"
      created_at: Thu Apr 01 20:01:02 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1377350254303965200
      id_str: "1377350254303965185"
      created_at: Wed Mar 31 20:01:05 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1376987865071095800
      id_str: "1376987865071095813"
      created_at: Tue Mar 30 20:01:04 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    doi: 10.1101/2021.02.23.432474
  tweets:
    - id: 1376625515310817300
      id_str: "1376625515310817280"
      created_at: Mon Mar 29 20:01:13 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.23.432474v1
- preprint:
    doi: 10.1101/2020.11.15.383323
  tweets:
    - id: 1375900686488064000
      id_str: "1375900686488064003"
      created_at: Sat Mar 27 20:01:01 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1
- preprint:
    doi: 10.1101/2020.12.28.424451
  tweets:
    - id: 1375538433821704200
      id_str: "1375538433821704198"
      created_at: Fri Mar 26 20:01:33 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.28.424451v1
- preprint:
    doi: 10.1101/2021.03.10.434840
  tweets:
    - id: 1375175997637623800
      id_str: "1375175997637623810"
      created_at: Thu Mar 25 20:01:22 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.03.10.434840v1
- preprint:
    doi: 10.1101/2021.01.06.425392
  tweets:
    - id: 1374813580890140700
      id_str: "1374813580890140678"
      created_at: Wed Mar 24 20:01:15 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.06.425392v1
- preprint:
    doi: 10.1101/2020.12.14.422737
  tweets:
    - id: 1374451411874812000
      id_str: "1374451411874811906"
      created_at: Tue Mar 23 20:02:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422737v1
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1374088948184707000
      id_str: "1374088948184707076"
      created_at: Mon Mar 22 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1373726589113020400
      id_str: "1373726589113020419"
      created_at: Sun Mar 21 20:01:56 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2021.02.02.429430
  tweets:
    - id: 1373364157131722800
      id_str: "1373364157131722755"
      created_at: Sat Mar 20 20:01:45 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.02.429430v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1373001859355525000
      id_str: "1373001859355525123"
      created_at: Fri Mar 19 20:02:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.02.01.429069
  tweets:
    - id: 1372639402132922400
      id_str: "1372639402132922374"
      created_at: Thu Mar 18 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.01.429069v1
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1372277012283465700
      id_str: "1372277012283465734"
      created_at: Wed Mar 17 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1371914700393435100
      id_str: "1371914700393435139"
      created_at: Tue Mar 16 20:02:08 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2021.01.18.426984
  tweets:
    - id: 1371573211175981000
      id_str: "1371573211175981057"
      created_at: Mon Mar 15 21:25:10 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.426984v1
- preprint:
    doi: 10.1101/2021.02.27.433180
  tweets:
    - id: 1371189849928130600
      id_str: "1371189849928130561"
      created_at: Sun Mar 14 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.27.433180v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1370827464495206400
      id_str: "1370827464495206409"
      created_at: Sat Mar 13 20:01:50 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1370465117482188800
      id_str: "1370465117482188800"
      created_at: Fri Mar 12 20:02:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1370102650881069000
      id_str: "1370102650881069065"
      created_at: Thu Mar 11 20:01:41 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1369741629448413200
      id_str: "1369741629448413185"
      created_at: Wed Mar 10 20:07:07 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.02.14.431043
  tweets:
    - id: 1369377905013371000
      id_str: "1369377905013370894"
      created_at: Tue Mar 09 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.14.431043v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1369015510231302100
      id_str: "1369015510231302146"
      created_at: Mon Mar 08 20:01:47 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    doi: 10.1101/2021.02.05.430003
  tweets:
    - id: 1368653129072394200
      id_str: "1368653129072394245"
      created_at: Sun Mar 07 20:01:48 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.05.430003v1
- preprint:
    doi: 10.1101/2020.10.14.338996
  tweets:
    - id: 1368290789562998800
      id_str: "1368290789562998787"
      created_at: Sat Mar 06 20:02:00 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.10.14.338996v2
- preprint:
    doi: 10.1101/2020.12.14.422555
  tweets:
    - id: 1367929833443975200
      id_str: "1367929833443975175"
      created_at: Fri Mar 05 20:07:41 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422555v1
- preprint:
    doi: 10.1101/782557
  tweets:
    - id: 1367567159413637000
      id_str: "1367567159413637121"
      created_at: Thu Mar 04 20:06:33 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/782557v1
- preprint:
    doi: 10.1101/2021.02.02.428884
  tweets:
    - id: 1367204793136140300
      id_str: "1367204793136140295"
      created_at: Wed Mar 03 20:06:38 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.02.02.428884v1
- preprint:
    doi: 10.1101/2020.12.14.422737
  tweets:
    - id: 1366842507267506200
      id_str: "1366842507267506177"
      created_at: Tue Mar 02 20:07:03 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.14.422737v1
- preprint:
    doi: 10.1101/2021.01.26.426986
  tweets:
    - id: 1366478811521577000
      id_str: "1366478811521576966"
      created_at: Mon Mar 01 20:01:51 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.26.426986v1
- preprint:
    doi: 10.1101/2020.11.15.383323
  tweets:
    - id: 1366116431893573600
      id_str: "1366116431893573639"
      created_at: Sun Feb 28 20:01:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1
- preprint:
    doi: 10.1101/2020.09.08.280818
  tweets:
    - id: 1365753983973875700
      id_str: "1365753983973875713"
      created_at: Sat Feb 27 20:01:38 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1
- preprint:
    doi: 10.1101/2021.01.06.425392
  tweets:
    - id: 1365633169492443100
      id_str: "1365633169492443139"
      created_at: Sat Feb 27 12:01:34 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.06.425392v1
- preprint:
    doi: 10.1101/2020.01.30.927871
  tweets:
    - id: 1365391554253316000
      id_str: "1365391554253316098"
      created_at: Fri Feb 26 20:01:28 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2
- preprint:
    doi: 10.1101/2021.01.25.428137
  tweets:
    - id: 1365029290052567000
      id_str: "1365029290052567040"
      created_at: Thu Feb 25 20:01:58 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.25.428137v1
- preprint:
    doi: 10.1101/2021.01.27.427998
  tweets:
    - id: 1364666801188200400
      id_str: "1364666801188200451"
      created_at: Wed Feb 24 20:01:34 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.27.427998v1
- preprint:
    doi: 10.1101/2020.06.01.128728
  tweets:
    - id: 1364304475507335200
      id_str: "1364304475507335170"
      created_at: Tue Feb 23 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://www.biorxiv.org/content/10.1101/2020.06.01.128728v1
- preprint:
    doi: 10.1101/2020.12.28.424451
  tweets:
    - id: 1363942004208636000
      id_str: "1363942004208635906"
      created_at: Mon Feb 22 20:01:29 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.28.424451v1
- preprint:
    doi: 10.1101/2020.12.12.422516
  tweets:
    - id: 1363579651197706200
      id_str: "1363579651197706241"
      created_at: Sun Feb 21 20:01:37 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.12.422516v1
- preprint:
    doi: 10.1101/2021.01.18.426984
  tweets:
    - id: 1363217219421888500
      id_str: "1363217219421888516"
      created_at: Sat Feb 20 20:01:27 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.426984v1
- preprint:
    doi: 10.1101/2020.12.31.425021
  tweets:
    - id: 1362854888024256500
      id_str: "1362854888024256512"
      created_at: Fri Feb 19 20:01:40 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2020.12.31.425021v1
- preprint:
    doi: 10.1101/2021.01.15.426911
  tweets:
    - id: 1362492537626374100
      id_str: "1362492537626374159"
      created_at: Thu Feb 18 20:01:49 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.15.426911v1
- preprint:
    doi: 10.1101/2021.01.18.427166
  tweets:
    - id: 1361405346942750700
      id_str: "1361405346942750721"
      created_at: Mon Feb 15 20:01:43 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.18.427166v1
- preprint:
    doi: 10.1101/2021.01.07.425740
  tweets:
    - id: 1361376954625233000
      id_str: "1361376954625232900"
      created_at: Mon Feb 15 18:08:53 +0000 2021
      entities:
        urls:
          - expanded_url: https://biorxiv.org/content/10.1101/2021.01.07.425740v1
- preprint:
    id: "141169"
    doi: 10.1101/2021.05.07.21256539
    first_posted: 2021-05-10
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.07.21256539v1
    url: https://api.rxivist.org/v1/papers/141169
    title: Immune profile of children with post-acute sequelae of SARS-CoV-2
      infection (Long Covid)
    category: pediatrics
    abstract: There is increasing reporting by patients organization and researchers
      of long covid (or post-acute sequelae of SARS-CoV-2 - PASC), characterized
      by symptoms such as fatigue, dyspnea, chest pain, cognitive and sleeping
      disturbances, arthralgia and decline in quality of life. Immune system
      dysregulation with a hyperinflammatory state, direct viral toxicity,
      endothelial damage and microvascular injury have been proposed as
      pathologenic mechanisms. Recently, cohorts of children with PASC have been
      reported in Italy, Sweden and Russia. However, immunological studies of
      children with PASC have never been performed. In this study, we documented
      significant immunologic differences between children that completely
      recovered from acute infection and those with PASC, providing the first
      objective laboratory sign of the existence of PASC in children.
    authors:
      - name: Gabriele Di Sante
        orcid: null
      - name: Danilo Buonsenso
        orcid: http://orcid.org/0000-0001-8567-2639
      - name: Cristina De Rose
        orcid: null
      - name: Piero Valentini
        orcid: null
      - name: Francesco Ria
        orcid: null
      - name: Maurizio Sanguinetti
        orcid: http://orcid.org/0000-0002-9780-7059
      - name: Michela Sali
        orcid: null
  comment:
    dislikes: 0
    thread: "8514441850"
    numReports: 0
    likes: 1
    id: "5379558205"
    createdAt: 2021-05-12T01:30:10
    author:
      username: heidiconnahs
      about: ""
      name: Heidi Connahs
      isPowerContributor: false
      profileUrl: https://disqus.com/by/heidiconnahs/
      url: ""
      location: ""
      id: "369226202"
    isApproved: true
    raw_message: Interesting paper! I have one comment though. I am noticing an
      increasing number of papers using the term post-exertional malaise (PEM)
      without providing any definition of what this condition represents. This
      is important because PEM is not a term widely known in the medical
      community and it has a distinct presentation. PEM is the worsening of a
      variety of symptoms following even minor physical or mental exertion and
      moreover, the severity of the impact is often delayed by hours or days and
      can take days, weeks or months to recover from. The reason why PEM is not
      widely known is because it is the cardinal symptom of the disease ME/CFS
      which has been significantly ignored and underfunded. PEM is unique to
      ME/CFS and any mention of PEM should really provide appropriate references
      to ME/CFS literature.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.07.21256539v1
  tweets:
    - created_at: Sat May 15 20:12:20 +0000 2021
      id: 1393660540510212000
      id_str: "1393660540510212096"
      text: >-
        üí¨ medRxiv comment on "Immune profile of children wit..."


        "Interesting paper! I have one comment though. I am notic‚Ä¶ https://t.co/DbZ2yzqMk2
      truncated: true
      entities:
        urls:
          - url: https://t.co/DbZ2yzqMk2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 15 20:12:20 +0000 2021
      id: 1393660541340631000
      id_str: "1393660541340631040"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/PMDM2HKZfz
      truncated: false
      entities:
        urls:
          - url: https://t.co/PMDM2HKZfz
      in_reply_to_status_id: 1393660540510212000
      in_reply_to_status_id_str: "1393660540510212096"
- preprint:
    id: 136561
    metric: 4079
    title: An emerging SARS-CoV-2 mutant evading cellular immunity and increasing
      viral infectivity
    url: https://api.rxivist.org/v1/papers/136561
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.02.438288v1
    doi: 10.1101/2021.04.02.438288
    category: microbiology
    first_posted: 2021-04-05
    abstract: During the current SARS-CoV-2 pandemic that is devastating the modern
      societies worldwide, many variants that naturally acquire multiple
      mutations have emerged. Emerging mutations can affect viral properties
      such as infectivity and immune resistance. Although the sensitivity of
      naturally occurring SARS-CoV-2 variants to humoral immunity has recently
      been investigated, that to human leukocyte antigen (HLA)-restricted
      cellular immunity remains unaddressed. Here we demonstrate that two
      recently emerging mutants in the receptor binding domain of the SARS-CoV-2
      spike protein, L452R (in B.1.427/429) and Y453F (in B.1.298), can escape
      from the HLA-24-restricted cellular immunity. These mutations reinforce
      the affinity to viral receptor ACE2, and notably, the L452R mutation
      increases protein stability, viral infectivity, and potentially promotes
      viral replication. Our data suggest that the HLA-restricted cellular
      immunity potentially affects the evolution of viral phenotypes, and the
      escape from cellular immunity can be a further threat of the SARS-CoV-2
      pandemic.
    authors:
      - name: Chihiro Motozono
      - name: Mako Toyoda
      - name: Jiri Zahradnik
      - name: Terumasa Ikeda
      - name: Akatsuki Saito
      - name: Toong Seng Tan
      - name: Isaac Ngare
      - name: Hesham Nasser
      - name: Izumi Kimura
      - name: Keiya Uriu
      - name: Yusuke Kosugi
      - name: Shiho Torii
      - name: Akiko Yonekawa
      - name: Nobuyuki Shimono
      - name: Yoji Nagasaki
      - name: Rumi Minami
      - name: Takashi Toya
      - name: Noritaka Sekiya
      - name: Takasuke Fukuhara
      - name: Yoshiharu Matsuura
      - name: Gideon Schreiber
      - name: The Genotype to Phenotype Japan (G2P-Japan) consortium
      - name: So Nakagawa
      - name: Takamasa Ueno
      - name: Kei Sato
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sat May 15 20:20:00 +0000 2021
      id: 1393662469558743000
      id_str: "1393662469558743048"
      text: >-
        üî• bioRxiv Microbiology preprint by C. Motozono et al:


        "An emerging SARS-CoV-2 mutant evading cellular immunity and‚Ä¶ https://t.co/rcjDkdXgxY
      truncated: true
      entities:
        urls:
          - url: https://t.co/rcjDkdXgxY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "108636"
    doi: 10.1101/2020.04.10.20057869
    first_posted: 2020-04-14
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.10.20057869v1
    url: https://api.rxivist.org/v1/papers/108636
    title: Multi-centre derivation and validation of a colitis-associated cancer
      risk prediction web-tool
    category: gastroenterology
    abstract: >-
      ObjectiveUlcerative colitis (UC) patients diagnosed with low-grade
      dysplasia (LGD) have increased risk of developing advanced neoplasia (AN;
      high-grade dysplasia or colorectal cancer). We aimed to develop and
      validate a predictor of AN risk in UC patients with LGD and create a
      visual web-tool to effectively communicate the risk.


      DesignIn our retrospective multi-centre validated cohort study, adult UC patients with an index diagnosis of LGD, identified from four UK centres between 2001-2019, were followed until progression to AN. In the discovery cohort (n=246), a multivariate risk prediction model was derived from clinicopathological features using Cox regression. Validation used data from 3 external centres (n=198). The validated model was embedded in a web-tool to calculate patient-specific risk.


      ResultsFour clinicopathological variables were significantly associated with AN progression in the discovery cohort: endoscopically visible LGD > 1 cm (HR = 2.7; 95% CI 1.2-5.9), unresectable or incomplete endoscopic resection (HR = 3.4; 95% CI 1.6-7.4), moderate/severe histological inflammation within 5 years of LGD diagnosis (HR = 3.1; 95% CI 1.5-6.7), and multifocality (HR = 2.9; 95% CI 1.3-6.2). In the validation cohort, this 4-variable model accurately predicted future AN cases with overall calibration Observed/Expected = 1 (95% CI 0.63-1.5), and achieved 100% specificity for the lowest risk group over 13 years of available follow-up.


      ConclusionMulti-cohort validation confirms that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing AN. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator (www.UC-CaRE.uk) can support treatment decision-making.


      SUMMARY BOXO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LIThe risk of ulcerative colitis-associated low-grade dysplasia (LGD) progression to more advanced neoplasia is currently not clearly defined. The literature consists of historical data from small heterogenous observational studies with limited follow-up or lack of information on endoscopic resection status.

      C_LI


      What are the new findings?O_LIWe present the results from the largest multi-centre cohort study to evaluate LGD long-term prognosis based on clinicopathological factors that are reflective of modern surveillance techniques.

      C_LIO_LIRecent moderate or severe active inflammation or LGD that is large, not fully resectable or is multifocal remain independent predictors of advanced neoplasia progression, even when stratified to reflect the most modern era of high definition endoscopic imaging, chromoendoscopy and advanced polypectomy techniques.

      C_LIO_LIColorectal cancer incidence after endoscopic resection of unifocal polypoid and non-polypoid dysplasia is 0.6 per 100 patient-years.

      C_LIO_LILong-term incidence of advanced neoplasia is similar if LGD is invisible or if LGD is visible but not completely endoscopically resected.

      C_LIO_LIUsing these data, we have designed and externally validated a cancer risk prediction tool for ulcerative colitis patients with LGD.

      C_LI


      How might it impact on clinical practice in the foreseeable future?O_LIThe UC-CaRE (Ulcerative Colitis-Cancer Risk Estimator) tool can be used to calculate and communicate individualised numerical cancer risk estimates to colitis patients with LGD.

      C_LIO_LIIt facilitates the risk stratification of the lowest-risk patients, who can be reassured by undergoing continued surveillance, and those at the highest-risk who may benefit from a prophylactic colectomy.

      C_LIO_LIThis visual aid presents the calculated risk in a graphical and pictorial form to optimise risk comprehension and informed treatment choices.

      C_LI
    authors:
      - name: Kit Curtius
        orcid: http://orcid.org/0000-0002-2678-0960
      - name: Misha Kabir
        orcid: http://orcid.org/0000-0003-3991-1015
      - name: Ibrahim Al Bakir
        orcid: null
      - name: Chang-Ho Ryan Choi
        orcid: null
      - name: Juanda L Hartono
        orcid: null
      - name: Michael Johnson
        orcid: null
      - name: James E. East
        orcid: http://orcid.org/0000-0001-8035-3700
      - name: Oxford IBD Cohort Study Investigators
        orcid: null
      - name: James O Lindsay
        orcid: http://orcid.org/0000-0003-3353-9590
      - name: Roser Vega
        orcid: http://orcid.org/0000-0002-0116-7211
      - name: Siwan Thomas-Gibson
        orcid: null
      - name: Janindra Warusavitarne
        orcid: null
      - name: Ana Wilson
        orcid: null
      - name: Trevor A Graham
        orcid: http://orcid.org/0000-0001-9582-1597
      - name: Ailsa Hart
        orcid: null
  comment:
    dislikes: 0
    thread: "8264437163"
    numReports: 0
    likes: 0
    id: "5383811963"
    createdAt: 2021-05-14T21:23:13
    author:
      username: kitcurtius
      about: ""
      name: Kit Curtius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/kitcurtius/
      url: ""
      location: ""
      id: "361053116"
    isApproved: true
    raw_message: We acknowledge Dr. Adam Brentnall (QMUL) for helpful discussions on
      statistical prediction modeling!
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.10.20057869v2
  tweets:
    - created_at: Sun May 16 00:41:42 +0000 2021
      id: 1393728330281758700
      id_str: "1393728330281758724"
      text: >-
        üí¨ medRxiv comment on "Multi-centre derivation and va..."


        "We acknowledge Dr. Adam Brentnall (QMUL) for helpful dis‚Ä¶ https://t.co/FZrfdoeSUQ
      truncated: true
      entities:
        urls:
          - url: https://t.co/FZrfdoeSUQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 16 00:41:43 +0000 2021
      id: 1393728331120525300
      id_str: "1393728331120525317"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/RAK59UjbvN
      truncated: false
      entities:
        urls:
          - url: https://t.co/RAK59UjbvN
      in_reply_to_status_id: 1393728330281758700
      in_reply_to_status_id_str: "1393728330281758724"
- preprint:
    id: 139187
    metric: 3346
    title: Rapid induction of antigen-specific CD4+ T cells guides coordinated
      humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination
    url: https://api.rxivist.org/v1/papers/139187
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.21.440862v1
    doi: 10.1101/2021.04.21.440862
    category: immunology
    first_posted: 2021-04-22
    abstract: The SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy,
      but questions remain about the nature and kinetics of T cell priming. We
      performed longitudinal antigen-specific T cell analyses in healthy
      individuals following mRNA vaccination. Vaccination induced rapid
      near-maximal antigen-specific CD4+ T cell responses in all subjects after
      the first vaccine dose. CD8+ T cell responses developed gradually after
      the first and second dose and were variable. Vaccine-induced T cells had
      central memory characteristics and included both Tfh and Th1 subsets,
      similar to natural infection. Th1 and Tfh responses following the first
      dose predicted post-boost CD8+ T cell and neutralizing antibody levels,
      respectively. Integrated analysis of 26 antigen-specific T cell and
      humoral responses revealed coordinated features of the immune response to
      vaccination. Lastly, whereas booster vaccination improved CD4+ and CD8+ T
      cell responses in SARS-CoV-2 naive subjects, the second vaccine dose had
      little effect on T cell responses in SARS-CoV-2 recovered individuals.
      Thus, longitudinal analysis revealed robust T cell responses to mRNA
      vaccination and highlighted early induction of antigen-specific CD4+ T
      cells.
    authors:
      - name: Mark M. Painter
      - name: Divij Mathew
      - name: Rishi R. Goel
      - name: Sokratis A. Apostolidis
      - name: Ajinkya Pattekar
      - name: Oliva Kuthuru
      - name: Amy E. Baxter
      - name: Ramin Herati
      - name: Derek A. Oldridge
      - name: Sigrid Gouma
      - name: Philip Hicks
      - name: Sarah Dysinger
      - name: Kendall A Lundgreen
      - name: Leticia Kuri-Cervantes
      - name: Sharon Adamski
      - name: Amanda Hicks
      - name: Scott Korte
      - name: Josephine R. Giles
      - name: Madison E. Weirick
      - name: Christopher M. McAllister
      - name: Jeanette Dougherty
      - name: Sherea Long
      - name: Kurt D'Andrea
      - name: Jacob T. Hamilton
      - name: Michael R. Betts
      - name: Paul Bates
      - name: Scott E Hensley
      - name: Alba Grifoni
      - name: Daniela Weiskopf
      - name: Alessandro Sette
      - name: Allison R. Greenplate
      - name: E John Wherry
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Sun May 16 20:19:55 +0000 2021
      id: 1394024838294122500
      id_str: "1394024838294122498"
      text: >-
        üî• bioRxiv Immunology preprint by M. M. Painter et al:


        "Rapid induction of antigen-specific CD4+ T cells guides coo‚Ä¶ https://t.co/eKwFidTTnt
      truncated: true
      entities:
        urls:
          - url: https://t.co/eKwFidTTnt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "127169"
    doi: 10.1101/2021.01.27.21250604
    first_posted: 2021-01-29
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.01.27.21250604v1
    url: https://api.rxivist.org/v1/papers/127169
    title: "The World Mortality Dataset: Tracking excess mortality across countries
      during the COVID-19 pandemic"
    category: epidemiology
    abstract: Comparing the impact of the COVID-19 pandemic between countries or
      across time is difficult because the reported numbers of cases and deaths
      can be strongly affected by testing capacity and reporting policy. Excess
      mortality, defined as the increase in all-cause mortality relative to the
      recent average, is widely considered as a more objective indicator of the
      COVID-19 death toll. However, there has been no central,
      frequently-updated repository of the all-cause mortality data across
      countries. To fill this gap, we have collected weekly, monthly, or
      quarterly all-cause mortality data from 77 countries, openly available as
      the regularly-updated World Mortality Dataset. We used this dataset to
      compute the excess mortality in each country during the COVID-19 pandemic.
      We found that in the worst-affected countries the annual mortality
      increased by over 50%, while in several other countries it decreased by
      over 5%, presumably due to lockdown measures decreasing the non-COVID
      mortality. Moreover, we found that while some countries have been
      reporting the COVID-19 deaths very accurately, many countries have been
      underreporting their COVID-19 deaths by an order of magnitude or more.
      Averaging across the entire dataset suggests that the world's COVID-19
      death toll may be at least 1.6 times higher than the reported number of
      confirmed deaths.
    authors:
      - name: Ariel Karlinsky
        orcid: null
      - name: Dmitry Kobak
        orcid: http://orcid.org/0000-0002-5639-7209
  comment:
    dislikes: 0
    thread: "8375844078"
    numReports: 0
    likes: 1
    id: "5383665582"
    createdAt: 2021-05-14T19:13:52
    author:
      username: disqus_rQjDV4hy9h
      about: ""
      name: John Smith
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_rQjDV4hy9h/
      url: ""
      location: ""
      id: "289967088"
    isApproved: true
    raw_message: Interesting report, I wonder if they will come back with a response.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.01.27.21250604v1
  tweets:
    - created_at: Mon May 17 00:37:37 +0000 2021
      id: 1394089690882461700
      id_str: "1394089690882461703"
      text: >-
        üí¨ medRxiv comment on "The World Mortality Dataset: T..."


        "Interesting report, I wonder if they will come back with‚Ä¶ https://t.co/c40ufjz4rJ
      truncated: true
      entities:
        urls:
          - url: https://t.co/c40ufjz4rJ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 00:37:38 +0000 2021
      id: 1394089691738083300
      id_str: "1394089691738083328"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/SYOosLErcL
      truncated: false
      entities:
        urls:
          - url: https://t.co/SYOosLErcL
      in_reply_to_status_id: 1394089690882461700
      in_reply_to_status_id_str: "1394089690882461703"
- preprint:
    id: "91759"
    doi: 10.1101/2020.07.21.212639
    first_posted: 2020-07-21
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1
    url: https://api.rxivist.org/v1/papers/91759
    title: SARS-CoV-2 infection induces a pro-inflammatory cytokine response through
      cGAS-STING and NF-Œ∫B
    category: microbiology
    abstract: >-
      SARS-CoV-2 is a novel virus that has rapidly spread, causing a global
      pandemic. In the majority of infected patients, SARS-CoV-2 leads to mild
      disease; however, in a significant proportion of infections, individuals
      develop severe symptoms that can lead to permanent lung damage or death.
      These severe cases are often associated with high levels of
      pro-inflammatory cytokines and low antiviral responses which can lead to
      systemic complications. We have evaluated transcriptional and cytokine
      secretion profiles from infected cell cultures and detected a distinct
      upregulation of inflammatory cytokines that parallels samples taken from
      infected patients. Building on these observations, we found a specific
      activation of NF-Œ∫B and a block of IRF3 nuclear translocation in
      SARS-CoV-2 infected cells. This NF-Œ∫B response is mediated by cGAS-STING
      activation and could be attenuated through STING targeting drugs. Our
      results show that SARS-CoV-2 curates a cGAS-STING mediated NF-Œ∫B driven
      inflammatory immune response in epithelial cells that likely contributes
      to inflammatory responses seen in patients and might be a target to
      suppress severe disease symptoms.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Christopher J. Neufeldt
        orcid: http://orcid.org/0000-0002-4551-1811
      - name: Berati Cerikan
        orcid: null
      - name: Mirko Cortese
        orcid: http://orcid.org/0000-0003-1786-4211
      - name: Jamie Frankish
        orcid: http://orcid.org/0000-0003-2200-4320
      - name: Ji-Young Lee
        orcid: http://orcid.org/0000-0002-7631-5127
      - name: Agnieszka Plociennikowska
        orcid: null
      - name: Florian Heigwer
        orcid: http://orcid.org/0000-0002-8230-1485
      - name: Sebastian Joecks
        orcid: null
      - name: Sandy S Burkart
        orcid: http://orcid.org/0000-0003-1096-0550
      - name: David Y Zander
        orcid: null
      - name: Mathieu Gendarme
        orcid: null
      - name: Bachir El Debs
        orcid: null
      - name: Niels Halama
        orcid: null
      - name: Uta Merle
        orcid: null
      - name: Michael Boutros
        orcid: http://orcid.org/0000-0003-1077-2031
      - name: Marco Binder
        orcid: http://orcid.org/0000-0002-5805-6109
      - name: Ralf Bartenschlager
        orcid: http://orcid.org/0000-0001-5601-9307
  comment:
    dislikes: 0
    thread: "8135625357"
    numReports: 0
    likes: 0
    id: "5385282156"
    createdAt: 2021-05-16T07:18:06
    author:
      username: ralfstephan
      about: ""
      name: Ralf Stephan
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ralfstephan/
      url: ""
      location: ""
      id: "63331807"
    isApproved: true
    raw_message: Has this been published? It would contradict results about STING
      binding by SARS-CoV-2 proteins 3CLpro and ORF3a (Rui et al, 2021; PMID
      33723219).
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.07.21.212639v1
  tweets:
    - created_at: Mon May 17 12:17:21 +0000 2021
      id: 1394265781341356000
      id_str: "1394265781341356034"
      text: >-
        üí¨ bioRxiv comment on "SARS-CoV-2 infection induces a..."


        "Has this been published? It would contradict results abo‚Ä¶ https://t.co/E5Yk0m9dlz
      truncated: true
      entities:
        urls:
          - url: https://t.co/E5Yk0m9dlz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 12:17:21 +0000 2021
      id: 1394265782238937000
      id_str: "1394265782238937091"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/hk06nOveos
      truncated: false
      entities:
        urls:
          - url: https://t.co/hk06nOveos
      in_reply_to_status_id: 1394265781341356000
      in_reply_to_status_id_str: "1394265781341356034"
- preprint:
    id: "129659"
    doi: 10.1101/2021.02.16.431518
    first_posted: 2021-02-17
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.16.431518v1
    url: https://api.rxivist.org/v1/papers/129659
    title: Leptin regulates glucose homeostasis via the canonical WNT pathway.
    category: physiology
    abstract: Leptin is a body weight regulatory hormone, but it is arguably even
      more potent at regulating blood glucose levels. To further our
      understanding of the molecular mechanisms by which leptin controls glucose
      homeostasis, we have used transgenic zebrafish models and conditional
      deletion of beta catenin in the mediobasal hypothalamus of adult mice to
      show that Wnt signalling in the brain mediates glucoregulatory effects of
      leptin. In zebrafish, under normal feeding conditions, leptin regulates
      glucose homeostasis but not adipostasis. In times of nutrient excess, we
      found that leptin also regulates body weight and size in this species.
      Using a Wnt signalling reporter fish, we show that leptin directly
      activates the canonical Wnt pathway in vivo. Pharmacological inhibition of
      this pathway prevented the leptin-induced improvement in glucose
      tolerance. In adult mice, conditional deletion of the key Wnt effector
      molecule, {beta}-catenin, in the mediobasal hypothalamus of male mice
      confirmed the essential role of the Wnt pathway in mediating leptin action
      and the neuroendocrine regulation of glucose homeostasis. Adult-onset
      {beta}-catenin deletion in the mediobasal hypothalamus led to glucose
      intolerance, exacerbation of caloric intake and body weight gain under
      high fat diet, as well as resistance to exogenous leptin.
    authors:
      - name: Kaj Kamstra
        orcid: null
      - name: Mohammed Rizwan
        orcid: null
      - name: Julia A Horsfield
        orcid: http://orcid.org/0000-0002-9536-7790
      - name: Dominik Pretz
        orcid: null
      - name: Peter R Shepherd
        orcid: null
      - name: David R Grattan
        orcid: null
      - name: Alexander Tups
        orcid: null
  comment:
    dislikes: 0
    thread: "8402405180"
    numReports: 0
    likes: 0
    id: "5385017408"
    createdAt: 2021-05-16T00:09:26
    author:
      username: pouriarostamiasrabadi
      about: ""
      name: POURIA ROSTAMIASRABADI
      isPowerContributor: false
      profileUrl: https://disqus.com/by/pouriarostamiasrabadi/
      url: ""
      location: ""
      id: "369427255"
    isApproved: true
    raw_message: >-
      Hello,


      Thanks so much for an amazing paper on leptin and the canonical WNT pathway. Overall, the paper was a very interesting read, and I learned a lot about the subject area. Here are some suggestions/comments regarding the figures and experiments you performed:


      - Figure 1 does not show how pyrvinium pamoate affects the canonical WNT pathway through fluorescence intensity. Although the paper mentions that pyrvinium pamoate inhibits the pathway, it would be more effective to show this effect through the transgenic zebrafish.

      - It would be best to move Figure 1E and 1F to supplementary to create more space for the fluorescent images.

      - Figure 2 should be broken into two separate figures. This also allows you to display the results on leptin-a and leptin-b deficient zebrafish for the glucose immersion experiment. This will also give you a chance to increase the size of the graphs for better visualization.  

      - For figure 4J, explicitly mention what pre and post-treatment refer to. I know that the figure legend explains it, but it would be best to have it directly on the figure.

      - Overall, the experiments were very well conducted. I am convinced that leptin regulates glucose homeostasis through the canonical WNT pathway. Nonetheless, for the glucose immersion and overfeeding experiments, adipose tissue level should have also been measured to show that leptin does not regulate adipostasis in zebrafish.  


      Thanks so much for taking the time to read this. I hope these comments can be of some help to your paper!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.16.431518v1
  tweets:
    - created_at: Mon May 17 16:25:09 +0000 2021
      id: 1394328145566867500
      id_str: "1394328145566867456"
      text: >-
        üí¨ bioRxiv comment on "Leptin regulates glucose homeo..."


        "Hello,


        Thanks so much for an amazing paper on leptin an‚Ä¶ https://t.co/NmnDb2FdkL
      truncated: true
      entities:
        urls:
          - url: https://t.co/NmnDb2FdkL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 16:25:10 +0000 2021
      id: 1394328146497974300
      id_str: "1394328146497974274"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/AhKlXFjF1A
      truncated: false
      entities:
        urls:
          - url: https://t.co/AhKlXFjF1A
      in_reply_to_status_id: 1394328145566867500
      in_reply_to_status_id_str: "1394328145566867456"
- preprint:
    id: "141782"
    doi: 10.1101/2021.05.13.444086
    first_posted: 2021-05-15
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.13.444086v1
    url: https://api.rxivist.org/v1/papers/141782
    title: Site-specific epigenetic marks in Trypanosoma brucei transcription
      termination, antigenic variation, and proliferation
    category: genetics
    abstract: In Trypanosoma brucei, genes assemble into polycistronic transcription
      units (PTUs). Transcription termination sites (TTSs) hold deposition sites
      for three non-essential chromatin factors, histone variants (H3v and H4v)
      and a DNA modification (base J, a hydroxyl-glucosyl dT). Here, I found
      that H4v is a major sign for transcription termination at TTSs and
      readthrough transcription machineries progress until they encounter the
      next bidirectional transcription start site. While having a secondary
      function at TTSs, H3v is important for monoallelic transcription of
      telomeric antigen genes. The simultaneous absence of both histone variants
      leads to proliferation and replication defects, which are exacerbated by
      the J deficiency, accompanied by accumulation of sub-G1 population. Base J
      likely contributes to DNA replication and cell-cycle control. I propose
      that the coordinated actions of H3v, H4v and J function in concert for
      cellular fate determination and provide compensatory mechanisms for each
      other in chromatin organization, transcription, and replication.
    authors:
      - name: Hee-Sook Kim
        orcid: http://orcid.org/0000-0003-2289-7827
  comment:
    dislikes: 0
    thread: "8521497228"
    numReports: 0
    likes: 0
    id: "5386427954"
    createdAt: 2021-05-17T08:46:33
    author:
      name: Nicolai Siegel
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      Excellent work!


      I am very curious about the VSG expression patterns in your DKO and TKO cells. In Figure 6D, did you account for differences in read mappability? Since some genes have more 'unique sequence' than others, mappability may affect your RPKM.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.13.444086v1
  tweets:
    - created_at: Mon May 17 20:13:03 +0000 2021
      id: 1394385498647392300
      id_str: "1394385498647392256"
      text: |-
        üí¨ bioRxiv comment on "Site-specific epigenetic marks..."

        "Excellent work!

        I am very curious about the VSG express‚Ä¶ https://t.co/vVZV9SMluC
      truncated: true
      entities:
        urls:
          - url: https://t.co/vVZV9SMluC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 17 20:13:04 +0000 2021
      id: 1394385499742109700
      id_str: "1394385499742109702"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/JHrcdxB0FQ
      truncated: false
      entities:
        urls:
          - url: https://t.co/JHrcdxB0FQ
      in_reply_to_status_id: 1394385498647392300
      in_reply_to_status_id_str: "1394385498647392256"
- preprint:
    id: 139398
    metric: 5704
    title: Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and
      P681R, in the second wave of COVID-19 in Maharashtra, India
    url: https://api.rxivist.org/v1/papers/139398
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.22.440932v1
    doi: 10.1101/2021.04.22.440932
    category: molecular-biology
    first_posted: 2021-04-24
    abstract: As the global severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome
      sequencing are being constantly used to investigate its transmissions and
      evolution. In the backdrop of the global emergence of variants of concern
      (VOCs) during December 2020 and an upsurge in a state in the western part
      of India since January 2021, whole genome sequencing and analysis of spike
      protein mutations using sequence and structural approaches was undertaken
      to identify possible new variants and gauge the fitness of current
      circulating strains. Phylogenetic analysis revealed that the predominant
      clade in circulation was a distinct newly identified lineage B.1.617
      possessing common signature mutations D111D, G142D, L452R, E484Q, D614G
      and P681R, in the spike protein including within the receptor binding
      domain (RBD). Of these, the mutations at residue positions 452, 484 and
      681 have been reported in other globally circulating lineages. The
      structural analysis of RBD mutations L452R and E484Q along with P681R in
      the furin cleavage site, revealed that these may possibly result in
      increased ACE2 binding and rate of S1-S2 cleavage resulting in better
      transmissibility. The same two RBD mutations indicated decreased binding
      to select monoclonal antibodies (mAbs) and may affect their neutralization
      potential. Experimental validation against a wider panel of mAbs, sera
      from vaccinees and those that recovered from natural infection needs to be
      studied. The emergence of such local variants through the accumulation of
      convergent mutations during the COVID-19 second wave needs to be further
      investigated for their public health impact in the rest of the country and
      its possibility of becoming a VOC.
    authors:
      - name: Sarah Cherian
      - name: Varsha Potdar
      - name: Santosh Jadhav
      - name: Pragya Yadav
      - name: Nivedita Gupta
      - name: Mousmi Das
      - name: Partha Rakshit
      - name: Sujeet Singh
      - name: Priya Abraham
      - name: Samiran Panda
      - name: NIC team
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 17 20:20:49 +0000 2021
      id: 1394387449552547800
      id_str: "1394387449552547846"
      text: >-
        üî• bioRxiv Molecular-biology preprint by S. Cherian et al:


        "Convergent evolution of SARS-CoV-2 spike mutations, L45‚Ä¶ https://t.co/ovG85u4GJo
      truncated: true
      entities:
        urls:
          - url: https://t.co/ovG85u4GJo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "141849"
    doi: 10.1101/2021.05.13.21257109
    first_posted: 2021-05-16
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.13.21257109v1
    url: https://api.rxivist.org/v1/papers/141849
    title: Opioid Prescribing Mediating State Policy Intervention Effects on Drug
      Overdose Mortality
    category: health-policy
    abstract: The Centers for Disease Control and Prevention reported 70 630 drug
      overdose deaths for 2019 in the United States, 70.5% of which were
      opioid-related. Preliminary estimates now warn that drug overdose deaths
      likely surpassed 86 000 during 2020. Despite a 57.4% decrease in opioid
      prescribing since a peak in 2012, the opioid death rate has increased
      105.8% through 2019, as the share of those deaths involving fentanyl
      increased from 16.4% to 72.9%. This letter seeks to determine whether the
      opioid prescribing and mortality paradox is robust to accepted methods of
      causal policy analysis and if prescribing rates mediate the effects of
      policy interventions on overdose deaths. Using loge-loge ordinary least
      squares with three different specifications as sensitivity analyses for
      all 50 states and Washington, DC for the period 2001-2019, the
      elasticities from the regressions with all control variables report
      operational prescription drug monitoring programs (PDMPs) reduce
      prescribing rates 8.7%, while mandatory PDMPs increase death rates from
      opioids 16.6%, heroin and fentanyl 19.0%, cocaine 17.3% and all drugs
      10.5%. There is also weak evidence that recreational marijuana laws reduce
      prescribing, increases in prescribing increase pain reliever deaths, pill
      mill laws increase cocaine deaths, and medical marijuana laws increase
      total overdose deaths, with demographic variables suggesting states with
      more male, less non-Hispanic white, and older citizens experience more
      overdoses. Weak mediation effects were observed for pain reliever,
      cocaine, and illicit opioid deaths, while broad reductions in prescribing
      have failed to reduce opioid overdoses.
    authors:
      - name: Jacob James Rich
        orcid: http://orcid.org/0000-0002-2272-5446
      - name: Robert Capodilupo
        orcid: null
  comment:
    dislikes: 0
    thread: "8522891427"
    numReports: 0
    likes: 0
    id: "5387217982"
    createdAt: 2021-05-17T21:44:07
    author:
      username: redlawhern
      about: Advocate and web author for chronic neurological facepain patients.
        Formerly webmaster for the US Trigeminal Neuralgia Association.
      name: Red Lawhern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/redlawhern/
      url: http://www.face-facts.org/Lawhern
      location: Fort Mill, SC
      id: "99089704"
    isApproved: true
    raw_message: >-
      In your paper you write 



      "drug monitoring programs (PDMPs) reduce prescribing rates 8.7%, while 

      mandatory PDMPs increase death rates from opioids 16.6%, heroin and 

      fentanyl 19.0%, cocaine 17.3% and all drugs 10.5%" 


      This phrasing seems to assert demonstrated cause and effect.  It is not at all clear to me that the techniques you are applying have the capability to establish that. 


      Likewise, there is an important question in this process that you do not address and I would hope you may be willing to attempt:  recognizing that predominant modes of overdose mortality involve multiple legal and illegal opioids in the great majority of deaths, is the contribution of opioids prescribed by doctors to their patients (not diverted) statistically significant  in the overall mortality rate due to all opioids, legal and illegal? Based on the relative rarity of addiction to medically managed prescription opioids,  I would suggest that it is not.  


      Your comments are invited.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.13.21257109v1
  tweets:
    - created_at: Tue May 18 00:41:53 +0000 2021
      id: 1394453151135137800
      id_str: "1394453151135137797"
      text: |-
        üí¨ medRxiv comment on "Opioid Prescribing Mediating S..."

        "In your paper you write 

        "drug monitoring programs (PDM‚Ä¶ https://t.co/3TZYvBaiel
      truncated: true
      entities:
        urls:
          - url: https://t.co/3TZYvBaiel
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 00:41:53 +0000 2021
      id: 1394453152129110000
      id_str: "1394453152129110016"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/csjma3h5nC
      truncated: false
      entities:
        urls:
          - url: https://t.co/csjma3h5nC
      in_reply_to_status_id: 1394453151135137800
      in_reply_to_status_id_str: "1394453151135137797"
- preprint:
    id: "122704"
    doi: 10.1101/2020.12.23.423904
    first_posted: 2020-12-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.23.423904v1
    url: https://api.rxivist.org/v1/papers/122704
    title: Cytosolic localization and in vitro assembly of human de novo thymidylate
      synthesis complex
    category: biochemistry
    abstract: "De novo thymidylate synthesis is a crucial pathway for normal and
      cancer cells. Deoxythymidine monophosphate (dTMP) is synthesized by the
      combined action of three enzymes: serine hydroxymethyltransferase (SHMT),
      dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS), the latter
      two targets of widely used chemotherapeutics such as antifolates and
      5-fluorouracil. These proteins translocate to the nucleus after
      SUMOylation and are suggested to assemble in this compartment into the
      thymidylate synthesis complex (dTMP-SC). We report the intracellular
      dynamics of the complex in lung cancer cells by in situ proximity ligation
      assay, showing that it is also detected in the cytoplasm. This result
      strongly indicates that the role of the dTMP-SC assembly may go beyond
      dTMP synthesis. We have successfully assembled the dTMP synthesis complex
      in vitro, employing tetrameric SHMT1 and a bifunctional chimeric enzyme
      comprising human TYMS and DHFR. We show that the SHMT1 tetrameric state is
      required for efficient complex assembly, indicating that this aggregation
      state is evolutionary selected in eukaryotes to optimize protein-protein
      interactions. Lastly, our results on the activity of the complete
      thymidylate cycle in vitro, may provide a useful tool to develop drugs
      targeting the entire complex instead of the individual components."
    authors:
      - name: Sharon Spizzichino
        orcid: null
      - name: Dalila Boi
        orcid: null
      - name: Giovanna Boumis
        orcid: http://orcid.org/0000-0001-5323-7288
      - name: Roberta Lucchi
        orcid: null
      - name: Francesca Romana Liberati
        orcid: null
      - name: Davide Capelli
        orcid: http://orcid.org/0000-0002-6716-3854
      - name: Roberta Montanari
        orcid: http://orcid.org/0000-0002-7533-5425
      - name: Giorgio Pochetti
        orcid: http://orcid.org/0000-0002-3980-3180
      - name: Alessio Paone
        orcid: http://orcid.org/0000-0001-9406-3982
      - name: Serena Rinaldo
        orcid: http://orcid.org/0000-0003-0682-023X
      - name: Roberto Contestabile
        orcid: http://orcid.org/0000-0002-5235-9993
      - name: Alessandro Paiardini
        orcid: http://orcid.org/0000-0001-9078-7545
      - name: Angela Tramonti
        orcid: http://orcid.org/0000-0002-5625-1170
      - name: Giorgio Giardina
        orcid: http://orcid.org/0000-0002-0802-1370
      - name: Francesca Cutruzzol√°
        orcid: http://orcid.org/0000-0002-4621-2135
  comment:
    dislikes: 0
    thread: "8378755337"
    numReports: 0
    likes: 0
    id: "5387170427"
    createdAt: 2021-05-17T20:59:10
    author:
      username: virginia_bain
      about: ""
      name: Virginia Bain
      isPowerContributor: false
      profileUrl: https://disqus.com/by/virginia_bain/
      url: ""
      location: ""
      id: "369529985"
    isApproved: true
    raw_message: Hello~ I have a question for the authors. It looks like there is
      nuclear DHFR by immunofluorescence in A549 cells in figure 2C but in 2F
      you nicely show that  DHFR is only in the cytoplasm. What do you make of
      the nuclear DHFR in figure 2C? Thanks!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.23.423904v2
  tweets:
    - created_at: Tue May 18 13:01:59 +0000 2021
      id: 1394639401880363000
      id_str: "1394639401880363017"
      text: >-
        üí¨ bioRxiv comment on "Cytosolic localization and in ..."


        "Hello~ I have a question for the authors. It looks like‚Ä¶ https://t.co/htIrFvsQaN
      truncated: true
      entities:
        urls:
          - url: https://t.co/htIrFvsQaN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 13:01:59 +0000 2021
      id: 1394639403071455200
      id_str: "1394639403071455235"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/QFqflcwef6
      truncated: false
      entities:
        urls:
          - url: https://t.co/QFqflcwef6
      in_reply_to_status_id: 1394639401880363000
      in_reply_to_status_id_str: "1394639401880363017"
- preprint:
    id: "80107"
    doi: 10.1101/2020.04.16.044255
    first_posted: 2020-04-17
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.04.16.044255v1
    url: https://api.rxivist.org/v1/papers/80107
    title: Stability of the vaginal microbiota during pregnancy and its importance
      for early infant colonization
    category: bioinformatics
    abstract: Early life microbiota has been linked to the development of chronic
      inflammatory diseases. It has been hypothesized that maternal vaginal
      microbiota is an important initial seeding source and therefore can have
      lifelong effects on disease risk. To understand maternal vaginal
      microbiota's role in seeding the child's microbiota and the extent of
      delivery mode-dependent transmission, we studied 700 mother-child dyads
      from the COPSAC2010 cohort. The maternal vaginal microbiota was evaluated
      in the third trimester and compared with the children's fecal and airway
      microbiota. The vaginal samples displayed known stable community state
      types and only 1:6 changed over time. Only one OTU were significantly
      transferred to children's fecal compartment, but an inflated number had
      positive transfer odds. A few taxonomic families showed early transfer
      enrichment to vaginally-born children, indicating vertical transfer, while
      half of the observed transfer effects were delivery mode independent
      enrichment with attenuating strength over time, indicating a common
      reservoir.
    authors:
      - name: Martin S. Mortensen
        orcid: http://orcid.org/0000-0001-5483-7533
      - name: Morten A. Rasmussen
        orcid: null
      - name: Jakob Stokholm
        orcid: http://orcid.org/0000-0003-4989-9769
      - name: Asker D. Brejnrod
        orcid: null
      - name: Christina Balle
        orcid: null
      - name: Jonathan Thorsen
        orcid: null
      - name: Karen A. Krogfelt
        orcid: http://orcid.org/0000-0001-7536-3453
      - name: Hans Bisgaard
        orcid: http://orcid.org/0000-0003-4131-7592
      - name: S√∏ren J. S√∏rensen
        orcid: http://orcid.org/0000-0001-6227-9906
  comment:
    dislikes: 0
    thread: "7975653931"
    numReports: 0
    likes: 0
    id: "5387820233"
    createdAt: 2021-05-18T12:28:19
    author:
      username: martinsteenmortensen
      about: ""
      name: Martin Steen Mortensen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/martinsteenmortensen/
      url: ""
      location: ""
      id: "105193295"
    isApproved: true
    raw_message: We had this article printed in eLife (10.7554/eLife.57051), but due
      to an updated title it does not seem to have been registered here.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.04.16.044255v1
  tweets:
    - created_at: Tue May 18 20:17:23 +0000 2021
      id: 1394748974083436500
      id_str: "1394748974083436544"
      text: >-
        üí¨ bioRxiv comment on "Stability of the vaginal micro..."


        "We had this article printed in eLife (10.7554/eLife.5705‚Ä¶ https://t.co/UH3K9yglqy
      truncated: true
      entities:
        urls:
          - url: https://t.co/UH3K9yglqy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 18 20:17:23 +0000 2021
      id: 1394748974976757800
      id_str: "1394748974976757761"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/ojArj6Z8J7
      truncated: false
      entities:
        urls:
          - url: https://t.co/ojArj6Z8J7
      in_reply_to_status_id: 1394748974083436500
      in_reply_to_status_id_str: "1394748974083436544"
- preprint:
    id: 127224
    metric: 4264
    title: Heterologous vaccination regimens with self-amplifying RNA and Adenoviral
      COVID vaccines induce robust immune responses in mice
    url: https://api.rxivist.org/v1/papers/127224
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.01.28.428665v1
    doi: 10.1101/2021.01.28.428665
    category: immunology
    first_posted: 2021-01-29
    abstract: Several vaccines have demonstrated efficacy against SARS-CoV-2
      mediated disease, yet there is limited data on the immune response induced
      by heterologous vaccination regimens using alternate vaccine modalities.
      Here, we present a detailed description of the immune response, in mice,
      following vaccination with a self-amplifying RNA (saRNA) vaccine and an
      adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2.
      We demonstrate that antibody responses are higher in two dose heterologous
      vaccination regimens than single dose regimens. Neutralising titres after
      heterologous prime-boost were at least comparable or higher than the
      titres measured after homologous prime boost vaccination with viral
      vectors. Importantly, the cellular immune response after a heterologous
      regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells which is
      superior to the response induced in homologous vaccination regimens in
      mice. These results underpin the need for clinical trials to investigate
      the immunogenicity of heterologous regimens with alternate vaccine
      technologies.
    authors:
      - name: Alexandra J Spencer
      - name: Paul F McKay
      - name: Sandra Belij-Rammerstorfer
      - name: Marta Ulaszewska
      - name: Cameron D Bissett
      - name: Kai Hu
      - name: Karnyart Samnuan
      - name: Anna K. Blakney
      - name: Hannah R Sharpe
      - name: Daniel Wright
      - name: Ciaran Gilbride
      - name: Adam Truby
      - name: Elizabeth R Allen
      - name: Sarah C Gilbert
      - name: Robin J Shattock
      - name: Teresa Lambe
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue May 18 20:25:30 +0000 2021
      id: 1394751018022359000
      id_str: "1394751018022359044"
      text: >-
        üî• bioRxiv Immunology preprint by A. J. Spencer et al:


        "Heterologous vaccination regimens with self-amplifying RNA‚Ä¶ https://t.co/CqHl2SBkG3
      truncated: true
      entities:
        urls:
          - url: https://t.co/CqHl2SBkG3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "130515"
    doi: 10.1101/2021.02.23.432421
    first_posted: 2021-02-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.23.432421v1
    url: https://api.rxivist.org/v1/papers/130515
    title: A more accurate method for colocalisation analysis allowing for multiple
      causal variants
    category: genetics
    abstract: In genome-wide association studies (GWAS) it is now common to search
      for, and find, multiple causal variants located in close proximity. It has
      also become standard to ask whether different traits share the same causal
      variants, but one of the popular methods to answer this question, coloc,
      makes the simplifying assumption that only a single causal variant exists
      for any given trait in any genomic region. Here, we examine the potential
      of the recently proposed Sum of Single Effects (SuSiE) regression
      framework, which can be used for fine-mapping genetic signals, for use
      with coloc. SuSiE is a novel approach that allows evidence for association
      at multiple causal variants to be evaluated simultaneously, whilst
      separating the statistical support for each variant conditional on the
      causal signal being considered. We show this results in more accurate
      coloc inference than other proposals to adapt coloc for multiple causal
      variants based on conditioning or masking. We therefore recommend that
      coloc be used in combination with SuSiE to optimise accuracy of
      colocalisation analyses when multiple causal variants exist.
    authors:
      - name: Chris Wallace
        orcid: http://orcid.org/0000-0001-9755-1703
  comment:
    dislikes: 0
    thread: "8410450800"
    numReports: 0
    likes: 0
    id: "5387656036"
    createdAt: 2021-05-18T08:18:43
    author:
      username: disqus_SKjVenadaX
      about: ""
      name: Chris Wallace üè≥Ô∏è‚Äçüåà  üá™üá∫
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_SKjVenadaX/
      url: ""
      location: ""
      id: "325883660"
    isApproved: true
    raw_message: >-
      Thank you for taking the time to review.  I haven't had a public review
      before to my knowledge, but they seem a thoroughly good thing.  I am not
      sure of the conventions, but hope it is in the right spirit to post a
      summary of my responses to each of your main points, which I think have
      improved the manuscript.  The changes I describe may be seen in version 2
      on biorxiv.


      1. I have adjusted coloc to use the Bayes factors that are now returned by susie_rss (thank you), so the back-calculation is no longer needed and I have removed that equation. I have also updated the relevant text to give more details on how susie_rss is called, and the number of colocalisation comparisons returned and how the pairwise probabilities of colocalisation may be interpreted.





      2. I completely agree it would be cheating to tell any method how many causal variants were simulated! I have updated the legend to figure 3, which hopefully clarifies what AA, BB etc signals are. 





      In the setting where each trait has 2 causal variants A and B, there should ideally be 4 comparisons: AA, AB, BA, BB.  Very occasionally there are more (a handful of times susie_rss reports > 2 signals).  Often there are fewer (due to power), and even when there are 4, they may not all be assignable to labelled groups and some will fall in ‚Äú?‚Äù. This is why the bar height, which is proportional to the number of comparisons performed in a given category divided by the number of simulations, doesn‚Äôt reach 1.





      3. Figure 1 has now been changed to show both the change in PIP at the causal variants and at the non-causal variants. Specifically, following the approach of coloc to consider comparisons between vectors of Bayes factors corresponding to detected credible sets, I took the colSums of obj$alpha[ obj$sets$cs_index, ] as a measure of the total PIP after a run of susie_rss(). Thus the total PIP can increase/decrease by 1 if a credible set is ‚Äúdiscovered‚Äù or ‚Äúlost‚Äù after trimming.  This view of the data shows false positives are indeed introduced after trimming. This is now described at the beginning of the Results section





      Fig 3 shows, however, that despite these false positives coloc with SuSiE outperforms the alternatives, and appears to do at least as well when trimming as not. Therefore, I expanded the Discussion on trimming to give a clearer warning that while trimming is possible for coloc, these results do not support its use in fine-mapping. 





      4. Thank you for these detailed explanations. I agree it would be preferable to never trim data. I have extended the discussion to cover these points, and acknowledged your comments in helping me to do that.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.23.432421v1
  tweets:
    - created_at: Wed May 19 00:38:04 +0000 2021
      id: 1394814579050418200
      id_str: "1394814579050418177"
      text: >-
        üí¨ bioRxiv comment on "A more accurate method for col..."


        "Thank you for taking the time to review.  I haven't had‚Ä¶ https://t.co/0t8vLXlLjk
      truncated: true
      entities:
        urls:
          - url: https://t.co/0t8vLXlLjk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 00:38:04 +0000 2021
      id: 1394814579805507600
      id_str: "1394814579805507588"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/mThs3YVlCp
      truncated: false
      entities:
        urls:
          - url: https://t.co/mThs3YVlCp
      in_reply_to_status_id: 1394814579050418200
      in_reply_to_status_id_str: "1394814579050418177"
- preprint:
    id: "124483"
    doi: 10.1101/2020.12.21.20248121
    first_posted: 2020-12-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.21.20248121v1
    url: https://api.rxivist.org/v1/papers/124483
    title: HLA-C* 04:01 is a Genetic Risk Allele for Severe Course of COVID-19
    category: genetic-and-genomic-medicine
    abstract: >-
      BackgroundSince the beginning of the coronavirus disease 2019 (COVID-19)
      pandemic, there has been increasing demand to identify predictors of
      severe clinical course in patients infected with severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA)
      have been suggested as potential genetic host factors. We sought to
      evaluate this hypothesis by conducting an international multicenter study
      using HLA sequencing with subsequent independent validation.


      MethodsWe analyzed a total of 332 samples. First, we enrolled 233 patients in Germany, Spain, and Switzerland for HLA and whole exome sequencing. Furthermore, we validated our results in a public data set (United States, n=99). Patients older than 18 years presenting with COVID-19 were included, representing the full spectrum of the disease. HLA candidate alleles were identified in the derivation cohort (n=92) and tested in two independent validation cohorts (n=240).


      ResultsWe identified HLA-C* 04:01 as a novel genetic predictor for severe clinical course in COVID-19. Carriers of HLA-C* 04:01 had twice the risk of intubation when infected with SARS-CoV-2 (hazard ratio 2.1, adjusted p-value=0.0036). Importantly, these findings were successfully replicated in an independent data set. Furthermore, our findings are biologically plausible, as HLA-C* 04:01 has fewer predicted bindings sites with relevant SARS-CoV-2 peptides as compared to other HLA alleles. Exome sequencing confirmed findings from HLA analysis.


      ConclusionsHLA-C* 04:01 carriage is associated with a twofold increased risk of intubation in patients infected with SARS-CoV-2. Testing for HLA-C* 04:01 could have clinical implications to identify high-risk patients and individualize management.
    authors:
      - name: Weiner January
        orcid: null
      - name: Suwalski Phillip
        orcid: null
      - name: Holtgrewe Manuel
        orcid: null
      - name: Thibeault Charlotte
        orcid: http://orcid.org/0000-0002-8979-9386
      - name: Melina M√ºller
        orcid: null
      - name: Patriki Dimitri
        orcid: null
      - name: Quedenau Claudia
        orcid: null
      - name: Ulrike Kr√ºger
        orcid: null
      - name: T. Helbig Elisa
        orcid: null
      - name: Lippert Lena
        orcid: null
      - name: Stubbemann Paula
        orcid: null
      - name: Real Luis Miguel
        orcid: null
      - name: Sanchez Juan Macias
        orcid: null
      - name: A. Pineda Juan
        orcid: null
      - name: Fernandez-Fuertes Marta
        orcid: null
      - name: Wang Xiaomin
        orcid: null
      - name: Karadeniz Zehra
        orcid: null
      - name: Saccomanno Jacopo
        orcid: null
      - name: Doehn Jan-Moritz
        orcid: null
      - name: H√ºbner Ralf-Harto
        orcid: null
      - name: Hinzmann Bernd
        orcid: null
      - name: Salvo Mauricio
        orcid: null
      - name: Blueher Anja
        orcid: null
      - name: Siemann Sandra
        orcid: null
      - name: Jurisic Stjepan
        orcid: null
      - name: Beer Hansjuerg
        orcid: null
      - name: Rutishauser Jonas
        orcid: null
      - name: Wiggli Benedikt
        orcid: null
      - name: Schmid Hansruedi
        orcid: null
      - name: Danninger Kathrin
        orcid: null
      - name: Binder Ronald
        orcid: null
      - name: M. Victor Corman
        orcid: null
      - name: M√ºhlemann Barbara
        orcid: null
      - name: Braun Alice
        orcid: null
      - name: Ripke Stephan
        orcid: null
      - name: C. Jones Terry
        orcid: null
      - name: Suttorp Norbert
        orcid: null
      - name: Witzenrath Martin
        orcid: null
      - name: Hippenstiel Stefan
        orcid: null
      - name: Zemojtel Tomasz
        orcid: null
      - name: Skurk Carsten
        orcid: null
      - name: Poller Wolfgang
        orcid: null
      - name: Borodina Tatiana
        orcid: null
      - name: Pa-COVID Study Group
        orcid: null
      - name: E. Sander Leif
        orcid: null
      - name: Beule Dieter
        orcid: null
      - name: Landmesser Ulf
        orcid: null
      - name: Guettouche Toumy
        orcid: null
      - name: Kurth Florian
        orcid: null
      - name: Heidecker Bettina
        orcid: null
  comment:
    dislikes: 0
    thread: "8328945006"
    numReports: 0
    likes: 0
    id: "5388394685"
    createdAt: 2021-05-18T20:33:29
    author:
      username: disqus_WaA83XvM0B
      about: ""
      name: Rene Warren
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WaA83XvM0B/
      url: ""
      location: ""
      id: "157460079"
    isApproved: true
    raw_message: "We have done that in our work using the Overmyer (New York) cohort
      and reported our findings on November 2nd, 2020:
      https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605564/"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.21.20248121v1
  tweets:
    - created_at: Wed May 19 12:17:09 +0000 2021
      id: 1394990509026914300
      id_str: "1394990509026914309"
      text: >-
        üí¨ medRxiv comment on "HLA-C* 04:01 is a Genetic Risk..."


        "We have done that in our work using the Overmyer (New Yo‚Ä¶ https://t.co/IYWHjQPThj
      truncated: true
      entities:
        urls:
          - url: https://t.co/IYWHjQPThj
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 12:17:09 +0000 2021
      id: 1394990509823828000
      id_str: "1394990509823827973"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/hPghHHcQqX
      truncated: false
      entities:
        urls:
          - url: https://t.co/hPghHHcQqX
      in_reply_to_status_id: 1394990509026914300
      in_reply_to_status_id_str: "1394990509026914309"
- preprint:
    id: "120813"
    doi: 10.1101/2020.12.01.20241919
    first_posted: 2020-12-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.12.01.20241919v1
    url: https://api.rxivist.org/v1/papers/120813
    title: bootComb - An R Package to Derive Confidence Intervals for Combinations
      of Independent Parameter Estimates
    category: epidemiology
    abstract: "Motivation. The epidemiologist sometimes needs to combine several
      independent parameter estimates: e.g. (i) adjust an incidence rate for
      healthcare utilisation, (ii) derive a disease prevalence from the
      conditional prevalence on another condition and the prevalence of that
      condition, (iii) adjust a seroprevalence for test sensitivity and
      specificity. While obtaining the combined parameter estimate is usually
      straightforward, deriving a corresponding confidence interval often is
      not. bootComb is an R package using parametric bootstrap sampling to
      derive such confidence intervals. Implementation. bootComb is a package
      for the statistical computation environment R. General features. As well
      as a function that returns confidence intervals for parameters combined
      from several independent estimates, bootComb provides auxiliary functions
      for 6 common distributions (beta, normal, exponential, gamma, Poisson and
      negative binomial) to derive best-fit distributions (and their sampling
      functions) for parameters given their reported confidence intervals.
      Availability. bootComb is available from the Comprehensive R Archive
      Network (https://CRAN.R-project.org/package=bootComb)."
    authors:
      - name: Marc YR Henrion
        orcid: http://orcid.org/0000-0003-1242-839X
  comment:
    dislikes: 0
    thread: "8306836802"
    numReports: 0
    likes: 0
    id: "5389485884"
    createdAt: 2021-05-19T17:50:25
    author:
      username: marchenrion
      about: ""
      name: marchenrion
      isPowerContributor: false
      profileUrl: https://disqus.com/by/marchenrion/
      url: ""
      location: ""
      id: "369633532"
    isApproved: true
    raw_message: >-
      This article has been accepted for publication in the International
      Journal of Epidemiology published by Oxford University Press.



      The DOI for the version of record is https://doi.org/10.1093/ije/dyab049.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.12.01.20241919v1
  tweets:
    - created_at: Wed May 19 20:12:34 +0000 2021
      id: 1395110151296794600
      id_str: "1395110151296794633"
      text: >-
        üí¨ medRxiv comment on "bootComb - An R Package to Der..."


        "This article has been accepted for publication in the In‚Ä¶ https://t.co/h1mkrF0BX1
      truncated: true
      entities:
        urls:
          - url: https://t.co/h1mkrF0BX1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 19 20:12:34 +0000 2021
      id: 1395110152177606700
      id_str: "1395110152177606658"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/zHk5Ao17H8
      truncated: false
      entities:
        urls:
          - url: https://t.co/zHk5Ao17H8
      in_reply_to_status_id: 1395110151296794600
      in_reply_to_status_id_str: "1395110151296794633"
- preprint:
    id: 104150
    metric: 4184
    title: Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine
      candidate
    url: https://api.rxivist.org/v1/papers/104150
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.11.16.384594v1
    doi: 10.1101/2020.11.16.384594
    category: biochemistry
    first_posted: 2020-11-16
    abstract: >-
      Severe acute respiratory syndrome coronavirus 2 is the causative pathogen
      of the COVID-19 pandemic which as of Nov 15, 2020 has claimed 1,319,946
      lives worldwide. Vaccine development focuses on the viral trimeric spike
      glycoprotein as the main target of the humoral immune response. Viral
      spikes carry glycans that facilitate immune evasion by shielding specific
      protein epitopes from antibody neutralisation. Immunogen integrity is
      therefore important for glycoprotein-based vaccine candidates. Here we
      show how site-specific glycosylation differs between virus-derived spikes
      and spike proteins derived from a viral vectored SARS-CoV-2 vaccine
      candidate. We show that their cellular secretion pathways are unique,
      resulting in different protein glycosylation and secretion, which may have
      implications for the resulting immune response and future vaccine design.


      ### Competing Interest Statement


      W.B.S. is a shareholder and consultant to Refeyn Ltd. All other authors declare no conflict of interest.
    authors:
      - name: Juliane Brun
      - name: Snezana Vasiljevic
      - name: Bevin Gangadharan
      - name: Mario Hensen
      - name: Anu V. Chandran
      - name: Michelle L. Hill
      - name: J.L. Kiappes
      - name: Raymond A. Dwek
      - name: Dominic S. Alonzi
      - name: Weston B. Struwe
      - name: Nicole Zitzmann
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed May 19 20:20:31 +0000 2021
      id: 1395112150230839300
      id_str: "1395112150230839303"
      text: >-
        üî• bioRxiv Biochemistry preprint by J. Brun et al:


        "Analysis of SARS-CoV-2 spike glycosylation reveals shedding of‚Ä¶ https://t.co/pUILp7mqvt
      truncated: true
      entities:
        urls:
          - url: https://t.co/pUILp7mqvt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "123354"
    doi: 10.1101/2020.12.31.425005
    first_posted: 2021-01-02
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.31.425005v1
    url: https://api.rxivist.org/v1/papers/123354
    title: YhcB (DUF1043), a novel cell division protein conserved across
      gamma-proteobacteria
    category: microbiology
    abstract: >-
      YhcB, an uncharacterized protein conserved across gamma-proteobacteria, is
      composed predominantly of a single Domain of Unknown Function (DUF 1043)
      with an N-terminal transmembrane -helix. Here, we show that E. coli YhcB
      is a conditionally essential protein that interacts with the proteins of
      the cell divisome (e.g., FtsI, FtsQ) and elongasome (e.g., RodZ, RodA). We
      found 7 interactions of YhcB that are conserved in Yersinia pestis and/or
      Vibrio cholerae. Furthermore, we identified several point mutations that
      abolished interactions of YhcB with FtsI and RodZ. The yhcB knock-out
      strain does not grow at 45{degrees}C and is hypersensitive to cell-wall
      acting antibiotics even in stationary phase. The deletion of yhcB leads to
      filamentation, abnormal FtsZ ring formation, and aberrant septa
      development. The 2.8 [A] crystal structure for the cytosolic domain from
      Haemophilus ducreyi YhcB shows a unique tetrameric -helical coiled-coil
      structure that combines parallel and anti-parallel coiled-coil
      intersubunit interactions. This structure is likely to organize
      interprotein oligomeric interactions on the inner surface of the
      cytoplasmic membrane, possibly involved in regulation of cell division
      and/or envelope biogenesis/integrity in proteobacteria. In summary, YhcB
      is a conserved and conditionally essential protein that is predicted to
      play a role in cell division and consequently or in addition affects
      envelope biogenesis.


      ImportanceOnly 0.8 % of the protein annotations in the UniProt are based on experimental evidence and thus, functional characterization of unknown proteins remains a rate-limiting step in molecular biology. Herein, the functional properties of YhcB (DUF1043) were investigated using an integrated approach combining X-ray crystallography with genetics and molecular biology. YhcB is a conserved protein that appears to be needed for the transition from exponential to stationary growth and is involved in cell division and/or envelope biogenesis/integrity. This study will serve as a starting point for future studies on this protein family and on how cells transit from exponential to stationary survival.
    authors:
      - name: Jitender Mehla
        orcid: http://orcid.org/0000-0002-7829-557X
      - name: George Liechti
        orcid: http://orcid.org/0000-0003-3028-8474
      - name: Randy Morgenstein
        orcid: http://orcid.org/0000-0003-0749-6830
      - name: J. Harry Caufield
        orcid: http://orcid.org/0000-0001-5705-7831
      - name: Ali Hosseinnia
        orcid: http://orcid.org/0000-0002-6499-0758
      - name: Alla Gagarinova
        orcid: http://orcid.org/0000-0002-6521-6406
      - name: Sadhna Phanse
        orcid: http://orcid.org/0000-0001-6306-0551
      - name: Mary Brockett
        orcid: http://orcid.org/0000-0002-5167-9231
      - name: Neha Sakhawalkar
        orcid: null
      - name: Mohan Babu
        orcid: null
      - name: Rong Xiao
        orcid: null
      - name: Gaetano T. Montelione
        orcid: http://orcid.org/0000-0002-9440-3059
      - name: Sergey Vorobiev
        orcid: http://orcid.org/0000-0001-8537-3671
      - name: Tanneke den Blaauwen
        orcid: http://orcid.org/0000-0002-5403-5597
      - name: John F. Hunt
        orcid: http://orcid.org/0000-0003-0034-5167
      - name: Peter Uetz
        orcid: http://orcid.org/0000-0001-6194-4927
  comment:
    dislikes: 0
    thread: "8346695005"
    numReports: 0
    likes: 0
    id: "5389262434"
    createdAt: 2021-05-19T15:03:33
    author:
      username: disqus_vbFUJ0jUw9
      about: ""
      name: Peter Uetz
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_vbFUJ0jUw9/
      url: https://www.facebook.com/app_scoped_user_id/YXNpZADpBWEV4UERQSHR4OTV5T1ZAiM0NaUXJoS3VfU1FHOW5uOUpOcjM1WDhvdU16WVkySmxSLVhEQzVEaVNoaVNzY1BRN1JmYTNwME56YWtwUU5XajdsREl6dml1WWZAuVGhKVmpEcDdC/
      location: ""
      id: "191120429"
    isApproved: true
    raw_message: "A revision of this paper has now been published in the Journal of
      Biological Chemistry: https://pubmed.ncbi.nlm.nih.gov/33895137/"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.31.425005v2
  tweets:
    - created_at: Thu May 20 00:35:52 +0000 2021
      id: 1395176410558472200
      id_str: "1395176410558472198"
      text: >-
        üí¨ bioRxiv comment on "YhcB (DUF1043), a novel cell d..."


        "A revision of this paper has now been published in the J‚Ä¶ https://t.co/m20d9V3ByV
      truncated: true
      entities:
        urls:
          - url: https://t.co/m20d9V3ByV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 00:35:52 +0000 2021
      id: 1395176411476922400
      id_str: "1395176411476922368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/vcWIH7J1wX
      truncated: false
      entities:
        urls:
          - url: https://t.co/vcWIH7J1wX
      in_reply_to_status_id: 1395176410558472200
      in_reply_to_status_id_str: "1395176410558472198"
- preprint:
    id: "109282"
    doi: 10.1101/2020.04.20.20073437
    first_posted: 2020-04-24
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.20.20073437v1
    url: https://api.rxivist.org/v1/papers/109282
    title: Estimated inequities in COVID-19 infection fatality rates by ethnicity
      for Aotearoa New Zealand
    category: epidemiology
    abstract: There is limited evidence as to how COVID-19 infection fatality rates
      (IFR) may vary by ethnicity. We combine demographic and health data for
      ethnic groupings in Aotearoa New Zealand with international data on IFR
      for different age groups to estimate inequities in IFR by ethnicity. We
      find that, if age is the dominant factor determining IFR, estimated IFR
      for M[a]ori is around 50% higher than non-M[a]ori. If underlying health
      conditions are more important than age per se, then estimated IFR for
      M[a]ori is more than 2.5 times that of New Zealand European, and estimated
      IFR for Pasifika is almost double that of New Zealand European. IFRs for
      M[a]ori and Pasifika are likely to be increased above these estimates by
      racism within the healthcare system and other inequities not reflected in
      official data. IFR does not account for differences among ethnicities in
      COVID-19 incidence, which could be higher in M[a]ori and Pasifika as a
      result of crowded housing and higher inter-generational contact rates.
      These factors should be included in future disease incidence modelling.
      The communities at the highest risk will be those with elderly
      populations, and M[a]ori and Pasifika communities, where the compounded
      effects of underlying health conditions, socioeconomic disadvantage, and
      structural racism result in imbricated risk of contracting COVID-19,
      becoming unwell, and death.
    authors:
      - name: Nicholas Steyn
        orcid: null
      - name: Rachelle N Binny
        orcid: http://orcid.org/0000-0002-3433-0417
      - name: Kate Hannah
        orcid: http://orcid.org/0000-0002-4934-7377
      - name: Shaun C Hendy
        orcid: http://orcid.org/0000-0003-3468-6517
      - name: Alex James
        orcid: http://orcid.org/0000-0002-1543-7139
      - name: Tahu Kukutai
        orcid: http://orcid.org/0000-0001-5080-2296
      - name: Audrey Lustig
        orcid: http://orcid.org/0000-0002-0869-3847
      - name: Melissa McLeod
        orcid: http://orcid.org/0000-0002-5834-7846
      - name: Michael J Plank
        orcid: http://orcid.org/0000-0002-7539-3465
      - name: Kannan Ridings
        orcid: null
      - name: Andrew Sporle
        orcid: null
  comment:
    dislikes: 0
    thread: "7990193862"
    numReports: 0
    likes: 0
    id: "5389829779"
    createdAt: 2021-05-19T22:26:18
    author:
      username: disqus_Pc9ZQufNd1
      about: ""
      name: Michael Plank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Pc9ZQufNd1/
      url: ""
      location: ""
      id: "369642137"
    isApproved: true
    raw_message: "This paper has now been published in the New Zealand Medical
      Journal and is available open access at:
      https://www.nzma.org.nz/journal-articles/estimated-inequities-in-covid-19\
      -infection-fatality-rates-by-ethnicity-for-aotearoa-new-zealand"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.20.20073437v1
  tweets:
    - created_at: Thu May 20 12:17:37 +0000 2021
      id: 1395353011673829400
      id_str: "1395353011673829376"
      text: >-
        üí¨ medRxiv comment on "Estimated inequities in COVID-..."


        "This paper has now been published in the New Zealand Med‚Ä¶ https://t.co/fcKfJUZwaQ
      truncated: true
      entities:
        urls:
          - url: https://t.co/fcKfJUZwaQ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 12:17:37 +0000 2021
      id: 1395353012579836000
      id_str: "1395353012579835910"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/1WFsniCwvc
      truncated: false
      entities:
        urls:
          - url: https://t.co/1WFsniCwvc
      in_reply_to_status_id: 1395353011673829400
      in_reply_to_status_id_str: "1395353011673829376"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5389554172"
    createdAt: 2021-05-19T18:42:43
    author:
      username: FredBass
      about: Preventive medicine physician concerned with our suicidal, massive
        ecological destruction.
      name: Fred Bass
      isPowerContributor: false
      profileUrl: https://disqus.com/by/FredBass/
      url: ""
      location: Vancouver BC Canada
      id: "215341"
    isApproved: true
    raw_message: Were the patients randomized into those getting usual and those
      getting 12 week delay?  Having 99 in one group and 73 in the other does
      not seem like a random split of 172 people!  A bias toward giving
      healthier seniors the longer interval might account for some or even all
      of the results.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Thu May 20 16:30:44 +0000 2021
      id: 1395416713546584000
      id_str: "1395416713546584075"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "Were the patients randomized into those getting usual an‚Ä¶ https://t.co/zKIlho8gD9
      truncated: true
      entities:
        urls:
          - url: https://t.co/zKIlho8gD9
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 16:30:44 +0000 2021
      id: 1395416714431565800
      id_str: "1395416714431565828"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV3f5Lu
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV3f5Lu
      in_reply_to_status_id: 1395416713546584000
      in_reply_to_status_id_str: "1395416713546584075"
- preprint:
    id: "142319"
    doi: 10.1101/2021.05.18.443629
    first_posted: 2021-05-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.18.443629v1
    url: https://api.rxivist.org/v1/papers/142319
    title: "Whole-ExM: Expansion microscopy imaging of all anatomical structures of
      whole larval zebrafish"
    category: developmental-biology
    abstract: Nanoscale imaging of all anatomical structures over whole vertebrates
      is needed for a systematic understanding of human diseases, but this has
      not yet been achieved. Here, we demonstrate whole-ExM, which enables
      nanoscale imaging of all anatomical structures of whole zebrafish larvae
      by labeling the proteins of the larvae with fluorophores and expanding
      them four-fold. We first optimize the fluorophore selection and labeling
      procedure to visualize a broader range of anatomical structures. We then
      develop an expansion protocol for zebrafish larvae having calcified body
      parts. Through this process, we visualize the nanoscale details of diverse
      larvae organs, which have corresponding organ counterparts in humans, over
      the intact larvae. We show that whole-ExM retains the fluorescence signals
      of fluorescent proteins, and its resolution is high enough to visualize
      various structures that can be imaged only with electron microscopy.
      Whole-ExM would enable the nanoscale study of the molecular mechanisms of
      human diseases.
    authors:
      - name: Jueun Sim
        orcid: null
      - name: Chan E Park
        orcid: null
      - name: In Cho
        orcid: null
      - name: Kyeongbae Min
        orcid: null
      - name: Jeong-Soo Lee
        orcid: null
      - name: Yosep Chong
        orcid: null
      - name: Jeewon Kim
        orcid: null
      - name: Jeong Seuk Kang
        orcid: null
      - name: Kiryl D Piatkevich
        orcid: http://orcid.org/0000-0002-7777-9468
      - name: Erica E. Jung
        orcid: null
      - name: Seok-Kyu Kwon
        orcid: http://orcid.org/0000-0002-7280-9867
      - name: Young-Gyu Yoon
        orcid: null
      - name: Edward S. Boyden
        orcid: http://orcid.org/0000-0002-0419-3351
      - name: Jae-Byum Chang
        orcid: null
  comment:
    dislikes: 0
    thread: "8530175268"
    numReports: 0
    likes: 0
    id: "5390733799"
    createdAt: 2021-05-20T17:14:04
    author:
      name: Tanya Whitfield
      url: ""
      profileUrl: ""
      emailHash: ""
    isApproved: true
    raw_message: >-
      Congratulations on this beautiful work.


      The ‚Äòunknown structures' that you have imaged in the olfactory epithelium and skin in Suppl. Fig. 32 are rodlet cells, which have been described in several previous papers, including in the zebrafish.  See: 

      Hansen and Zeiske (1998) The Peripheral Olfactory Organ of the Zebrafish, Danio rerio: an Ultrastructural Study.  Chem. Senses 23: 39-48

      DePasquale, J. A. (2020). Tropomyosin and alpha-actinin in teleost rodlet cells. Acta Zool. 00, 1‚Äì10. doi: 10.1111/azo.12344


      We included some discussion on rodlet cells in our recent paper on a different cell type, olfactory rod cells, which have a single actin-rich projection (and are also visible in your Suppl. Video 14).  See Cheung et al. (2021).  Olfactory Rod Cells: A Rare Cell Type in the Larval Zebrafish Olfactory Epithelium With a Large Actin-Rich Apical Projection. Front Physiol. 12:626080. doi: 10.3389/fphys.2021.626080

      PMID: 33716772
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.18.443629v1
  tweets:
    - created_at: Thu May 20 20:10:46 +0000 2021
      id: 1395472085175050200
      id_str: "1395472085175050240"
      text: |-
        üí¨ bioRxiv comment on "Whole-ExM: Expansion microscop..."

        "Congratulations on this beautiful work.

        The ‚Äòunknown st‚Ä¶ https://t.co/fFnrcv4BP8
      truncated: true
      entities:
        urls:
          - url: https://t.co/fFnrcv4BP8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 20 20:10:46 +0000 2021
      id: 1395472086018130000
      id_str: "1395472086018129923"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IDj4DEiLfL
      truncated: false
      entities:
        urls:
          - url: https://t.co/IDj4DEiLfL
      in_reply_to_status_id: 1395472085175050200
      in_reply_to_status_id_str: "1395472085175050240"
- preprint:
    id: 140989
    metric: 7077
    title: SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades
      antibodies induced by infection and vaccination
    url: https://api.rxivist.org/v1/papers/140989
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.04.442663v1
    doi: 10.1101/2021.05.04.442663
    category: molecular-biology
    first_posted: 2021-05-05
    abstract: The emergence of SARS-CoV-2 variants threatens efforts to contain the
      COVID-19 pandemic. The number of COVID-19 cases and deaths in India has
      risen steeply in recent weeks and a novel SARS-CoV-2 variant, B.1.617, is
      believed to be responsible for many of these cases. The spike protein of
      B.1.617 harbors two mutations in the receptor binding domain, which
      interacts with the ACE2 receptor and constitutes the main target of
      neutralizing antibodies. Therefore, we analyzed whether B.1.617 is more
      adept in entering cells and/or evades antibody responses. B.1.617 entered
      two out of eight cell lines tested with slightly increased efficiency and
      was blocked by entry inhibitors. In contrast, B.1.617 was resistant
      against Bamlanivimab, an antibody used for COVID-19 treatment. Finally,
      B.1.617 evaded antibodies induced by infection or vaccination, although
      with moderate efficiency. Collectively, our study reveals that antibody
      evasion of B.1.617 may contribute to the rapid spread of this variant.
    authors:
      - name: Markus Hoffmann
      - name: Heike Hofmann-Winkler
      - name: Nadine Krueger
      - name: Amy Kempf
      - name: Inga Nehlmeier
      - name: Luise Graichen
      - name: Anzhalika Sidarovich
      - name: Anna-Sophie Moldenhauer
      - name: Martin S Winkler
      - name: Sebastian Schulz
      - name: Hans-Martin Jaeck
      - name: Metodi V Stankov
      - name: Georg M. N. Behrens
      - name: Stefan Poehlmann
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu May 20 20:18:31 +0000 2021
      id: 1395474037866905600
      id_str: "1395474037866905606"
      text: >-
        üî• bioRxiv Molecular-biology preprint by M. Hoffmann et al:


        "SARS-CoV-2 variant B.1.617 is resistant to Bamlanivima‚Ä¶ https://t.co/uOoc6GFu46
      truncated: true
      entities:
        urls:
          - url: https://t.co/uOoc6GFu46
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "109399"
    doi: 10.1101/2020.04.23.20074575
    first_posted: 2020-04-28
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.23.20074575v1
    url: https://api.rxivist.org/v1/papers/109399
    title: Wisconsin April 2020 Election Not Associated with Increase in COVID-19
      Infection Rates
    category: public-and-global-health
    abstract: "Background: Wisconsin (WI) held a primary election in the midst of
      the COVID-19 pandemic. Live voting at polls was allowed despite concern
      over increasing the spread of COVID-19. In addition to 1.1 million
      absentee ballots cast, 453,222 persons voted live. The purpose of our
      study was to determine if an increase in COVID-19 activity was associated
      with the election. Methods: Using the voting age population for the United
      States (US), WI, and its 3 largest counties, and daily new COVID-19 case
      reports from various COVID-19 web-based dashboards, daily new case rates
      were calculated. With election day April 7, the incubation period included
      April 12-21. The new case activity in the rest of the US was compared with
      the Wisconsin activity during the incubation period. Results: WI daily new
      case rates were lower than those of the rest of the US for the 10-day
      period before the election and remained lower during the post exposure
      incubation period. The ratio of Wisconsin new case rates to US new case
      rates was 0.34 WI: 1 US for the 10 days leading up to the election and
      declined to 0.28 WI: 1 US for the 10-day post-incubation period after the
      election. Similar analysis for Milwaukee county showed a pre-election
      ratio of 1.02 Milwaukee: 1 US and after the election the ratio was 0.63
      Milwaukee: 1 US. Dane county had a pre-election ratio of 0.21 Dane: 1 US
      case, and it fell to 0.13 Dane: 1 US after the election. Waukesha county
      had a pre-election ratio of 0.27 Waukesha: 1 US case and that fell to 0.19
      Waukesha: 1 US after the election. Conclusions: There was no increase in
      COVID-19 new case daily rates observed for Wisconsin or its 3 largest
      counties following the election on April 7, 2020, as compared to the US,
      during the post-incubation interval period."
    authors:
      - name: Andrew C Berry
        orcid: http://orcid.org/0000-0001-8952-6559
      - name: Madhuri S Mulekar
        orcid: null
      - name: Bruce B Berry
        orcid: null
  comment:
    dislikes: 0
    thread: "7996288688"
    numReports: 0
    likes: 0
    id: "5390833960"
    createdAt: 2021-05-20T18:34:22
    author:
      username: disqus_MR50o7ZtSH
      about: ""
      name: Andrew
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_MR50o7ZtSH/
      url: ""
      location: ""
      id: "369691865"
    isApproved: true
    raw_message: >-
      PEER REVIEWED UPDATED PAPER:

      https://clinmedjournals.org/articles/jide/journal-of-infectious-diseases-and-epidemiology-jide-6-148.php?jid=jide.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.23.20074575v1
  tweets:
    - created_at: Fri May 21 12:17:41 +0000 2021
      id: 1395715419080740900
      id_str: "1395715419080740868"
      text: |-
        üí¨ medRxiv comment on "Wisconsin April 2020 Election ..."

        "PEER REVIEWED UPDATED PAPER:
        https://t.co/q7jN7jWcNU."

        https://t.co/yHwXoYBGaD
      truncated: false
      entities:
        urls:
          - url: https://t.co/q7jN7jWcNU
          - url: https://t.co/yHwXoYBGaD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 12:17:41 +0000 2021
      id: 1395715419764314000
      id_str: "1395715419764314113"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/96w1lfgg2e
      truncated: false
      entities:
        urls:
          - url: https://t.co/96w1lfgg2e
      in_reply_to_status_id: 1395715419080740900
      in_reply_to_status_id_str: "1395715419080740868"
- preprint:
    id: "83104"
    doi: 10.1101/2020.05.11.084202
    first_posted: 2020-05-12
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.05.11.084202v1
    url: https://api.rxivist.org/v1/papers/83104
    title: Metric and chronological time in human episodic memory
    category: neuroscience
    abstract: >-
      The relative contributions of metric and chronological time in the
      encoding of episodic memories are unknown. One hundred one healthy young
      adults viewed 48 unique episodes of visual events and were later tested on
      recall of the order of events (chronological time) and the precise timing
      of events (metric time). The behavioral results show that metric recall
      accuracy correlates with chronological accuracy for events within
      episodes, but does not play a role on larger time-scales across episodes.
      Functional magnetic resonance imaging during encoding and recall showed
      that metric time was represented in the posterior medial entorhinal
      cortex, as well as the temporal pole and the cerebellum, whereas
      chronological time was represented in a widespread brain network including
      the anterior lateral entorhinal cortex, hippocampus, parahippocampal
      cortex and the prefrontal cortex. We conclude that metric time has a role
      in episodic memory on short time-scales and is mainly subserved by medial
      temporal lobe structures.


      ### Competing Interest Statement


      The authors have declared no competing interest.
    authors:
      - name: Hallvard R√∏e Evensmoen
        orcid: http://orcid.org/0000-0002-2926-7476
      - name: Lars M. Rimol
        orcid: http://orcid.org/0000-0002-1243-0396
      - name: Henning Hoel Rise
        orcid: http://orcid.org/0000-0002-0954-4018
      - name: Tor Ivar Hansen
        orcid: null
      - name: Hamed Nili
        orcid: http://orcid.org/0000-0002-6629-7957
      - name: Anderson Winkler
        orcid: http://orcid.org/0000-0002-4169-9781
      - name: Asta H√•berg
        orcid: null
  comment:
    dislikes: 0
    thread: "8021687075"
    numReports: 0
    likes: 0
    id: "5390831307"
    createdAt: 2021-05-20T18:32:15
    author:
      username: hallvardreevensmoen
      about: ""
      name: Hallvard R√∏e Evensmoen
      isPowerContributor: false
      profileUrl: https://disqus.com/by/hallvardreevensmoen/
      url: ""
      location: ""
      id: "369691697"
    isApproved: true
    raw_message: Thank you so much, and thank you for creating such an excellent
      R-package. I`ll definitively include the citation.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.05.11.084202v1
  tweets:
    - created_at: Fri May 21 16:25:21 +0000 2021
      id: 1395777747054731300
      id_str: "1395777747054731264"
      text: >-
        üí¨ bioRxiv comment on "Metric and chronological time ..."


        "Thank you so much, and thank you for creating such an ex‚Ä¶ https://t.co/pe2ZeaogRt
      truncated: true
      entities:
        urls:
          - url: https://t.co/pe2ZeaogRt
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 16:25:22 +0000 2021
      id: 1395777747830591500
      id_str: "1395777747830591489"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/muz2C2wvuV
      truncated: false
      entities:
        urls:
          - url: https://t.co/muz2C2wvuV
      in_reply_to_status_id: 1395777747054731300
      in_reply_to_status_id_str: "1395777747054731264"
- preprint:
    id: "122406"
    doi: 10.1101/2020.12.19.423561
    first_posted: 2020-12-21
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.12.19.423561v1
    url: https://api.rxivist.org/v1/papers/122406
    title: Invasive garlic mustard demonstrates stronger relationships with
      pathotrophic than mycorrhizal fungi
    category: ecology
    abstract: Garlic mustard (Alliaria petiolata) has long been known to degrade
      mycorrhizal mutualisms in soils it invades and may also promote the
      abundance of microbial pathogens harmful to native plants or alter
      saprotrophic communities to disrupt nutrient cycling. Phenology of other
      invasive species, like Lepidium latifolium and Lonicera maackii, plays a
      role in their interactions with soil microbial communities, and so we may
      expect garlic mustard phenology to influence its effects on native soil
      microbiomes as well. Here, we investigate differences in fungal,
      bacterial, and archaeal community structure, as well as the abundance of
      key functional groups, between garlic mustard present, absent, and removed
      treatments in central-Illinois forest soils across different stages of the
      garlic mustard life cycle. Across its phenology, garlic mustard present
      soils had different overall fungal community structure and greater
      abundance of pathotrophic fungi than soils where garlic mustard was absent
      or removed. However, abundance of ectomycorrhizal and saprotrophic fungi
      as well as bacterial and archaeal community structure were similar between
      treatments and did not interact with garlic mustard phenology. The most
      abundant overall fungal taxon was a plant pathogen, Entorrhiza
      aschersoniana, that was greatest in garlic mustard present soils,
      particularly while the plants were flowering. These results support the
      hypothesis that invasive plants form active relationships with microbial
      pathogens that could contribute to their overall success in invading
      ecosystems.
    authors:
      - name: Joseph D. Edwards
        orcid: null
      - name: Wendy H Yang
        orcid: null
      - name: Anthony C. Yannarell
        orcid: null
  comment:
    dislikes: 0
    thread: "8325281704"
    numReports: 0
    likes: 0
    id: "5391745614"
    createdAt: 2021-05-21T14:14:59
    author:
      username: rgregthorn
      about: ""
      name: R Greg Thorn
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rgregthorn/
      url: ""
      location: ""
      id: "369732656"
    isApproved: true
    raw_message: Nice work and potentially an important concept in invasion biology,
      but please clarify the identification step of your bioinformatics
      pipeline. An approximate match in QIIME/UNITE is not an identification.
      Talaromyces marneffei is (we hope!) unlikely to be a common fungus in
      Illinois soils. It is a serious human pathogen that is, so far as we know,
      restricted to southeast Asia, centered on Laos, Cambodia and Vietnam. Some
      other IDs are equally suspect. Please don't let this get into print.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.12.19.423561v1
  tweets:
    - created_at: Fri May 21 20:12:54 +0000 2021
      id: 1395835011580969000
      id_str: "1395835011580968960"
      text: >-
        üí¨ bioRxiv comment on "Invasive garlic mustard demons..."


        "Nice work and potentially an important concept in invasi‚Ä¶ https://t.co/tovratjq84
      truncated: true
      entities:
        urls:
          - url: https://t.co/tovratjq84
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 21 20:12:54 +0000 2021
      id: 1395835012436594700
      id_str: "1395835012436594692"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IAxBtJFaSp
      truncated: false
      entities:
        urls:
          - url: https://t.co/IAxBtJFaSp
      in_reply_to_status_id: 1395835011580969000
      in_reply_to_status_id_str: "1395835011580968960"
- preprint:
    id: 140997
    metric: 5984
    title: Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike
      and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with
      Matrix-M Adjuvant
    url: https://api.rxivist.org/v1/papers/140997
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.05.442782v1
    doi: 10.1101/2021.05.05.442782
    category: immunology
    first_posted: 2021-05-05
    abstract: The 2019 outbreak of a severe respiratory disease caused by an
      emerging coronavirus, SARS-CoV-2, has spread globally with high morbidity
      and mortality. Co-circulating seasonal influenza has greatly diminished
      recently, but expected to return with novel strains emerging, thus
      requiring annual strain adjustments. We have developed a recombinant
      hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV)
      produced using an established recombinant insect cell expression system to
      produce nanoparticles. Influenza qNIV adjuvanted with Matrix-M was
      well-tolerated and induced robust antibody and cellular responses, notably
      against both homologous and drifted A/H3N2 viruses in Phase 1, 2, and 3
      trials. We also developed a full-length SARS-CoV-2 spike protein vaccine
      stable in the prefusion conformation (NVX-CoV2373) using the same platform
      technology. In phase 3 clinical trials, NVX-CoV2373 is highly immunogenic
      and protective against the prototype strain and B.1.1.7 variant. Here we
      describe the immunogenicity and efficacy of a combination quadrivalent
      seasonal flu and COVID-19 vaccine (qNIV/CoV2373). In ferret and hamster
      models, qNIV/CoV2373 vaccine produces high titer influenza
      hemagglutination inhibiting (HAI) and neutralizing antibodies against
      influenza A and B strains. The combination vaccine also elicited
      antibodies that block SARS-CoV-2 spike protein binding to the human
      angiotensin converting enzyme-2 (hACE2) receptor. Significantly, hamsters
      immunized with qNIV/CoV2373 vaccine and challenged with SARS-CoV-2 were
      protected against weight loss and were free of replicating SARS-CoV-2 in
      the upper and lower respiratory tract with no evidence of viral pneumonia.
      This study supports evaluation of qNIV/CoV2373 combination vaccine as a
      preventive measure for seasonal influenza and CoVID-19.
    authors:
      - name: Micheal J Massare
      - name: Nita Patel
      - name: Bin Zhou
      - name: Sonia Maciejewski
      - name: Rhonda Flores
      - name: Mimi Guebre-Xabier
      - name: Jing-Hui Tian
      - name: Alyse D Portnoff
      - name: Louis Fries
      - name: Vivek Shinde
      - name: Larry R Ellingsworth
      - name: Greg Glenn
      - name: Gale Smith
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Fri May 21 20:20:50 +0000 2021
      id: 1395837005880246300
      id_str: "1395837005880246276"
      text: >-
        üî• bioRxiv Immunology preprint by M. J. Massare et al:


        "Combination Respiratory Vaccine Containing Recombinant SARS‚Ä¶ https://t.co/JDSzZdP5dZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/JDSzZdP5dZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "40679"
    doi: 10.1101/507590
    first_posted: 2018-12-28
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/507590v4
    url: https://api.rxivist.org/v1/papers/40679
    title: Plants emit informative airborne sounds under stress
    category: plant-biology
    abstract: Stressed plants show altered phenotypes, including changes in color,
      smell, and shape. Yet, the possibility that plants emit airborne sounds
      when stressed ‚Äì similarly to many animals ‚Äì has not been investigated.
      Here we show, to our knowledge for the first time, that stressed plants
      emit airborne sounds that can be recorded remotely, both in acoustic
      chambers and in greenhouses. We recorded ‚àº65 dBSPL ultrasonic sounds 10 cm
      from tomato and tobacco plants, implying that these sounds could be
      detected by some organisms from up to several meters away. We developed
      machine learning models that were capable of distinguishing between plant
      sounds and general noises, and identifying the condition of the plants ‚Äì
      dry, cut, or intact ‚Äì based solely on the emitted sounds. Our results
      suggest that animals, humans, and possibly even other plants, could use
      sounds emitted by a plant to gain information about the plant‚Äôs condition.
      More investigation on plant bioacoustics in general and on sound emission
      in plants in particular may open new avenues for understanding plants and
      their interactions with the environment, and it may also have a
      significant impact on agriculture.
    authors:
      - name: I. Khait
        orcid: null
      - name: Ohad Lewin-Epstein
        orcid: http://orcid.org/0000-0002-8636-9006
      - name: R. Sharon
        orcid: null
      - name: K. Saban
        orcid: null
      - name: R. Perelman
        orcid: null
      - name: A. Boonman
        orcid: null
      - name: Y. Yovel
        orcid: null
      - name: L. Hadany
        orcid: null
  comment:
    dislikes: 0
    thread: "7743645557"
    numReports: 0
    likes: 0
    id: "5392045414"
    createdAt: 2021-05-21T18:32:43
    author:
      username: disqus_TTEjfexw3K
      about: ""
      name: Hoya
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_TTEjfexw3K/
      url: ""
      location: ""
      id: "327716968"
    isApproved: true
    raw_message: Its caused by cavitations that plants create within their cells
      when under stress. Like bubbles underwater carrying sound.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/507590v4
  tweets:
    - created_at: Sat May 22 00:38:55 +0000 2021
      id: 1395901953939497000
      id_str: "1395901953939496960"
      text: >-
        üí¨ bioRxiv comment on "Plants emit informative airbor..."


        "Its caused by cavitations that plants create within thei‚Ä¶ https://t.co/QqqYwscFw8
      truncated: true
      entities:
        urls:
          - url: https://t.co/QqqYwscFw8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 00:38:55 +0000 2021
      id: 1395901954744856600
      id_str: "1395901954744856576"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/j5uJLr3XOS
      truncated: false
      entities:
        urls:
          - url: https://t.co/j5uJLr3XOS
      in_reply_to_status_id: 1395901953939497000
      in_reply_to_status_id_str: "1395901953939496960"
- preprint:
    id: "142319"
    doi: 10.1101/2021.05.18.443629
    first_posted: 2021-05-18
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.18.443629v1
    url: https://api.rxivist.org/v1/papers/142319
    title: "Whole-ExM: Expansion microscopy imaging of all anatomical structures of
      whole larval zebrafish"
    category: developmental-biology
    abstract: Nanoscale imaging of all anatomical structures over whole vertebrates
      is needed for a systematic understanding of human diseases, but this has
      not yet been achieved. Here, we demonstrate whole-ExM, which enables
      nanoscale imaging of all anatomical structures of whole zebrafish larvae
      by labeling the proteins of the larvae with fluorophores and expanding
      them four-fold. We first optimize the fluorophore selection and labeling
      procedure to visualize a broader range of anatomical structures. We then
      develop an expansion protocol for zebrafish larvae having calcified body
      parts. Through this process, we visualize the nanoscale details of diverse
      larvae organs, which have corresponding organ counterparts in humans, over
      the intact larvae. We show that whole-ExM retains the fluorescence signals
      of fluorescent proteins, and its resolution is high enough to visualize
      various structures that can be imaged only with electron microscopy.
      Whole-ExM would enable the nanoscale study of the molecular mechanisms of
      human diseases.
    authors:
      - name: Jueun Sim
        orcid: null
      - name: Chan E Park
        orcid: null
      - name: In Cho
        orcid: null
      - name: Kyeongbae Min
        orcid: null
      - name: Jeong-Soo Lee
        orcid: null
      - name: Yosep Chong
        orcid: null
      - name: Jeewon Kim
        orcid: null
      - name: Jeong Seuk Kang
        orcid: null
      - name: Kiryl D Piatkevich
        orcid: http://orcid.org/0000-0002-7777-9468
      - name: Erica E. Jung
        orcid: null
      - name: Seok-Kyu Kwon
        orcid: http://orcid.org/0000-0002-7280-9867
      - name: Young-Gyu Yoon
        orcid: null
      - name: Edward S. Boyden
        orcid: http://orcid.org/0000-0002-0419-3351
      - name: Jae-Byum Chang
        orcid: null
  comment:
    dislikes: 0
    thread: "8530175268"
    numReports: 0
    likes: 1
    id: "5391279863"
    createdAt: 2021-05-21T02:22:22
    author:
      username: jaebyumchang
      about: ""
      name: jaebyumchang
      isPowerContributor: false
      profileUrl: https://disqus.com/by/jaebyumchang/
      url: ""
      location: ""
      id: "369710841"
    isApproved: true
    raw_message: >-
      Hi Dr. Whitfield, 


      Thank you so much for letting us know the identity of the unknown structures. Also, thank you for letting us know the details on olfactory rod cells! We will add those information to the manuscript when we submit a revised version!
    forum: biorxivstage
    points: 1
    link: https://www.biorxiv.org/content/10.1101/2021.05.18.443629v1
  tweets:
    - created_at: Sat May 22 12:16:36 +0000 2021
      id: 1396077534270288000
      id_str: "1396077534270287874"
      text: |-
        üí¨ bioRxiv comment on "Whole-ExM: Expansion microscop..."

        "Hi Dr. Whitfield, 

        Thank you so much for letting us kno‚Ä¶ https://t.co/UWYBUOEONU
      truncated: true
      entities:
        urls:
          - url: https://t.co/UWYBUOEONU
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 12:16:36 +0000 2021
      id: 1396077535255941000
      id_str: "1396077535255941120"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/IDj4DEiLfL
      truncated: false
      entities:
        urls:
          - url: https://t.co/IDj4DEiLfL
      in_reply_to_status_id: 1396077534270288000
      in_reply_to_status_id_str: "1396077534270287874"
- preprint:
    id: "108561"
    doi: 10.1101/2020.04.08.20058743
    first_posted: 2020-04-11
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2020.04.08.20058743v1
    url: https://api.rxivist.org/v1/papers/108561
    title: A stochastic model for COVID-19 spread and the effects of Alert Level 4
      in Aotearoa New Zealand
    category: epidemiology
    abstract: While case numbers remain low, population-wide control methods
      combined with efficient tracing, testing, and case isolation, offer the
      opportunity for New Zealand to contain and eliminate COVID-19. We use a
      stochastic model to investigate containment and elimination scenarios for
      COVID-19 in New Zealand, as the country considers the exit from its four
      week period of strong Level 4 population-wide control measures. In
      particular we consider how the effectiveness of its case isolation
      operations influence the outcome of lifting these strong population-wide
      controls. The model is parameterised for New Zealand and is initialised
      using current case data, although we do not make use of information
      concerning the geographic dispersion of cases and the model is not
      stratified for age or co-morbidities. We find that fast tracing and case
      isolation (i.e. operations that are sustained at rates comparable to that
      at the early stages of New Zealand's response) can lead to containment or
      elimination, as long as strong population-wide controls remain in place.
      Slow case isolation can lead to containment (but not elimination) as long
      as strong Level 4 population-wide controls remain in place. However, we
      find that relaxing strong population-wide controls after four weeks will
      most likely lead to a further outbreak, although the speed of growth of
      this outbreak can be reduced by fast case isolation, by tracing, testing,
      or otherwise. We find that elimination is only likely if case isolation is
      combined with strong population-wide controls that are maintained for
      longer than four weeks. Further versions of this model will include an
      age-structured population as well as considering the effects of geographic
      dispersion and contact network structure, the possibility of regional
      containment combined with inter-regional travel restrictions, and the
      potential for harm to at risk communities and essential workers.
    authors:
      - name: Michael J Plank
        orcid: http://orcid.org/0000-0002-7539-3465
      - name: Rachelle N Binny
        orcid: http://orcid.org/0000-0002-3433-0417
      - name: Shaun C Hendy
        orcid: http://orcid.org/0000-0003-3468-6517
      - name: Audrey Lustig
        orcid: http://orcid.org/0000-0002-0869-3847
      - name: Alex James
        orcid: http://orcid.org/0000-0002-1543-7139
      - name: Nicholas Steyn
        orcid: null
  comment:
    dislikes: 0
    thread: "7964122231"
    numReports: 0
    likes: 0
    id: "5392404304"
    createdAt: 2021-05-22T00:45:46
    author:
      username: disqus_Pc9ZQufNd1
      about: ""
      name: Michael Plank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Pc9ZQufNd1/
      url: ""
      location: ""
      id: "369642137"
    isApproved: true
    raw_message: "The model and results in this pre-print are now part of an article
      published in the Journal of the Royal Society of New Zealand, available
      open access at: https://doi.org/10.1080/03036758.2021.1876111"
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2020.04.08.20058743v1
  tweets:
    - created_at: Sat May 22 16:23:52 +0000 2021
      id: 1396139760490528800
      id_str: "1396139760490528768"
      text: >-
        üí¨ medRxiv comment on "A stochastic model for COVID-1..."


        "The model and results in this pre-print are now part of‚Ä¶ https://t.co/D1dj1ptVum
      truncated: true
      entities:
        urls:
          - url: https://t.co/D1dj1ptVum
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 16:23:52 +0000 2021
      id: 1396139761279115300
      id_str: "1396139761279115271"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/2qx6zHwlI9
      truncated: false
      entities:
        urls:
          - url: https://t.co/2qx6zHwlI9
      in_reply_to_status_id: 1396139760490528800
      in_reply_to_status_id_str: "1396139760490528768"
- preprint:
    id: "142725"
    doi: 10.1101/2021.05.19.21257429
    first_posted: 2021-05-21
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.19.21257429v1
    url: https://api.rxivist.org/v1/papers/142725
    title: "Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with
      COVID-19 compared to standard treatment: Randomized controlled trial"
    category: epidemiology
    abstract: "Background: COVID-19 is a pandemic disease caused by SARS-CoV-2,
      which is an RNA virus similar to HCV in the replication process.
      Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV
      infection. This study investigates the efficacy of Sofosbuvir/ledipasvir
      as a treatment for patients with moderate COVID-19 infection.. Methods:
      This is a single-blinded parallel-randomized controlled trial. The
      participants were randomized equally into the intervention group received
      Sofosbuvir/ledipasvir (S.L. group), and the control group received
      Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary
      outcomes were the cure rate over time and the incidence of serious adverse
      events. The secondary outcomes included the laboratory findings. Results:
      Two hundred and fifty patients were divided equally into each group. Both
      groups were similar regarding gender, but age was higher in the S.L. group
      (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only
      51 (40.8%) patients were cured in the OCH group. The cure rate was
      significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir
      plot showed a considerably higher cure over time in the S.L. group
      (Log-rank test, p=0.032). There were no deaths in the S.L. group, but
      there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven
      patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group
      were admitted to ICU (RR=1.17, P=0.776). There was no significant
      difference between treatment groups regarding Total Leukocyte Count,
      Neutrophils count, Lymph, Alanine transaminase, and Urea. Conclusion:
      Sofosbuvir/ledipasvir is suggestive of being effective in treating
      patients with moderate COVID-19 infection. Further studies are needed to
      compare Sofosbuvir/ledipasvir with the new treatment protocols."
    authors:
      - name: Mohamed Abdel-Salam Elgohary
        orcid: null
      - name: Eman Medhat Hasan
        orcid: null
      - name: Amany Ahmad Ibrahim
        orcid: null
      - name: Mohamed Farouk Ahmed
        orcid: null
      - name: Raafat Zaher Abdel-Rahman
        orcid: null
      - name: Ashraf Ibrahim Zaki
        orcid: null
      - name: Mohamed Bakr Elaatar
        orcid: null
      - name: Mohamed Thabet Elnagar
        orcid: null
      - name: Mohamed Emam Emam
        orcid: null
      - name: Mahmoud Moustafa Hamada
        orcid: null
      - name: Taimour Mohamed Abdel-Hamid
        orcid: null
      - name: Ahmad Samir Abdel-Hafez
        orcid: null
      - name: Mohamed G. Seadawy
        orcid: null
      - name: Ahmad Rashad Fatoh
        orcid: null
      - name: Mohamed Ali Elsaied
        orcid: null
      - name: Marwa Abdel-Rahman Sakr
        orcid: null
      - name: Ahmed Omar Elkady
        orcid: null
      - name: Mohamed Muawad Shehata
        orcid: null
      - name: Osama Mohamed Nawar
        orcid: null
      - name: Mohamed Abu-elnaga Selem
        orcid: null
      - name: Mohamed Saeed Abd-aal
        orcid: null
      - name: Hany Hafez Lotfy
        orcid: null
      - name: Tarek Refaat Elnagdy
        orcid: null
      - name: Sherine Helmy
        orcid: null
      - name: Magdy Amin Mubark
        orcid: null
  comment:
    dislikes: 0
    thread: "8539627995"
    numReports: 0
    likes: 0
    id: "5392315732"
    createdAt: 2021-05-21T22:52:28
    author:
      username: ilmarihaavisto
      about: ""
      name: Ilmari Haavisto
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ilmarihaavisto/
      url: ""
      location: ""
      id: "296100347"
    isApproved: true
    raw_message: The beginning state of medication of disease is very important. Was
      it equal to both groups?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1
  tweets:
    - created_at: Sat May 22 20:12:23 +0000 2021
      id: 1396197267585917000
      id_str: "1396197267585916930"
      text: >-
        üí¨ medRxiv comment on "Efficacy of Sofosbuvir plus Le..."


        "The beginning state of medication of disease is very imp‚Ä¶ https://t.co/cXiiRrQtyz
      truncated: true
      entities:
        urls:
          - url: https://t.co/cXiiRrQtyz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 22 20:12:23 +0000 2021
      id: 1396197268554846200
      id_str: "1396197268554846209"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/xi29SUZYMS
      truncated: false
      entities:
        urls:
          - url: https://t.co/xi29SUZYMS
      in_reply_to_status_id: 1396197267585917000
      in_reply_to_status_id_str: "1396197267585916930"
- preprint:
    id: "132578"
    doi: 10.1101/2021.03.07.21253098
    first_posted: 2021-03-09
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.07.21253098v1
    url: https://api.rxivist.org/v1/papers/132578
    title: The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by
      non-neutralizing antibodies that target both the NTD and the RBD
    category: infectious-diseases
    abstract: In this study we profiled vaccine-induced polyclonal antibodies as
      well as plasmablast derived mAbs from subjects who received SARS-CoV-2
      spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust
      and comparable to or exceeded those seen after natural infection. However,
      that the ratio of binding to neutralizing antibodies after vaccination was
      greater than that after natural infection and, at the monoclonal level, we
      found that the majority of vaccine-induced antibodies did not have
      neutralizing activity. We also found a co-dominance of mAbs targeting the
      NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like
      backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins.
      Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical
      viral isolate carrying E484K as well as extensive changes in the NTD was
      abolished, suggesting that a proportion of vaccine induced RBD binding
      antibodies may provide substantial protection against viral variants
      carrying E484K.
    authors:
      - name: Fatima Amanat
        orcid: http://orcid.org/0000-0002-8029-8227
      - name: Mahima Thapa
        orcid: null
      - name: Tingting Lei
        orcid: null
      - name: Shaza M. Sayed Ahmed
        orcid: null
      - name: Daniel C. Adelsberg
        orcid: null
      - name: Juan Manuel Carreno
        orcid: null
      - name: Shirin Strohmeier
        orcid: null
      - name: Aaron J Schmitz
        orcid: null
      - name: Sarah Zafar
        orcid: null
      - name: Julian Q Zhou
        orcid: http://orcid.org/0000-0001-9602-2092
      - name: Willemijn Rijnink
        orcid: null
      - name: Hala Alshammary
        orcid: null
      - name: Nicholas Borcherding
        orcid: http://orcid.org/0000-0003-1427-6342
      - name: Ana Gonzalez Reiche
        orcid: null
      - name: Komal Srivastava
        orcid: null
      - name: Emilia M Sordillo
        orcid: http://orcid.org/0000-0001-7787-3051
      - name: Harm van Bakel
        orcid: http://orcid.org/0000-0002-1376-6916
      - name: Jackson S Turner
        orcid: http://orcid.org/0000-0002-4396-6265
      - name: Goran Bajic
        orcid: http://orcid.org/0000-0003-0480-4324
      - name: Viviana M Simon
        orcid: null
      - name: Ali H. Ellebedy
        orcid: http://orcid.org/0000-0002-6129-2532
      - name: Florian Krammer
        orcid: http://orcid.org/0000-0003-4121-776X
  comment:
    dislikes: 0
    thread: "8501801389"
    numReports: 0
    likes: 0
    id: "5392249349"
    createdAt: 2021-05-21T21:38:46
    author:
      username: lbaustin
      about: ""
      name: lbaustin
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lbaustin/
      url: ""
      location: Austin, TX
      id: "7360516"
    isApproved: true
    raw_message: Has this been submitted to a MEDLINE indexed journal?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.03.07.21253098v2
  tweets:
    - created_at: Sun May 23 00:44:16 +0000 2021
      id: 1396265688575119400
      id_str: "1396265688575119365"
      text: |-
        üí¨ medRxiv comment on "The plasmablast response to SA..."

        "Has this been submitted to a MEDLINE indexed journal?"

        https://t.co/uVjMN8D3Ce
      truncated: false
      entities:
        urls:
          - url: https://t.co/uVjMN8D3Ce
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 00:44:16 +0000 2021
      id: 1396265689401499600
      id_str: "1396265689401499651"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/lNgUKY3gxH
      truncated: false
      entities:
        urls:
          - url: https://t.co/lNgUKY3gxH
      in_reply_to_status_id: 1396265688575119400
      in_reply_to_status_id_str: "1396265688575119365"
- preprint:
    id: "139760"
    doi: 10.1101/2021.04.21.21255898
    first_posted: 2021-04-27
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.04.21.21255898v1
    url: https://api.rxivist.org/v1/papers/139760
    title: Practical Indicators for Risk of Airborne Transmission in Shared Indoor
      Environments and their application to COVID-19 Outbreaks
    category: infectious-diseases
    abstract: "Some infectious diseases, including COVID-19, can be transmitted via
      aerosols that are emitted by an infectious person and inhaled by
      susceptible individuals. Although physical distancing effectively reduces
      short-range airborne transmission, many infections have occurred when
      sharing room air despite maintaining distancing. We propose two simple
      parameters as indicators of infection risk for this situation. They
      combine the key factors that control airborne disease transmission
      indoors: virus-containing aerosol generation rate, breathing flow rate,
      masking and its quality, ventilation and air cleaning rates, number of
      occupants, and duration of exposure. COVID-19 outbreaks show a clear trend
      in relation to these parameters that is consistent with an airborne
      infection model, supporting the importance of airborne transmission for
      these outbreaks. The observed trends of outbreak size vs. risk parameters
      allow us to recommend values of the parameters to minimize COVID-19 indoor
      infection risk. All of the pre-pandemic spaces are in a regime where they
      are highly sensitive to mitigation efforts. Measles outbreaks occur at
      much lower risk parameter values than COVID-19, while tuberculosis
      outbreaks are observed at much higher risk parameter values. Since both
      diseases are accepted as airborne, the fact that COVID-19 is less
      contagious than measles does not rule out airborne transmission. It is
      important that future outbreak reports include ventilation information, to
      allow expanding our knowledge of the circumstances conducive to airborne
      transmission of different diseases."
    authors:
      - name: Zhe Peng
        orcid: http://orcid.org/0000-0002-6823-452X
      - name: William Bahnfleth
        orcid: null
      - name: Giorgio Buonanno
        orcid: null
      - name: Stephanie J. Dancer
        orcid: null
      - name: Jarek Kurnitski
        orcid: null
      - name: Yuguo Li
        orcid: http://orcid.org/0000-0002-2281-4529
      - name: Marcel G.L.C. Loomans
        orcid: null
      - name: Linsey C. Marr
        orcid: http://orcid.org/0000-0003-3628-6891
      - name: Lidia Morawska
        orcid: null
      - name: William Nazaroff
        orcid: null
      - name: Catherine Noakes
        orcid: null
      - name: Xavier Querol
        orcid: null
      - name: Chandra Sekhar
        orcid: null
      - name: Raymond Tellier
        orcid: null
      - name: Trisha Greenhalgh
        orcid: http://orcid.org/0000-0003-2369-8088
      - name: Lydia Bourouiba
        orcid: null
      - name: Atze Boerstra
        orcid: null
      - name: Julian Tang
        orcid: null
      - name: Shelly Miller
        orcid: http://orcid.org/0000-0002-1967-7551
      - name: Jose L Jimenez
        orcid: http://orcid.org/0000-0001-6203-1847
  comment:
    dislikes: 0
    thread: "8509938572"
    numReports: 0
    likes: 0
    id: "5392210208"
    createdAt: 2021-05-21T20:59:55
    author:
      username: haroldthimbleby
      about: ""
      name: Harold Thimbleby
      isPowerContributor: false
      profileUrl: https://disqus.com/by/haroldthimbleby/
      url: ""
      location: ""
      id: "369749286"
    isApproved: true
    raw_message: >-
      From harold@thimbleby.net


      I mailed the author for correspondence constructively two weeks ago but I have had no reply. 


      I am a professor of computer science. The Excel spreadsheet is, sadly, appalling and needs a lot of professional work to be believable. There is no useful documentation about how it is intended to work. It is obscure and impossible to check. I doubt it is correct, unless evidence can be provided. In short, the results described in this paper cannot be relied on or used for any public health purposes.


      Have any of the authors carefully reviewed the spreadsheet? Any independent parties? If so I think the paper should say so.


      Best wishes, though, with this important work.


      -Harold
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.04.21.21255898v2
  tweets:
    - created_at: Sun May 23 12:16:57 +0000 2021
      id: 1396440010526691300
      id_str: "1396440010526691328"
      text: |-
        üí¨ medRxiv comment on "Practical Indicators for Risk ..."

        "From harold@thimbleby.net

        I mailed the author for corre‚Ä¶ https://t.co/T2EYF5Er7Y
      truncated: true
      entities:
        urls:
          - url: https://t.co/T2EYF5Er7Y
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 12:16:58 +0000 2021
      id: 1396440011516567600
      id_str: "1396440011516567557"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/t6Sw09nOAz
      truncated: false
      entities:
        urls:
          - url: https://t.co/t6Sw09nOAz
      in_reply_to_status_id: 1396440010526691300
      in_reply_to_status_id_str: "1396440010526691328"
- preprint:
    id: "141912"
    doi: 10.1101/2021.05.15.21257017
    first_posted: 2021-05-17
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.15.21257017v1
    url: https://api.rxivist.org/v1/papers/141912
    title: Extended interval BNT162b2 vaccination enhances peak antibody generation
      in older people
    category: infectious-diseases
    abstract: "Abstract Objectives: To assess the relative immunogenicity of
      standard or extended interval BNT162b2 vaccination. Design: Population
      based cohort study comparing immune responses 2 weeks after the second
      vaccine, with appropriate time-matched samples in participants who
      received standard or extended interval double vaccination. Setting:
      Primary care networks, Birmingham, UK. December 2020 to April 2021.
      Participants: 175 people aged over 80 years of age. All donors received
      the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a
      standard 3 week interval between doses or an extended interval schedule.
      Main outcome measures: Peak quantitative spike-specific antibody and
      cellular immune responses. Results: In donors without evidence of previous
      infection the peak antibody response was 3.5-fold higher in donors who had
      undergone delayed interval vaccination. Cellular immune responses were
      3.6-fold lower. Conclusion: Peak antibody responses after the second
      BNT162b2 vaccine are markedly enhanced in older people when this is
      delayed to 12 weeks although cellular responses are lower. Extended
      interval vaccination may therefore offer the potential to enhance and
      extend humoral immunity. Further follow up is now required to assess long
      term immunity and clinical protection."
    authors:
      - name: Helen M Parry
        orcid: http://orcid.org/0000-0002-9707-8167
      - name: Rachel Bruton
        orcid: null
      - name: Christine Stephens
        orcid: null
      - name: Kevin Brown
        orcid: null
      - name: Gayatri Amirthalingam
        orcid: http://orcid.org/0000-0003-2078-0975
      - name: Bassam Hallis
        orcid: http://orcid.org/0000-0002-8461-0038
      - name: Ashley Otter
        orcid: null
      - name: Jianmin Zuo
        orcid: http://orcid.org/0000-0002-8341-465X
      - name: Paul Moss
        orcid: null
  comment:
    dislikes: 0
    thread: "8524358522"
    numReports: 0
    likes: 0
    id: "5392137838"
    createdAt: 2021-05-21T19:55:16
    author:
      username: honourary
      about: ""
      name: Honourary
      isPowerContributor: false
      profileUrl: https://disqus.com/by/honourary/
      url: ""
      location: ""
      id: "345738756"
    isApproved: true
    raw_message: All of your concerns about potential sample bias are covered in the
      section titled ‚ÄòStatistical Analysis‚Äô. It wasn‚Äôt a random split because
      they couldn‚Äôt assume a normal distribution.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1
  tweets:
    - created_at: Sun May 23 16:23:59 +0000 2021
      id: 1396502175510003700
      id_str: "1396502175510003715"
      text: >-
        üí¨ medRxiv comment on "Extended interval BNT162b2 vac..."


        "All of your concerns about potential sample bias are cov‚Ä¶ https://t.co/xoGuOMEqzI
      truncated: true
      entities:
        urls:
          - url: https://t.co/xoGuOMEqzI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 23 16:23:59 +0000 2021
      id: 1396502176499835000
      id_str: "1396502176499834883"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/x0AIV2XumU
      truncated: false
      entities:
        urls:
          - url: https://t.co/x0AIV2XumU
      in_reply_to_status_id: 1396502175510003700
      in_reply_to_status_id_str: "1396502175510003715"
- preprint:
    id: 140428
    metric: 4531
    title: N440K variant of SARS-CoV-2 has Higher Infectious Fitness
    url: https://api.rxivist.org/v1/papers/140428
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.30.441434v1
    doi: 10.1101/2021.04.30.441434
    category: microbiology
    first_posted: 2021-04-30
    abstract: Several variants of SARS-CoV-2 have been emerging across the globe,
      continuing to threaten the efforts to end COVID-19 pandemic. Recent data
      indicate the prevalence of variants with N440K Spike substitution in
      several parts of India, which is under the second wave of the pandemic.
      Here, we first analyze the prevalence of N440K variants within the
      sequences submitted from India and identify a rising trend of its spread
      across various clusters. We then compare the replicative fitness and
      infectivity of a prototype of this variant with two other previously
      prevalent strains. The N440K variant produced ten times higher infectious
      viral titers than a prevalent A2a strain, and over 1000 folds higher
      titers than a much less prevalent A3i strain prototype in Caco2 cells.
      Similar results were detected in Calu-3 cells as well, confirming the
      increased potency of the N440K variant. Interestingly, A3i strain showed
      the highest viral RNA levels, but the lowest infectious titers in the
      culture supernatants, indicating the absence of correlation between the
      RNA content and the infectivity of the sample. N440K mutation has been
      reported in several viral sequences across India and based on our results,
      we predict that the higher infectious titers achieved by this strain could
      possibly lead to its higher rate of transmission. Availability of more
      sequencing data in the immediate future would help understand the
      potential spread of this variant in more detail.
    authors:
      - name: Dixit Tandel
      - name: Divya Gupta
      - name: Vishal Sah
      - name: Krishnan Harinivas Harshan
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 24 20:21:27 +0000 2021
      id: 1396924323974295600
      id_str: "1396924323974295556"
      text: >-
        üî• bioRxiv Microbiology preprint by D. Tandel et al:


        "N440K variant of SARS-CoV-2 has Higher Infectious Fitness"‚Ä¶ https://t.co/RaV0xfhP8O
      truncated: true
      entities:
        urls:
          - url: https://t.co/RaV0xfhP8O
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "119116"
    doi: 10.1101/2020.11.26.384925
    first_posted: 2020-11-27
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2020.11.26.384925v1
    url: https://api.rxivist.org/v1/papers/119116
    title: Muscle Van Gogh-like 2 shapes the neuromuscular synapse by regulating
      MuSK signaling activity
    category: neuroscience
    abstract: The development of the neuromuscular junction (NMJ) requires dynamic
      trans-synaptic coordination orchestrated by secreted factors, including
      the morphogens of the Wnt family. Yet, how the signal of these synaptic
      cues is transduced, and particularly during the regulation of
      acetylcholine receptor (AChR) accumulation in the postsynaptic membrane
      remains unclear. We explored the function of Van Gogh-Like protein 2
      (Vangl2), a core component of Wnt planar cell polarity signaling. We
      showed that the conditional genetic ablation of Vangl2 in muscle
      reproduces the NMJ differentiation defects in mice with constitutive
      Vangl2 deletion. These alterations persisted into adulthood with NMJs
      disassembly leading to an impairment of neurotransmission and motor
      function deficits. Mechanistically, we found that Vangl2 and the
      muscle-specific kinase MuSK acted in the same genetic pathway and that
      Vangl2 binds MuSK, thus controlling its signaling activity. Our results
      identify Vangl2 as a key player of the core complex of molecules shaping
      neuromuscular synapses and shed light on the molecular mechanisms
      underlying NMJ assembly.
    authors:
      - name: Myriam Bo√´x
        orcid: null
      - name: Julien Mess√©ant
        orcid: null
      - name: Steve Cottin
        orcid: null
      - name: Marius Halliez
        orcid: null
      - name: St√©phanie Bauch√©
        orcid: null
      - name: C√©line Buon
        orcid: null
      - name: Nathalie Sans
        orcid: http://orcid.org/0000-0001-7658-2471
      - name: M Montcouquiol
        orcid: http://orcid.org/0000-0001-8739-6519
      - name: Jordi Molg√≥
        orcid: null
      - name: Muriel Amar
        orcid: null
      - name: Arnaud Ferry
        orcid: null
      - name: M√©gane Lemaitre
        orcid: null
      - name: Andr√©e Rouche
        orcid: null
      - name: Dominique Langui
        orcid: null
      - name: Asha Baskaran
        orcid: null
      - name: Bertrand Fontaine
        orcid: null
      - name: Laure Strochlic
        orcid: http://orcid.org/0000-0001-5373-4284
  comment:
    dislikes: 0
    thread: "8319683835"
    numReports: 0
    likes: 0
    id: "5395644447"
    createdAt: 2021-05-24T22:53:30
    author:
      username: disqus_Dfdg8RCumO
      about: ""
      name: ESHA CHAWLA
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Dfdg8RCumO/
      url: ""
      location: ""
      id: "369904596"
    isApproved: true
    raw_message: >-
      Recently, my biomedical research seminar had the opportunity to read and
      discuss your paper. Detailed below are some of the comments we had on your
      work. 


      Strengths: We appreciated your figures also diagrammed your methods ‚Äì for example, Figure 1A made it extremely clear what you were knocking out and how you were doing so. We also really appreciated that your figures were not all graphs/quantitative data, but also the IHC stains that were eventually used for data analysis (i.e. Figures 1D, 2C, 3A, 6C, 7A). 


      Weaknesses/Suggestions: While we did appreciate the IHC images, the quantitative graphs were too small and need to be enlarged to allow for easier data analysis. Additionally, certain figures were redundant ‚Äì for example, both 4A and 4B show absolute force; similarly, both 4E and 4D show stimulation frequency and CMAP amplitude. Such redundancies convoluted the conversation, as students were confused what new information (if any) they were being presented with. Finally, the images need to be made more accessible to all readers ‚Äì consider using magenta/blue stains to make data readable to colorblind readers, and include arrows in IHC stains so readers know what they are looking for. 


      Overall, we really appreciated your scientific writing and the significance of your work ‚Äì finding the mechanism by which Vangl2 interacts with MuSK to affect neuromuscular activity. We believe that with these small revisions, you can improve your data presentation and make the science more accessible to the readers.
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2020.11.26.384925v2
  tweets:
    - created_at: Tue May 25 00:41:03 +0000 2021
      id: 1396989657552855000
      id_str: "1396989657552855042"
      text: >-
        üí¨ bioRxiv comment on "Muscle Van Gogh-like 2 shapes ..."


        "Recently, my biomedical research seminar had the opportu‚Ä¶ https://t.co/tMlUNXAwM5
      truncated: true
      entities:
        urls:
          - url: https://t.co/tMlUNXAwM5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 25 00:41:04 +0000 2021
      id: 1396989658685329400
      id_str: "1396989658685329408"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/WW8Eaz1Ksz
      truncated: false
      entities:
        urls:
          - url: https://t.co/WW8Eaz1Ksz
      in_reply_to_status_id: 1396989657552855000
      in_reply_to_status_id_str: "1396989657552855042"
- preprint:
    id: "143059"
    doi: 10.1101/2021.05.24.445329
    first_posted: 2021-05-24
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.24.445329v1
    url: https://api.rxivist.org/v1/papers/143059
    title: Principles of gene regulation quantitatively connect DNA to RNA and
      proteins in bacteria
    category: systems-biology
    abstract: "Bacteria allocate their proteome to cellular functions differently in
      different growth conditions. It is largely unknown how such allocation
      arises from known mechanisms of gene regulation while constrained by
      limited translation capacity and fixed protein density. Here, we performed
      absolute transcriptomic and proteomic analysis for E. coli across many
      conditions, obtaining a plethora of results on promoters and mRNAs
      characteristics that clash with conventional expectations: the majority of
      mRNAs exhibit similar translational efficiencies, while the promoter
      strengths are vastly different across genes. These characteristics
      prescribe two principles of gene regulation guiding bacteria to attain the
      desired protein allocation under global constraints: Total transcriptional
      output is tightly coordinated with ribosomal activity, and the
      concentrations of individual proteins are largely set by transcription.
      These two principles lead to a quantitative formulation of Central Dogma
      which unravels the complex relationship between gene regulatory activities
      and mRNA/protein concentrations across conditions. The knowledge obtained
      will be invaluable for accurately inferring gene regulatory interactions
      from 'omics data, as well as for guiding the design of genetic circuits
      for synthetic biology applications in E. coli and other organisms."
    authors:
      - name: Rohan Balakrishnan
        orcid: http://orcid.org/0000-0002-7547-8565
      - name: Matteo Mori
        orcid: http://orcid.org/0000-0002-6263-8021
      - name: Igor Segota
        orcid: null
      - name: Zhongge Zhang
        orcid: http://orcid.org/0000-0002-6474-7045
      - name: Ruedi Aebersold
        orcid: http://orcid.org/0000-0002-9576-3267
      - name: Christina Ludwig
        orcid: http://orcid.org/0000-0002-6131-7322
      - name: Terence Hwa
        orcid: http://orcid.org/0000-0003-1837-6842
  comment:
    dislikes: 0
    thread: "8547788914"
    numReports: 0
    likes: 0
    id: "5395629598"
    createdAt: 2021-05-24T22:36:53
    author:
      username: disqus_QL326OaLB9
      about: ""
      name: Howard Salis
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_QL326OaLB9/
      url: https://plus.google.com/107639019335100166999
      location: ""
      id: "242280388"
    isApproved: true
    raw_message: >-
      Readers note: The authors make the following assumptions in all their
      analysis, which critically undermines several of their most important (and
      controversial) conclusions:


      1.   The authors are treating their ribosome profiling experiments as a measurement of translation rate. That's incorrect. Ribosome profiling measures the relative density of ribosomes bound to mRNAs. It is not a direct measurement of translation rate nor is it a direct measurement of translational efficiency.  


      Let me be clear with these terms: Translation rate is the number of proteins produced per mRNA per time. Translational efficiency is the number of proteins produced by a single transcript before it is degraded. Ribosome density is the translation initiation rate divided by the mRNA's translation elongation rate. 


      2.  The authors assume that all mRNAs have the same translation elongation rate in order to convert ribosome densities into translation rates. For example, in their Equation 5, epsilon (translation elongation rate) is just a single constant, used throughout to relate translation rates to protein synthesis rates and protein concentrations. This is incorrect. mRNAs do not all have the same translation elongation rate. There is a whole genre of literature on synonymous codon usage, the effects of synonymous codons on ribosome translocation speeds, and the use of codon optimization to increase heterologous protein expression levels. Epsilon is not a single constant. At the very least, if we only care about protein concentrations, one must consider the CDS-averaged translation elongation rate for each mRNA transcript in the transcriptome. 


      The authors' conclusion "Translation initiation rates are similar across mRNAs and growth conditions" needs to be revisited without assuming that all translation elongation rates are the same. Likewise, the conclusion that "Total mRNA abundance matches the translational capacity" depends on the veracity of this conclusion. The conclusion that "Constancy of ribosome spacing across mRNA and nutrient conditions" is more accurately viewed as "Constancy of *ribosome density* across mRNA and nutrient conditions".  Finally, the conclusion that "Total mRNA synthesis flux is adjusted to match translational capacity" is again dependent on the veracity of the first conclusion. 


      Concluding that all mRNAs have the same translation rate is bold. But it's not supported by data. If you see someone using ribosome profiling to make this claim, be skeptical!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.24.445329v1
  tweets:
    - created_at: Tue May 25 12:19:40 +0000 2021
      id: 1397165467492667400
      id_str: "1397165467492667398"
      text: >-
        üí¨ bioRxiv comment on "Principles of gene regulation ..."


        "Readers note: The authors make the following assumptions‚Ä¶ https://t.co/MaP8DWp5Ry
      truncated: true
      entities:
        urls:
          - url: https://t.co/MaP8DWp5Ry
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue May 25 12:19:40 +0000 2021
      id: 1397165468411179000
      id_str: "1397165468411179016"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/Q8gYXIKA8R
      truncated: false
      entities:
        urls:
          - url: https://t.co/Q8gYXIKA8R
      in_reply_to_status_id: 1397165467492667400
      in_reply_to_status_id_str: "1397165467492667398"
- preprint:
    id: "134118"
    doi: 10.1101/2021.03.19.436082
    first_posted: 2021-03-19
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.19.436082v1
    url: https://api.rxivist.org/v1/papers/134118
    title: Pronounced genetic separation among varieties of the Primula cusickiana
      species complex, a Great Basin endemic
    category: evolutionary-biology
    abstract: Distinguishing between unique species and populations with strong
      genetic structure is a common challenge in population genetics, especially
      in fragmented habitats where allopatric speciation may be widespread and
      distinct groups may be morphologically similar. Such is often the case
      with species complexes across sky island environments. In these scenarios,
      biogeography may help to explain the relations between species complex
      members, and RADseq methods are commonly used to compare closely related
      species across thousands of genetic loci. Here we use RADseq to clarify
      the relations between geographically distinct but morphologically similar
      varieties of the Primula cusickiana species complex, and to contextualize
      past findings of strong genetic structure among populations within
      varieties. Our genomic analyses demonstrate pronounced separation between
      isolated populations of this Great Basin endemic, indicating that the
      current varietal classification of complex members is inaccurate and
      emphasizing their conservation importance. We discuss how these results
      correspond to recent biogeographical models used to describe the
      distribution of other sky island taxa in western North America. Our
      findings also fit into a wider trend observed for alpine Primula species
      complexes, and we consider how heterostylous breeding systems may be
      contributing to frequent diversification via allopatric speciation in this
      genus.
    authors:
      - name: Austin Koontz
        orcid: http://orcid.org/0000-0002-6103-5894
      - name: William D. Pearse
        orcid: http://orcid.org/0000-0002-6241-3164
      - name: Paul Wolf
        orcid: http://orcid.org/0000-0002-4317-6976
  comment:
    dislikes: 0
    thread: "8444467131"
    numReports: 0
    likes: 0
    id: "5396630337"
    createdAt: 2021-05-25T18:52:04
    author:
      username: disqus_wmUv5Zir8n
      about: ""
      name: KW
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wmUv5Zir8n/
      url: ""
      location: ""
      id: "369275119"
    isApproved: true
    raw_message: Best of luck!
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.19.436082v1
  tweets:
    - created_at: Wed May 26 00:49:36 +0000 2021
      id: 1397354197306196000
      id_str: "1397354197306195970"
      text: |-
        üí¨ bioRxiv comment on "Pronounced genetic separation ..."

        "Best of luck!"

        https://t.co/7GhuBK9Fmx
      truncated: false
      entities:
        urls:
          - url: https://t.co/7GhuBK9Fmx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 00:49:37 +0000 2021
      id: 1397354198006653000
      id_str: "1397354198006652929"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/uqranEVcds
      truncated: false
      entities:
        urls:
          - url: https://t.co/uqranEVcds
      in_reply_to_status_id: 1397354197306196000
      in_reply_to_status_id_str: "1397354197306195970"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5397065865"
    createdAt: 2021-05-26T02:24:19
    author:
      username: disqus_WhklNKQ0tI
      about: ""
      name: ŸÖÿ±ÿ™ÿ∂€å ŸÜ€åÿß€å€å
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WhklNKQ0tI/
      url: ""
      location: ""
      id: "369965509"
    isApproved: true
    raw_message: Hi, I'm Dr.Niaee and I was surprised that even basic data from our
      RCT is completely mispresented and is WRONG. We had 60 indivisuals in
      control groups and 120 in intervention groups and even this simple thing
      is mispresrntated.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 12:22:00 +0000 2021
      id: 1397528445459091500
      id_str: "1397528445459091458"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Hi, I'm Dr.Niaee and I was surprised that even basic dat‚Ä¶ https://t.co/w47gys9bo0
      truncated: true
      entities:
        urls:
          - url: https://t.co/w47gys9bo0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 12:22:01 +0000 2021
      id: 1397528446302138400
      id_str: "1397528446302138368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397528445459091500
      in_reply_to_status_id_str: "1397528445459091458"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5397127949"
    createdAt: 2021-05-26T03:59:44
    author:
      username: stevekirsch
      about: ""
      name: Steve Kirsch
      isPowerContributor: false
      profileUrl: https://disqus.com/by/stevekirsch/
      url: ""
      location: ""
      id: "56290616"
    isApproved: true
    raw_message: >-
      Why hasn't this paper been retracted yet?


      They reversed the numbers for the Niaee study which was pivotal to their conclusion. See <a href="https://twitter.com/Covid19Crusher/status/1397214174766325765">this tweet from CovidAnalysis</a> for details on the switch. There is also a video from Niaee himself attesting to the fact ivermectin works. 


      When you use the correct data, it shows ivermectin works. No surprise.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 17:04:50 +0000 2021
      id: 1397599621183119400
      id_str: "1397599621183119360"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Why hasn't this paper been retracted yet?

        They reversed‚Ä¶ https://t.co/kAlMrYY2gp
      truncated: true
      entities:
        urls:
          - url: https://t.co/kAlMrYY2gp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 17:04:50 +0000 2021
      id: 1397599621908729900
      id_str: "1397599621908729857"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397599621183119400
      in_reply_to_status_id_str: "1397599621183119360"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5397292434"
    createdAt: 2021-05-26T09:30:26
    author:
      username: norbertszolnoky
      about: ""
      name: Norbert Szolnoky
      isPowerContributor: false
      profileUrl: https://disqus.com/by/norbertszolnoky/
      url: https://www.expertenglish.jp
      location: Toyama, Japan
      id: "105834632"
    isApproved: true
    raw_message: >-
      "...a yet-proven truth, that all the wearing of masks was futile..."

      Man, you are waaaay behind on real evidence. There's plenty of real research and data to show that no type of mask stops the SARS-CoV-2 virus and make no difference in COVID-19 infections, because the virus spreads through aerosol. 


      If you just wanna look at one place to see the list of evidence then look here: 

      1. https://swprs.org/face-masks-evidence/

      2. Or perhaps this section as well: 

      https://swprs.org/covid-update-may-2021/#virus-transmission
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed May 26 20:37:37 +0000 2021
      id: 1397653170063659000
      id_str: "1397653170063659010"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        ""...a yet-proven truth, that all the wearing of masks wa‚Ä¶ https://t.co/zF8gDOnd5L
      truncated: true
      entities:
        urls:
          - url: https://t.co/zF8gDOnd5L
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 20:37:37 +0000 2021
      id: 1397653171007328300
      id_str: "1397653171007328260"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1397653170063659000
      in_reply_to_status_id_str: "1397653170063659010"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5396809572"
    createdAt: 2021-05-25T21:27:31
    author:
      username: disqus_0dfmguf04M
      about: ""
      name: Alex
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0dfmguf04M/
      url: ""
      location: ""
      id: "366966096"
    isApproved: true
    raw_message: >-
      Can you please double check? 


      It is mentioned <a href=https://twitter.com/Covid19Crusher/status/1397214174766325765"#"><b>here</b></a> that arm data from the key Niaee study appears to have been swapped, and that when put back in the right order ivermectin worked much better than reported (66% lower risk of death, p=.031).
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Wed May 26 22:30:36 +0000 2021
      id: 1397681601409077200
      id_str: "1397681601409077252"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Can you please double check? 

        It is mentioned &lt;a href=‚Ä¶ https://t.co/nYKQIsLQXM
      truncated: true
      entities:
        urls:
          - url: https://t.co/nYKQIsLQXM
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed May 26 22:30:36 +0000 2021
      id: 1397681602247995400
      id_str: "1397681602247995392"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397681601409077200
      in_reply_to_status_id_str: "1397681601409077252"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5396747902"
    createdAt: 2021-05-25T20:30:08
    author:
      username: disqus_haqbHtjpTs
      about: ""
      name: Marek J
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_haqbHtjpTs/
      url: ""
      location: ""
      id: "246931175"
    isApproved: true
    raw_message: >-
      You have wrong data in the mortality analysis for Niaee study. You swaped
      IVM for Control. According to the study, 4 deaths from 116 occured in IVM
      and 11/49 occured in Control.


      Looking forward to your recalculation.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 01:44:53 +0000 2021
      id: 1397730495778234400
      id_str: "1397730495778234373"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "You have wrong data in the mortality analysis for Niaee‚Ä¶ https://t.co/XwOJDZoO7X
      truncated: true
      entities:
        urls:
          - url: https://t.co/XwOJDZoO7X
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 01:44:53 +0000 2021
      id: 1397730496461918200
      id_str: "1397730496461918212"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397730495778234400
      in_reply_to_status_id_str: "1397730495778234373"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 5
    id: "5397814595"
    createdAt: 2021-05-26T17:57:17
    author:
      username: disqus_4sBBARIHtf
      about: ""
      name: Jeremy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_4sBBARIHtf/
      url: ""
      location: ""
      id: "249175760"
    isApproved: true
    raw_message: The study literally states that mask usage didn't slow the spread
      of the virus. Whether it helped the wearer or not is a moot point, since
      the data clearly showed it helped no one.
    forum: medrxiv
    points: 5
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 12:53:26 +0000 2021
      id: 1397898740149543000
      id_str: "1397898740149542912"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The study literally states that mask usage didn't slow t‚Ä¶ https://t.co/TkFV17lJMf
      truncated: true
      entities:
        urls:
          - url: https://t.co/TkFV17lJMf
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 12:53:26 +0000 2021
      id: 1397898741118509000
      id_str: "1397898741118509058"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1397898740149543000
      in_reply_to_status_id_str: "1397898740149542912"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 4
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5397842480"
    createdAt: 2021-05-26T18:19:28
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: Keep looking, Norbert-man. Seems you cherry pick, which is what I
      suspect these researchers of doing too. That's politics, not science.
      Aerosol can get through, which means the effectiveness is not 100%. Unless
      there is  smart steering on board the tiny particles, or the mask material
      actually repels them, the mask will stop some. (It would be interesint for
      someone to find a smart mask material that draws the aerosol.) Note too,
      how vapor saturation of masks from the wearer's breath increases mask
      effectiveness. This is out there as well.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 14:40:58 +0000 2021
      id: 1397925802327502800
      id_str: "1397925802327502862"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Keep looking, Norbert-man. Seems you cherry pick, which‚Ä¶ https://t.co/7wuETvvZis
      truncated: true
      entities:
        urls:
          - url: https://t.co/7wuETvvZis
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 14:40:58 +0000 2021
      id: 1397925803409567700
      id_str: "1397925803409567744"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1397925802327502800
      in_reply_to_status_id_str: "1397925802327502862"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 3
    id: "5396741277"
    createdAt: 2021-05-25T20:24:16
    author:
      username: disqus_NW5PxcfXXi
      about: Synchronicity & Spiritus Mundi
      name: Green Ranger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_NW5PxcfXXi/
      url: ""
      location: Earth
      id: "207417544"
    isApproved: true
    raw_message: >-
      The results and conclusions of this study are wrong.  The authors mistook
      the ivermectin and control arms of one of the RCTs that they
      included.  Look at figure 2.  The results from Niaee 2020 are dramatically
      misreported.  The actual results for that study are as follows:


      Control groups: 11 deaths out of 60 patients.

      Ivermectin groups: 4 deaths out of 90 patients.


      When this is corrected, the results of this meta-analysis confirm what other meta-analyses have found.  Ivermectin use is associated with approximately 66% reduction in Covid fatalities.  And this result is statistically significant.  


      <a href="https://twitter.com/julienpotet/status/1397234802617630725">A source for this.</a>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 17:16:53 +0000 2021
      id: 1397965039865368600
      id_str: "1397965039865368587"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "The results and conclusions of this study are wrong.  Th‚Ä¶ https://t.co/MToLOVpeLx
      truncated: true
      entities:
        urls:
          - url: https://t.co/MToLOVpeLx
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 17:16:53 +0000 2021
      id: 1397965040695791600
      id_str: "1397965040695791617"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397965039865368600
      in_reply_to_status_id_str: "1397965039865368587"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 3
    id: "5396630537"
    createdAt: 2021-05-25T18:52:14
    author:
      username: stephenjcollings
      about: ""
      name: Stephen J. Collings
      isPowerContributor: false
      profileUrl: https://disqus.com/by/stephenjcollings/
      url: ""
      location: ""
      id: "113031321"
    isApproved: true
    raw_message: Looks like an error in the extraction of data from Niaee 2020 has
      led to an incorrect mortality conclusion. Please correct as a matter of
      urgency.
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 19:04:27 +0000 2021
      id: 1397992109655875600
      id_str: "1397992109655875588"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Looks like an error in the extraction of data from Niaee‚Ä¶ https://t.co/1ojKMGhQJ2
      truncated: true
      entities:
        urls:
          - url: https://t.co/1ojKMGhQJ2
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 19:04:27 +0000 2021
      id: 1397992110448652300
      id_str: "1397992110448652288"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1397992109655875600
      in_reply_to_status_id_str: "1397992109655875588"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8549959681"
    numReports: 0
    likes: 2
    id: "5398389706"
    createdAt: 2021-05-27T04:05:21
    author:
      username: andrewdavidshillermd
      about: ""
      name: Andrew David Shiller MD
      isPowerContributor: false
      profileUrl: https://disqus.com/by/andrewdavidshillermd/
      url: ""
      location: ""
      id: "147885763"
    isApproved: true
    raw_message: Interesting.   I see all the comments reporting that the authors
      mixed up the data.  Very disturbing, but exactly why we have peer
      review.  What's odd is that those comments show up here in version 1 of
      the medrxiv publication.  And there is also a "version 2" of the
      publication
      (https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2) which
      appears to have the same abstract, but no comments pointing toward the
      mixed up data and conclusions.  What's up with that?
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v1
  tweets:
    - created_at: Thu May 27 20:34:34 +0000 2021
      id: 1398014791050989600
      id_str: "1398014791050989571"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Interesting.   I see all the comments reporting that the‚Ä¶ https://t.co/zV7SC1FxLY
      truncated: true
      entities:
        urls:
          - url: https://t.co/zV7SC1FxLY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 20:34:34 +0000 2021
      id: 1398014791734681600
      id_str: "1398014791734681602"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398014791050989600
      in_reply_to_status_id_str: "1398014791050989571"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 17
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398246952"
    createdAt: 2021-05-27T00:37:03
    author:
      username: danielansari
      about: ""
      name: Daniel Ansari
      isPowerContributor: false
      profileUrl: https://disqus.com/by/danielansari/
      url: ""
      location: ""
      id: "254725529"
    isApproved: true
    raw_message: >-
      From your first link (1) - point (4) is misinformation and discredits the
      entire article and thus the site.


      The technical report in point is https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-face-masks-community-first-update.pdf, which states:


      "The evidence regarding the effectiveness of medical face masks for the prevention of COVID-19 in the community is compatible with a small to moderate protective effect, but there are still significant uncertainties about the size of this effect.", and


      "Although the evidence for the use of medical face masks in the community to prevent COVID-19 is limited, face masks should be considered as a non-pharmaceutical intervention in combination with other measures as part of efforts to control the COVID-19 pandemic."


      I'm not even going to bother going over the other cherry-picked/misrepresented studies/reports.
    forum: medrxiv
    points: -15
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu May 27 22:31:23 +0000 2021
      id: 1398044187900141600
      id_str: "1398044187900141572"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "From your first link (1) - point (4) is misinformation a‚Ä¶ https://t.co/MZqfknv7rp
      truncated: true
      entities:
        urls:
          - url: https://t.co/MZqfknv7rp
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu May 27 22:31:23 +0000 2021
      id: 1398044188751679500
      id_str: "1398044188751679488"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398044187900141600
      in_reply_to_status_id_str: "1398044187900141572"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 37
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5396692581"
    createdAt: 2021-05-25T19:41:53
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: >-
      A further point needs to be made, before we throw away our masks -- that
      masks do not help the individual wearer. This research barely touches on
      that, thus is open to be used politically to cause virus spread.  And if
      an individual thought that this research showed that a mask does not help
      the wearer, it could cause many to shed their masks when it would be
      dangerous. 


      Here in my city, we just dropped off the "high risk" or "red" category last week, which means too many spreaders were walking around town, many willy nilly. Should I still be wearing a mask, can it stop the virus from getting to me? This study does not answer that question. If masks help as many studies shown or at least indicated, then public health officials need help now in getting the message out.


      Let's backtrack and attempt the assumptive leap for a moment and try to affirm that this study points to a yet-proven truth, that all the wearing of masks was futile, because of the ineffectiveness of the mask only, which even causes problems for wearers. Let's try to affirm that with a thought experiment. Imagine with me that what got invented is the dream 100% mask back in April 2020, that (1) when worn, causes no discomfort or infection in the wearer and (2) completely prevents any wearer from being able to catch the covid virus. What if any difference would this have made to the results of this study? The hypotheses this leads to have to do with how human behavior and politics help viruses spread -- even in the face of mask-wearing. 


      For instance, consider the work of Ngaire Woods, founding dean of the Blavatnik School of Government and professor of Global Economic Governance at the University of Oxford. In his article, "What factors have determined how well countries have done in responding to the pandemic?," Richard Smith, a fellow of the Royal College of Physicians of Edinburgh, writes that "Woods identified three factors that had a strong influence on how well countries did," and, "The single most important factor, she argued, was effective collaboration between national and subnational governments." 


      Could this be translated for our purposes here, to be that there was little "subversion" by the populace too, that more successful countries had fewer parties or funerals where masks were shed, events which I witnessed and attended. It only takes one bullet to hit a target, so catch the target when the mask is off or down under the nose. In other words, if you were a virus, how would you enlist "subversive grandmother soldiers," say, to unmask around their grandchildren, allowing a snaking trail of the virus to spread from household to household. How many people broke their social bubbles?
    forum: medrxiv
    points: -35
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 01:53:57 +0000 2021
      id: 1398095167597551600
      id_str: "1398095167597551617"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "A further point needs to be made, before we throw away o‚Ä¶ https://t.co/9apo2ZMVDZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/9apo2ZMVDZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 01:53:58 +0000 2021
      id: 1398095168318980000
      id_str: "1398095168318980103"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398095167597551600
      in_reply_to_status_id_str: "1398095167597551617"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398809648"
    createdAt: 2021-05-27T14:27:10
    author:
      username: michaelwperry
      about: ""
      name: Michael W. Perry
      isPowerContributor: false
      profileUrl: https://disqus.com/by/michaelwperry/
      url: ""
      location: ""
      id: "57866673"
    isApproved: true
    raw_message: >-
      This study reinforces an earlier Danish one published in the <i>Annals of
      Internal Medicine</i> which found that the result of mask wearing had so
      little statistical significance it could be "compatible with a 46%
      reduction to a 23% increase in infection."


      <blockquote>Results:

      A total of 3030 participants were randomly assigned to the recommendation to wear masks, and 2994 were assigned to control; 4862 completed the study. Infection with SARS-CoV-2 occurred in 42 participants recommended masks (1.8%) and 53 control participants (2.1%). The between-group difference was ‚àí0.3 percentage point (95% CI, ‚àí1.2 to 0.4 percentage point; P‚Äâ= 0.38) (odds ratio, 0.82 [CI, 0.54 to 1.23]; P‚Äâ= 0.33). Multiple imputation accounting for loss to follow-up yielded similar results. Although the difference observed was not statistically significant, the 95% CIs are compatible with a 46% reduction to a 23% increase in infection.

      https://www.acpjournals.org/doi/10.7326/M20-6817</blockquote>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 12:56:48 +0000 2021
      id: 1398261976795656200
      id_str: "1398261976795656194"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This study reinforces an earlier Danish one published in‚Ä¶ https://t.co/2DCfROClsI
      truncated: true
      entities:
        urls:
          - url: https://t.co/2DCfROClsI
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 12:56:48 +0000 2021
      id: 1398261977517113300
      id_str: "1398261977517113346"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398261976795656200
      in_reply_to_status_id_str: "1398261976795656194"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 6
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398455261"
    createdAt: 2021-05-27T06:20:33
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      Well, it‚Äôs not whether there is a mandate in place, is it?

      <b>It‚Äôs whether the mandate is adhered to.

      And when people actually comply, and wear the masks, Covid spread declines.</b>

      <code>https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249891</code>


      Funny how a disease spread primarily through droplet spread can be halted by methods that stop droplet spread, isn‚Äôt it?

      ...Who would have thought it?
    forum: medrxiv
    points: -3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 14:37:16 +0000 2021
      id: 1398287260101976000
      id_str: "1398287260101976066"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Well, it‚Äôs not whether there is a mandate in place, is i‚Ä¶ https://t.co/E8yWGubU0J
      truncated: true
      entities:
        urls:
          - url: https://t.co/E8yWGubU0J
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 14:37:16 +0000 2021
      id: 1398287261020541000
      id_str: "1398287261020540939"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1398287260101976000
      in_reply_to_status_id_str: "1398287260101976066"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 1
    thread: "8550177462"
    numReports: 0
    likes: 5
    id: "5399193302"
    createdAt: 2021-05-27T19:49:37
    author:
      username: Kaliix
      about: ""
      name: Kaliix
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Kaliix/
      url: ""
      location: ""
      id: "31779148"
    isApproved: true
    raw_message: It is not possible for masks to work. The virus size is akin to
      that of smoke of vaporizer particles. Cloth masks can't filter that sized
      particle. This has been know for years. Masks, like an N-95, must be
      fitted to be at all effective. Otherwise, you create strong side vent
      outgasings that just disperse the exhaled breath around the mask.
    forum: medrxiv
    points: 4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 17:15:30 +0000 2021
      id: 1398327079465259000
      id_str: "1398327079465259013"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "It is not possible for masks to work. The virus size is‚Ä¶ https://t.co/IGKVjEP99N
      truncated: true
      entities:
        urls:
          - url: https://t.co/IGKVjEP99N
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 17:15:30 +0000 2021
      id: 1398327080312610800
      id_str: "1398327080312610816"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398327079465259000
      in_reply_to_status_id_str: "1398327079465259013"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 7
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5399211411"
    createdAt: 2021-05-27T20:05:21
    author:
      username: NC91
      about: ""
      name: NC91
      isPowerContributor: false
      profileUrl: https://disqus.com/by/NC91/
      url: ""
      location: ""
      id: "18641112"
    isApproved: true
    raw_message: No one mentions the caution at the top of the article.
    forum: medrxiv
    points: -4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 19:15:33 +0000 2021
      id: 1398357292546879500
      id_str: "1398357292546879489"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "No one mentions the caution at the top of the article."

        https://t.co/UxDCA6r4Ij
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA6r4Ij
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 19:15:33 +0000 2021
      id: 1398357293356372000
      id_str: "1398357293356371969"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1398357292546879500
      in_reply_to_status_id_str: "1398357292546879489"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 4
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5399049181"
    createdAt: 2021-05-27T17:47:20
    author:
      username: disqus_EKGoKRJzoO
      about: ""
      name: Right Warrior
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_EKGoKRJzoO/
      url: ""
      location: ""
      id: "353159389"
    isApproved: true
    raw_message: This hasn't been subject to peer review yet.  Why are we supposed
      to take this at face value?
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 20:43:07 +0000 2021
      id: 1398379331139915800
      id_str: "1398379331139915778"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This hasn't been subject to peer review yet.  Why are we‚Ä¶ https://t.co/dwnyQ3juSb
      truncated: true
      entities:
        urls:
          - url: https://t.co/dwnyQ3juSb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 20:43:08 +0000 2021
      id: 1398379331865415700
      id_str: "1398379331865415682"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398379331139915800
      in_reply_to_status_id_str: "1398379331139915778"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398871329"
    createdAt: 2021-05-27T15:20:16
    author:
      username: disqus_5aza9C29Vf
      about: wear the uniform; live life
      name: J√§ger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5aza9C29Vf/
      url: ""
      location: Flathead County
      id: "116324005"
    isApproved: true
    raw_message: >-
      01 Dec 2020

            A large randomized community-based trial in which 4862 healthy
              participants were divided into a group wearing medical/surgical
              masks and a control group found no difference in infection with
              SARS-CoV-2. A recent systematic review found nine trials (of
              which eight were cluster-randomized controlled trials in which
              clusters of people, versus individuals, were randomized)
              comparing medical/surgical masks versus no masks to prevent the
              spread of viral respiratory illness. Two trials were with
              healthcare workers and seven in the community. The review
              concluded that wearing a mask may make little or no difference
              to the prevention of influenza-like illness.https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri May 28 22:35:12 +0000 2021
      id: 1398407535388942300
      id_str: "1398407535388942337"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "01 Dec 2020

              A large randomized community-based tr‚Ä¶ https://t.co/4bfUtNbYPK
      truncated: true
      entities:
        urls:
          - url: https://t.co/4bfUtNbYPK
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri May 28 22:35:12 +0000 2021
      id: 1398407536122990600
      id_str: "1398407536122990592"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398407535388942300
      in_reply_to_status_id_str: "1398407535388942337"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 10
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398406513"
    createdAt: 2021-05-27T04:38:06
    author:
      username: rusbowden
      about: ""
      name: rusbowden
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rusbowden/
      url: ""
      location: ""
      id: "10245173"
    isApproved: true
    raw_message: The study does not show what you say it does, and from your
      response, my fear that people will use it to think that unmasking is as
      safe as masking, means we have study here that puts people in peril.
    forum: medrxiv
    points: -8
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 02:10:21 +0000 2021
      id: 1398461681068560400
      id_str: "1398461681068560386"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The study does not show what you say it does, and from y‚Ä¶ https://t.co/vKU6j1rpqF
      truncated: true
      entities:
        urls:
          - url: https://t.co/vKU6j1rpqF
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 02:10:21 +0000 2021
      id: 1398461681844605000
      id_str: "1398461681844604931"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398461681068560400
      in_reply_to_status_id_str: "1398461681068560386"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 3
    id: "5398864745"
    createdAt: 2021-05-27T15:14:45
    author:
      username: notanotherskippy
      about: ""
      name: notanotherskippy
      isPowerContributor: false
      profileUrl: https://disqus.com/by/notanotherskippy/
      url: ""
      location: ""
      id: "24425828"
    isApproved: true
    raw_message: >-
      Read your own reference:


      <blockquote>However, this effect was not statistically significant in several studies, and the quality of the evidence was

      assessed as low in several studies, so the results should be interpreted with caution.

      Looking at the evidence from studies in healthcare settings or other diseases than COVID-19 (i.e. influenza

      and other respiratory viral infections) did not improve the certainty of the evidence.</blockquote>
    forum: medrxiv
    points: 3
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 12:58:52 +0000 2021
      id: 1398624883735679000
      id_str: "1398624883735678980"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "Read your own reference:

        &lt;blockquote&gt;However, this effe‚Ä¶ https://t.co/95uCa95KtG
      truncated: true
      entities:
        urls:
          - url: https://t.co/95uCa95KtG
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 12:58:52 +0000 2021
      id: 1398624884452962300
      id_str: "1398624884452962307"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398624883735679000
      in_reply_to_status_id_str: "1398624883735678980"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5399187781"
    createdAt: 2021-05-27T19:44:53
    author:
      username: rolandwalkenhorst
      about: ""
      name: Roland
      isPowerContributor: false
      profileUrl: https://disqus.com/by/rolandwalkenhorst/
      url: ""
      location: ""
      id: "59375167"
    isApproved: true
    raw_message: >-
      <blockquote>Note too, how vapor saturation of masks from the wearer's
      breath increases mask effectiveness. This is out there as
      well.</blockquote>

      I would like to read about that if you can provide a link. It makes more sense to me that as your mask gets coated with spit, it begins to act as a mesh nebulizer to convert the previously harmless big drops into aerosol droplets every time you exhale through the mask's tiny pores. Those can float around for hours and be inhaled by other people. In other words, if you are infected, putting on a mask turns you into a walking covid mosquito fogger.

      If masks worked as well as the faithful claim they do, we would see overwhelming correlation between mask use and reduced cases, deaths and hospitalizations. We don't. <a href="https://twitter.com/ianmsc">Ian Miller</a> tweets the non-proof every day.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 14:38:53 +0000 2021
      id: 1398650055855415300
      id_str: "1398650055855415301"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "&lt;blockquote&gt;Note too, how vapor saturation of masks from‚Ä¶ https://t.co/IzJD1m4R6F
      truncated: true
      entities:
        urls:
          - url: https://t.co/IzJD1m4R6F
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 14:38:53 +0000 2021
      id: 1398650056694173700
      id_str: "1398650056694173699"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398650055855415300
      in_reply_to_status_id_str: "1398650055855415301"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5398869493"
    createdAt: 2021-05-27T15:18:44
    author:
      username: disqus_5aza9C29Vf
      about: wear the uniform; live life
      name: J√§ger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_5aza9C29Vf/
      url: ""
      location: Flathead County
      id: "116324005"
    isApproved: true
    raw_message: >-
      And what you're continuing is cherrypicking fear mongering - not
      science.  With word salad cherrypicking, hoping to get away with calling
      it "science".



      Jan 2021 U.S. Department of Health and Human Services

            According to the current knowledge, the virus SARS-CoV-2 has a
              diameter of 60 nm to 140 nm [nanometers (billionth of a meter)],
              while medical and non-medical facemasks‚Äô thread diameter ranges
              from 55 ¬µm to 440 ¬µm [micrometers (one millionth of a meter),
              which is more than 1000 times larger.  Due to the difference in
              sizes between SARS-CoV-2 diameter and facemasks thread diameter,
              SARS-CoV-2 can easily pass through any facemask.

            

            A meta-analysis among health care workers
              found that compared to no masks, surgical mask and N95
              respirators were not effective against transmission of viral
              infections or influenza-like illness based on six RCTs. Using
              separate analysis of 23 observational studies, this meta-analysis
              found no protective effect of medical mask or N95 respirators
              against SARS virus. A recent systematic review of 39 studies
              including 33,867 participants in community settings (self-report
              illness), found no difference between N95 respirators versus
              surgical masks and surgical mask versus no masks in the risk for
              developing influenza or influenza-like illness, suggesting their
              ineffectiveness of blocking viral transmissions in community
              settings.

            https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680614/
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 17:21:27 +0000 2021
      id: 1398690965871804400
      id_str: "1398690965871804416"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "And what you're continuing is cherrypicking fear mongeri‚Ä¶ https://t.co/fK7xK36NTS
      truncated: true
      entities:
        urls:
          - url: https://t.co/fK7xK36NTS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 17:21:27 +0000 2021
      id: 1398690966614249500
      id_str: "1398690966614249474"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398690965871804400
      in_reply_to_status_id_str: "1398690965871804416"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400767226"
    createdAt: 2021-05-29T04:09:06
    author:
      username: sailcat_the_banned
      about: ""
      name: sailcat_the_stranger
      isPowerContributor: false
      profileUrl: https://disqus.com/by/sailcat_the_banned/
      url: ""
      location: ""
      id: "92926218"
    isApproved: true
    raw_message: |-
      No one wears a mask correctly.
      Surgical masks are meant to be one use, not hung from the rear view.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 19:24:22 +0000 2021
      id: 1398721900222861300
      id_str: "1398721900222861315"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "No one wears a mask correctly.
        Surgical masks are meant‚Ä¶ https://t.co/UkdWSE1S6O
      truncated: true
      entities:
        urls:
          - url: https://t.co/UkdWSE1S6O
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 19:24:22 +0000 2021
      id: 1398721900960944000
      id_str: "1398721900960944135"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398721900222861300
      in_reply_to_status_id_str: "1398721900222861315"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399735000"
    createdAt: 2021-05-28T08:48:55
    author:
      username: disqus_DK5eeDLz0I
      about: ""
      name: Enzo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DK5eeDLz0I/
      url: ""
      location: ""
      id: "354888269"
    isApproved: true
    raw_message: >-
      Yet another huge double mistake :

      In Fig.6 (viral clearance) for Karamat study, the number of events are WRONG, and they're represented on the WRONG SIDE. 

      Karamat counts nb of viral clearance at day 3 (17 IVM vs 2 control), then the *additional* number at day 7 (20 more in IVM group vs 18 more in control group). Fig.6 only counts the additional count between day 3 and day 7, and forgets what happened till day 3. 

      Hence the figures in Fig.6 for Karamat should be either "17 for Ivermectin and 2 for Control" or "37 for Ivermectin and 20 for Control". 

      And these figures are IN FAVOR of ivermectin. Even the wrong "20" and "18" should have been represented on the "favors IVM " side.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sat May 29 20:47:30 +0000 2021
      id: 1398742821763354600
      id_str: "1398742821763354625"
      text: |-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."

        "Yet another huge double mistake :
        In Fig.6 (viral cleara‚Ä¶ https://t.co/wx7vIf9LLH
      truncated: true
      entities:
        urls:
          - url: https://t.co/wx7vIf9LLH
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 20:47:30 +0000 2021
      id: 1398742822778376200
      id_str: "1398742822778376192"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx56p3x
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx56p3x
      in_reply_to_status_id: 1398742821763354600
      in_reply_to_status_id_str: "1398742821763354625"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400753754"
    createdAt: 2021-05-29T03:44:48
    author:
      username: Ispythegov
      about: ""
      name: You Know you thought the same.
      isPowerContributor: false
      profileUrl: https://disqus.com/by/Ispythegov/
      url: ""
      location: Some Where in the Once Free USA
      id: "22553928"
    isApproved: true
    raw_message: |-
      But the CDC has known this for years.
      https://wwwnc.cdc.gov/eid/article/26/5/19-0994_article
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sat May 29 22:37:07 +0000 2021
      id: 1398770404685144000
      id_str: "1398770404685144066"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "But the CDC has known this for years.
        "

        https://t.co/UxDCA69tQL
      truncated: false
      entities:
        urls:
          - url: https://t.co/UxDCA69tQL
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sat May 29 22:37:07 +0000 2021
      id: 1398770405243068400
      id_str: "1398770405243068417"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1398770404685144000
      in_reply_to_status_id_str: "1398770404685144066"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399650102"
    createdAt: 2021-05-28T05:59:35
    author:
      username: disqus_WhklNKQ0tI
      about: ""
      name: ŸÖÿ±ÿ™ÿ∂€å ŸÜ€åÿß€å€å
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_WhklNKQ0tI/
      url: ""
      location: ""
      id: "369965509"
    isApproved: true
    raw_message: Hi, I'm Dr.Niaee and I was surprised that even basic data from our
      RCT is completely mispresented and is WRONG. We had 60 indivisuals in
      control groups and 120 in intervention groups and even this simple thing
      is mispresented.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 02:24:45 +0000 2021
      id: 1398827692993224700
      id_str: "1398827692993224712"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Hi, I'm Dr.Niaee and I was surprised that even basic dat‚Ä¶ https://t.co/SK7UgbHgH3
      truncated: true
      entities:
        urls:
          - url: https://t.co/SK7UgbHgH3
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 02:24:45 +0000 2021
      id: 1398827693702008800
      id_str: "1398827693702008834"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398827692993224700
      in_reply_to_status_id_str: "1398827692993224712"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5399634852"
    createdAt: 2021-05-28T05:26:03
    author:
      username: disqus_DK5eeDLz0I
      about: ""
      name: Enzo
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DK5eeDLz0I/
      url: ""
      location: ""
      id: "354888269"
    isApproved: true
    raw_message: >-
      Other mistakes seem to weigh on the results and on the conclusions.
      Examples :

      In Figure 3, how could the mean length of stay in Niaee's control group be smaller than the one in ivermectin group, when Niaee finds a significant reduction of stay with IVM ?

      In Figure 2 (Mortality), how can RR for Chaccour be 1 when there's no event ? (Shouldn't it be "not calculatable" ?)

      In Figure 5, (severe adverse events), one is included despite Krolewiecki mentions the one reported "has not been reported in association to IVM"
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 12:58:45 +0000 2021
      id: 1398987242631278600
      id_str: "1398987242631278592"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Other mistakes seem to weigh on the results and on the c‚Ä¶ https://t.co/aq1sMbhbAZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/aq1sMbhbAZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 12:58:45 +0000 2021
      id: 1398987243658809300
      id_str: "1398987243658809349"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1398987242631278600
      in_reply_to_status_id_str: "1398987242631278592"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5399577042"
    createdAt: 2021-05-28T03:32:40
    author:
      username: joshuagibbons
      about: ""
      name: Joshua Gibbons
      isPowerContributor: false
      profileUrl: https://disqus.com/by/joshuagibbons/
      url: ""
      location: ""
      id: "81913636"
    isApproved: true
    raw_message: You're not, feel free to rebuke it, that's why it's been presented
      to the public, so peer review can happen. Pretty hard to get peer review
      without presenting your study, no? Pretty obvious stuff here.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 14:40:51 +0000 2021
      id: 1399012937331843000
      id_str: "1399012937331843073"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "You're not, feel free to rebuke it, that's why it's been‚Ä¶ https://t.co/mZs84AneGc
      truncated: true
      entities:
        urls:
          - url: https://t.co/mZs84AneGc
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 14:40:51 +0000 2021
      id: 1399012938049073200
      id_str: "1399012938049073162"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399012937331843000
      in_reply_to_status_id_str: "1399012937331843073"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400593481"
    createdAt: 2021-05-28T23:54:05
    author:
      username: beamansurchit
      about: ""
      name: beamansurchit
      isPowerContributor: false
      profileUrl: https://disqus.com/by/beamansurchit/
      url: ""
      location: ""
      id: "125228403"
    isApproved: true
    raw_message: >-
      A legitimate question.  Will you take it at face value after it has been
      peer reviewed?

      I've been looking into the science behind mask mandates for a while now and there is literally NOT ONE RCT study which has found masks (or respirators for that matter) to be effective to reduce the transmission of viral illness.  Other things like droplets, sure, but not viral illness.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 17:19:04 +0000 2021
      id: 1399052754669219800
      id_str: "1399052754669219848"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "A legitimate question.  Will you take it at face value a‚Ä¶ https://t.co/aN07LQRhD8
      truncated: true
      entities:
        urls:
          - url: https://t.co/aN07LQRhD8
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 17:19:04 +0000 2021
      id: 1399052755537383400
      id_str: "1399052755537383425"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399052754669219800
      in_reply_to_status_id_str: "1399052754669219848"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 0
    id: "5402311185"
    createdAt: 2021-05-30T17:55:22
    author:
      username: fatlas
      about: ""
      name: fatlas
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fatlas/
      url: ""
      location: ""
      id: "370182889"
    isApproved: true
    raw_message: >-
      When the data for Niaee study was corrected for version 2 the weights
      given to the studies were also changed. The weights in figure 2 changed in
      a way that is hard to explain by the Niaee data fix alone.


      Was any other parameter adjusted for version 2 than data for Niaee study? If so, on what basis was the other parameters changed?
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 19:20:58 +0000 2021
      id: 1399083430458052600
      id_str: "1399083430458052612"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "When the data for Niaee study was corrected for version‚Ä¶ https://t.co/fzlxBR2MM0
      truncated: true
      entities:
        urls:
          - url: https://t.co/fzlxBR2MM0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 19:20:58 +0000 2021
      id: 1399083431330463700
      id_str: "1399083431330463745"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399083430458052600
      in_reply_to_status_id_str: "1399083430458052612"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401827647"
    createdAt: 2021-05-30T05:39:10
    author:
      username: fatboyjddiesel
      about: ""
      name: FatBoy ‚ÄúJD‚Äù Diesel
      isPowerContributor: false
      profileUrl: https://disqus.com/by/fatboyjddiesel/
      url: ""
      location: ""
      id: "295719846"
    isApproved: true
    raw_message: >-
      Seeing people going back and forth here, but I'll just point this out:


      If wearing masks are really that effective, as some claim, how are medical staff getting infected <i>on the job</i> despite the extra medical gear, protection, and protocols? The overwhelming majority of you can only provide conjecture <i>at best.</i> If medical staff adhering to strict sanitation protocols still get infected by a respiratory illness </I>on site,</I> what makes anyone believe that less effective equipment, or less physical coverage provided by said equipment, would be effective for a general population less equipped to adhere to stricter sanitation protocols?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Sun May 30 20:48:27 +0000 2021
      id: 1399105448054345700
      id_str: "1399105448054345737"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Seeing people going back and forth here, but I'll just p‚Ä¶ https://t.co/d7sSHuysxO
      truncated: true
      entities:
        urls:
          - url: https://t.co/d7sSHuysxO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 20:48:27 +0000 2021
      id: 1399105448825999400
      id_str: "1399105448825999368"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399105448054345700
      in_reply_to_status_id_str: "1399105448054345737"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5401473605"
    createdAt: 2021-05-29T20:55:44
    author:
      username: RGregoryClark
      about: I teach math at an east coast U.S. university.
      name: Robert Clark
      isPowerContributor: false
      profileUrl: https://disqus.com/by/RGregoryClark/
      url: http://exoscientist.blogspot.com
      location: Philadelphia, PA
      id: "41262611"
    isApproved: true
    raw_message: >-
      Seriously, it‚Äôs like some researchers opposed to the concept of EARLY
      treatment of COVID will go to any lengths to provide evidence against it,
      even if it crosses the line of scientific ethics.


      Sorry, to have to say this but the authors no longer have any credibility on this issue.

       Extremely important to recognize the importance of this: to provide evidence against IVM researchers have had to change data to fit their conclusion.

       What does that tell you about the effectiveness of IVM?

        Robert Clark
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Sun May 30 22:39:14 +0000 2021
      id: 1399133326473056300
      id_str: "1399133326473056259"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "Seriously, it‚Äôs like some researchers opposed to the con‚Ä¶ https://t.co/kcOLJgHSNE
      truncated: true
      entities:
        urls:
          - url: https://t.co/kcOLJgHSNE
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Sun May 30 22:39:14 +0000 2021
      id: 1399133328469540900
      id_str: "1399133328469540865"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399133326473056300
      in_reply_to_status_id_str: "1399133326473056259"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401226162"
    createdAt: 2021-05-29T16:36:40
    author:
      username: disqus_xTMdo65OVv
      about: ""
      name: BajaRon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_xTMdo65OVv/
      url: ""
      location: ""
      id: "39358479"
    isApproved: true
    raw_message: If you follow real science (of which there is a great deal on this
      subject). There has never been any that can show any advantage of mask
      wearing for a viral issue. Theories on water droplet dispersion rates,
      etc., abound. But the hard evidence clearly and repeatedly shows that the
      spread of any virus is not affected in the least by wearing a mask. It's
      like trying to keep flies out with a chain link fence.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 02:35:48 +0000 2021
      id: 1399192862936416300
      id_str: "1399192862936416259"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "If you follow real science (of which there is a great de‚Ä¶ https://t.co/GBErMbE0bo
      truncated: true
      entities:
        urls:
          - url: https://t.co/GBErMbE0bo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 02:35:49 +0000 2021
      id: 1399192863737516000
      id_str: "1399192863737516034"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399192862936416300
      in_reply_to_status_id_str: "1399192862936416259"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 2
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5402275797"
    createdAt: 2021-05-30T17:20:05
    author:
      username: badger_vanamburgh
      about: ""
      name: Badger Vanamburgh
      isPowerContributor: false
      profileUrl: https://disqus.com/by/badger_vanamburgh/
      url: ""
      location: ""
      id: "360872283"
    isApproved: true
    raw_message: It‚Äôs astonishing that anyone thinks that this study is in any way
      scientific, controlled, with conclusions based on anything but bias. It‚Äôs
      alarming that such nonsense writings like these are even taken seriously
      enough for someone to decide to publish it, spread it around the internet.
      The times of truth, fact and reality ruling the day, are behind us. They
      are destroying science and destroying our democracy. That is very sad
      indeed.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 13:01:14 +0000 2021
      id: 1399350254609342500
      id_str: "1399350254609342470"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "It‚Äôs astonishing that anyone thinks that this study is i‚Ä¶ https://t.co/ZvgHr037jq
      truncated: true
      entities:
        urls:
          - url: https://t.co/ZvgHr037jq
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 13:01:14 +0000 2021
      id: 1399350255435530200
      id_str: "1399350255435530240"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399350254609342500
      in_reply_to_status_id_str: "1399350254609342470"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401702515"
    createdAt: 2021-05-30T01:48:50
    author:
      username: DeanAnniballi
      about: ""
      name: Dean Anniballi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/DeanAnniballi/
      url: ""
      location: ""
      id: "81416142"
    isApproved: true
    raw_message: The disease is spread primarily by aerosolized particles, not
      droplets.  That's why the masks are pretty much useless.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 14:39:29 +0000 2021
      id: 1399374981314850800
      id_str: "1399374981314850823"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The disease is spread primarily by aerosolized particles‚Ä¶ https://t.co/swp4mPxQIw
      truncated: true
      entities:
        urls:
          - url: https://t.co/swp4mPxQIw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 14:39:29 +0000 2021
      id: 1399374982124347400
      id_str: "1399374982124347398"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399374981314850800
      in_reply_to_status_id_str: "1399374981314850823"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5401706081"
    createdAt: 2021-05-30T01:54:15
    author:
      username: DeanAnniballi
      about: ""
      name: Dean Anniballi
      isPowerContributor: false
      profileUrl: https://disqus.com/by/DeanAnniballi/
      url: ""
      location: ""
      id: "81416142"
    isApproved: true
    raw_message: I find it interesting that those states that implemented early mask
      mandates have slightly high death rates than states that never implemented
      masking.  In addition, when new case rates were at the highest we also had
      >93% mask compliance in those states that required masks.  The real world
      data seems to refute your position.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 17:41:07 +0000 2021
      id: 1399420690223317000
      id_str: "1399420690223317000"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I find it interesting that those states that implemented‚Ä¶ https://t.co/6AbayYTUfV
      truncated: true
      entities:
        urls:
          - url: https://t.co/6AbayYTUfV
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 17:41:07 +0000 2021
      id: 1399420691016032300
      id_str: "1399420691016032268"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399420690223317000
      in_reply_to_status_id_str: "1399420690223317000"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 2
    id: "5400974494"
    createdAt: 2021-05-29T11:28:54
    author:
      username: lunararmor
      about: ""
      name: LunarArmor
      isPowerContributor: false
      profileUrl: https://disqus.com/by/lunararmor/
      url: ""
      location: ""
      id: "281578529"
    isApproved: true
    raw_message: You obviously don't grasp what they are saying.  Mandates
      absolutely increased the amount of people wearing masks.  Even though
      those mandates were in place, the data shows that it did not slow the
      spread of Covid during times of Covid surges.  Ergo, the mandate and
      wearing masks do decrease the rate of transmission.
    forum: medrxiv
    points: 2
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 19:50:46 +0000 2021
      id: 1399453318896832500
      id_str: "1399453318896832513"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "You obviously don't grasp what they are saying.  Mandate‚Ä¶ https://t.co/UbrlXCrpL5
      truncated: true
      entities:
        urls:
          - url: https://t.co/UbrlXCrpL5
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 19:50:46 +0000 2021
      id: 1399453319719002000
      id_str: "1399453319719002115"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399453318896832500
      in_reply_to_status_id_str: "1399453318896832513"
- preprint:
    id: 141863
    metric: 16417
    title: The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified
      in India Provide Partial Resistance to Vaccine-elicited and Therapeutic
      Monoclonal Antibodies.
    url: https://api.rxivist.org/v1/papers/141863
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.14.444076v1
    doi: 10.1101/2021.05.14.444076
    category: immunology
    first_posted: 2021-05-16
    abstract: Highly transmissible SARS-CoV-2 variants recently identified in India
      designated B.1.617 and B.1.618 have mutations within the spike protein
      that may contribute to their increased transmissibility and that could
      potentially result in re-infection or resistance to vaccine-elicited
      antibody. B.1.617 encodes a spike protein with mutations L452R, E484Q,
      D614G and P681R while the B.1.618 spike has mutations {Delta}145-146,
      E484K and D614G. We generated lentiviruses pseudotyped by the variant
      proteins and determined their resistance to neutralization by convalescent
      sera, vaccine-elicited antibodies and therapeutic monoclonal antibodies.
      Viruses with B.1.617 and B.1.618 spike were neutralized with a 2-5-fold
      decrease in titer by convalescent sera and vaccine-elicited antibodies.
      The E484Q and E484K versions were neutralized with a 2-4-fold decrease in
      titer. Virus with the B.1.617 spike protein was neutralized with a
      4.7-fold decrease in titer by the Regeneron monoclonal antibody cocktail
      as a result of the L452R mutation. The modest neutralization resistance of
      the variant spike proteins to vaccine elicited antibody suggests that
      current vaccines will remain protective against the B.1.617 and B.1.618
      variants.
    authors:
      - name: Takuya Tada
      - name: Hao Zhou
      - name: Belinda M Dcosta
      - name: Marie I. Samanovic
      - name: Mark J Mulligan
      - name: Nathaniel R Landau
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Mon May 31 21:13:12 +0000 2021
      id: 1399474064666906600
      id_str: "1399474064666906624"
      text: >-
        üî• bioRxiv Immunology preprint by T. Tada et al:


        "The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Ide‚Ä¶ https://t.co/RkZe4QYK56
      truncated: true
      entities:
        urls:
          - url: https://t.co/RkZe4QYK56
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5401161627"
    createdAt: 2021-05-29T15:27:58
    author:
      username: thomaseddlem
      about: History Teacher, Freelance Writer, Father, Constitutionalist
      name: Thomas Eddlem
      isPowerContributor: false
      profileUrl: https://disqus.com/by/thomaseddlem/
      url: ""
      location: Taunton. Massachusetts
      id: "61626577"
    isApproved: true
    raw_message: >-
      I'm skeptical of both studies. The one you linked to has a small sample
      size, and I don't like that it reported a coefficient (140 cases/100,000),
      which is small, and doesn't note that there were wide overlapping
      confidence intervals in its conclusions. Really wide. Did you check the
      chart? 


      This study on this page seems anti-mask agenda-driven, and its conclusions in the summary are over-generalized. There probably is not a statistically significant difference between mask-mandate states and non-mask mandate states, but that doesn't mean masks never work. 


      A mandate to wear a mask walking down a city street is not the same as a mandate to wear one when visiting someone in a hospital or a brief visit in some other close-up situation. But both studies tend to treat these as roughly the same. 


      There's clearly a lot more research needed on this. Most of the studies done in 2020 are junk, proven inaccurate by the historical data.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 21:18:45 +0000 2021
      id: 1399475460988452900
      id_str: "1399475460988452870"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I'm skeptical of both studies. The one you linked to has‚Ä¶ https://t.co/AsGf2mxbBD
      truncated: true
      entities:
        urls:
          - url: https://t.co/AsGf2mxbBD
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 21:18:45 +0000 2021
      id: 1399475461860823000
      id_str: "1399475461860823041"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399475460988452900
      in_reply_to_status_id_str: "1399475460988452870"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 5
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400794931"
    createdAt: 2021-05-29T05:06:51
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      The study states the mandate didn‚Äôt slow spread.

      But we know that the mandate is irrelevant, it‚Äôs whether it is properly adhered to and whether people are compliant with a range of measures that is important.
    forum: medrxiv
    points: -4
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Mon May 31 22:51:25 +0000 2021
      id: 1399498783063433200
      id_str: "1399498783063433219"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "The study states the mandate didn‚Äôt slow spread.
        But we‚Ä¶ https://t.co/TwkizeeP4s
      truncated: true
      entities:
        urls:
          - url: https://t.co/TwkizeeP4s
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Mon May 31 22:51:26 +0000 2021
      id: 1399498783956910000
      id_str: "1399498783956910080"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399498783063433200
      in_reply_to_status_id_str: "1399498783063433219"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 8
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5400793613"
    createdAt: 2021-05-29T05:03:42
    author:
      username: disqus_0bT5QNRHDf
      about: ""
      name: Mike Stevens
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_0bT5QNRHDf/
      url: ""
      location: ""
      id: "68437046"
    isApproved: true
    raw_message: >-
      Well, your argument would just verify my point...it‚Äôs the wearing of masks
      that cuts Covid transmission, not whether there is some advice in place to
      do so.

      But of course one needs to wear them properly, or they may not work. 


      An suitable analogy might be as follows:

      ‚ÄúInstallation of clean water and sewage facilities does not cut dysentery risk‚Äù

      If one finds that a significant number of the population are refusing to practice basic hygiene and are still defecating in the wells used for drinking, do you think the study conclusion should be ‚ÄúPublic health interventions do not stop the spread of dysentery‚Äù, and for governments to cease to provide tap water and toilets for their citizens?


      PS: The reuse of surgical masks depends upon their contamination. They are used for 4-6 hours continuously in hospital settings. It‚Äôs advised that you wear a new mask if as a member of the public you are taking one off and then need to remask. There is an elements of common sense here... if I am going into say Tesco‚Äôs for a few minutes, then into Boots 5 minutes later, I might for the sake of convenience just put on the mask again, assuming I have kept it clean in the interim. I notice some people ‚Äúwearing their mask‚Äù in open air spaces in towns, usually because they are going from one shop to the next a few doors down. Taking the mask off between those times seems more trouble than it‚Äôs worth, so they leave it on. This week I was dropping in at the petrol station attached to my local Tesco superstore, so I didn‚Äôt bother to take off my mask, drove 300 yds in the car while wearing my mask, then got petrol. No big deal. I didn‚Äôt die from hypoxia, but no doubt some antimasker laughed when they saw me wearing the mask in the car.

      Just use your common sense, I say. There‚Äôs not much of that about these days.
    forum: medrxiv
    points: -7
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 03:03:23 +0000 2021
      id: 1399562190080798700
      id_str: "1399562190080798720"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Well, your argument would just verify my point...it‚Äôs th‚Ä¶ https://t.co/K3UxMeN3Px
      truncated: true
      entities:
        urls:
          - url: https://t.co/K3UxMeN3Px
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 03:03:23 +0000 2021
      id: 1399562191028686800
      id_str: "1399562191028686853"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1399562190080798700
      in_reply_to_status_id_str: "1399562190080798720"
- preprint:
    id: "143188"
    doi: 10.1101/2021.05.21.21257595
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.21.21257595v1
    url: https://api.rxivist.org/v1/papers/143188
    title: "Ivermectin for the treatment of COVID-19: A systematic review and
      meta-analysis of randomized controlled trials"
    category: infectious-diseases
    abstract: "Background: We systematically assessed benefits and harms of the use
      of ivermectin (IVM) in COVID-19 patients. Methods: Published and preprint
      randomized controlled trials (RCTs) assessing IVM effects on COVID-19
      adult patients were searched until March 15, 2021 in five engines. Primary
      outcomes were all-cause mortality, length of stay (LOS), and adverse
      events (AE). Secondary outcomes included viral clearance and severe AEs.
      We evaluated risk of bias (RoB) using the Cochrane RoB 2.0 tool. Inverse
      variance random effect meta-analyses were performed with quality of
      evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by
      severity of disease and RoB, and sensitivity analyses by time of follow-up
      were conducted. Results: Ten RCTs (n=1173) were included. Controls were
      standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample
      size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and
      severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and
      mild and moderate in one RCT. IVM did not reduce all-cause mortality vs.
      controls (RR 1.11, 95%CI 0.16-7.65, very low QoE). IVM did not reduce LOS
      vs. controls (MD 0.72 days, 95%CI -0.86 to 2.29, very low QoE). AEs,
      severe AE and viral clearance were similar between IVM and controls (low
      QoE for these three outcomes). Subgroup analyses by severity of COVID-19
      disease or RoB were consistent with main analyses. Sensitivity analyses
      excluding RCTs with follow up <21 days showed no difference in all-cause
      mortality but diminished heterogeneity (I2=0%). Conclusions: In comparison
      to SOC or placebo, IVM did not reduce all-cause mortality, length of stay
      or viral clearance in RCTs in COVID-19 patients with mostly mild disease.
      IVM did not have effect on AEs or SAEs. IVM is not a viable option to
      treat COVID-19 patients."
    authors:
      - name: Yuani M Roman
        orcid: http://orcid.org/0000-0001-8176-4464
      - name: Paula A Burela
        orcid: http://orcid.org/0000-0003-3746-4338
      - name: Vinay Pasupuleti
        orcid: http://orcid.org/0000-0002-5964-9520
      - name: Alejandro Piscoya
        orcid: http://orcid.org/0000-0002-4420-2419
      - name: Jose E Vidal
        orcid: http://orcid.org/0000-0001-7830-8716
      - name: Adrian V Hernandez
        orcid: http://orcid.org/0000-0002-9999-4003
  comment:
    dislikes: 0
    thread: "8552957443"
    numReports: 0
    likes: 1
    id: "5402212445"
    createdAt: 2021-05-30T16:14:37
    author:
      username: docj1
      about: ""
      name: wj
      isPowerContributor: false
      profileUrl: https://disqus.com/by/docj1/
      url: ""
      location: ""
      id: "368482963"
    isApproved: true
    raw_message: The amount of misrepresentation of data in this meta-analysis as
      outlined in below comments reaches the level of <i>scientific
      misconduct</i>, given that the Niaee RR was corrected but the associated
      conclusion was not. I have faith that peer reviewers will reject based on
      this glaring falsity if the authors do not retract beforehand.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.21.21257595v2
  tweets:
    - created_at: Tue Jun 01 13:16:45 +0000 2021
      id: 1399716549850718200
      id_str: "1399716549850718213"
      text: >-
        üí¨ medRxiv comment on "Ivermectin for the treatment o..."


        "The amount of misrepresentation of data in this meta-ana‚Ä¶ https://t.co/0JqyussVTw
      truncated: true
      entities:
        urls:
          - url: https://t.co/0JqyussVTw
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 13:16:45 +0000 2021
      id: 1399716550605742000
      id_str: "1399716550605742087"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/jDpPx4OObZ
      truncated: false
      entities:
        urls:
          - url: https://t.co/jDpPx4OObZ
      in_reply_to_status_id: 1399716549850718200
      in_reply_to_status_id_str: "1399716549850718213"
- preprint:
    id: "129733"
    doi: 10.1101/2021.02.17.431604
    first_posted: 2021-02-17
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.02.17.431604v1
    url: https://api.rxivist.org/v1/papers/129733
    title: The IL-10GFP (VeRT-X) mouse strain is not suitable for the detection of
      IL-10 production by granulocytes during lung inflammation
    category: immunology
    abstract: The clear and unequivocal identification of immune effector functions
      is essential to understand immune responses. The cytokine IL-10 is a
      critical immune regulator and was shown, for example, to limit pathology
      during various lung diseases. However, the clear identification of
      IL-10-producing cells is challenging and, therefore, reporter mouse lines
      were developed to facilitate their detection. Several such reporter lines
      utilize GFP, including the IL-10 GFP (VeRT-X) reporter strain studied
      here. In line with previous reports, we found that this IL-10 GFP line
      faithfully reports on the IL-10 production of lymphoid cells. However, we
      show that the IL-10 GFP reporter is not suitable to analyse IL-10
      production of myeloid cells during inflammations. During inflammation, the
      autofluorescence of myeloid cells increased to an extent that entirely
      masked the IL-10-specific GFP-signal. Our data illustrate a general and
      important technical caveat using GFP-reporter lines for the analysis of
      myeloid cells and suggest that previous reports on effector functions of
      myeloid cells using such GFP-based reporters might require re-evaluation.
    authors:
      - name: M√ºge √ñzkan
        orcid: http://orcid.org/0000-0002-3927-1882
      - name: Yusuf  Cem Eskiocak
        orcid: null
      - name: Gerhard Wingender
        orcid: http://orcid.org/0000-0002-7115-298X
  comment:
    dislikes: 0
    thread: "8402814496"
    numReports: 0
    likes: 0
    id: "5403029660"
    createdAt: 2021-05-31T11:32:09
    author:
      username: gerhardwingender
      about: ""
      name: Gerhard WINGENDER
      isPowerContributor: false
      profileUrl: https://disqus.com/by/gerhardwingender/
      url: ""
      location: ""
      id: "370218532"
    isApproved: true
    raw_message: "This study has been published:
      https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247895"
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.02.17.431604v1
  tweets:
    - created_at: Tue Jun 01 14:50:52 +0000 2021
      id: 1399740233244098600
      id_str: "1399740233244098562"
      text: |-
        üí¨ bioRxiv comment on "The IL-10GFP (VeRT-X) mouse st..."

        "This study has been published: "

        https://t.co/SbhjbOgAGN
      truncated: false
      entities:
        urls:
          - url: https://t.co/SbhjbOgAGN
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 14:50:52 +0000 2021
      id: 1399740233952989200
      id_str: "1399740233952989184"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/H4MbuXXBbD
      truncated: false
      entities:
        urls:
          - url: https://t.co/H4MbuXXBbD
      in_reply_to_status_id: 1399740233244098600
      in_reply_to_status_id_str: "1399740233244098562"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5403947977"
    createdAt: 2021-06-01T04:43:20
    author:
      username: ARMSTROB
      about: ""
      name: ARMSTROB
      isPowerContributor: false
      profileUrl: https://disqus.com/by/ARMSTROB/
      url: ""
      location: ""
      id: "21380356"
    isApproved: true
    raw_message: I agree.  Also, why don't the surges disappear or get smaller as
      time goes by if the masks are working?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 18:08:21 +0000 2021
      id: 1399789931816538000
      id_str: "1399789931816538114"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I agree.  Also, why don't the surges disappear or get sm‚Ä¶ https://t.co/WzZMuLuVA4
      truncated: true
      entities:
        urls:
          - url: https://t.co/WzZMuLuVA4
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 18:08:21 +0000 2021
      id: 1399789932613341200
      id_str: "1399789932613341191"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399789931816538000
      in_reply_to_status_id_str: "1399789931816538114"
- preprint:
    id: 86387
    metric: 34
    title: "ANANSE: An enhancer network-based computational approach for predicting
      key transcription factors in cell fate determination"
    url: https://api.rxivist.org/v1/papers/86387
    biorxiv_url: https://www.biorxiv.org/content/10.1101/2020.06.05.135798v2
    doi: 10.1101/2020.06.05.135798
    category: systems-biology
    first_posted: 2020-06-06
    abstract: Proper cell fate determination is largely orchestrated by complex gene
      regulatory networks centered around transcription factors. However,
      experimental elucidation of key transcription factors that drive cellular
      identity is currently often intractable. Here, we present ANANSE (ANalysis
      Algorithm for Networks Specified by Enhancers), a network-based method
      that exploits enhancerencoded regulatory information to identify the key
      transcription factors in cell fate determination. As cell type-specific
      transcription factors predominantly bind to enhancers, we use regulatory
      networks based on enhancer properties to prioritize transcription factors.
      First, we predict genome-wide binding profiles of transcription factors in
      various cell types using enhancer activity and transcription factor
      binding motifs. Subsequently, applying these inferred binding profiles, we
      construct cell type-specific gene regulatory networks, and then predict
      key transcription factors controlling cell fate conversions using
      differential gene networks between cell types. This method outperforms
      existing approaches in correctly predicting major transcription factors
      previously identified to be sufficient for trans-differentiation. Finally,
      we apply ANANSE to define an atlas of key transcription factors in 18
      normal human tissues. In conclusion, we present a ready-to-implement
      computational tool for efficient prediction of transcription factors in
      cell fate determination and to study transcription factor-mediated
      regulatory mechanisms. ANANSE is freely available at
      https://github.com/vanheeringen-lab/ANANSE.
    authors:
      - name: Quan Xu
      - name: Georgios Georgiou
      - name: Siebren Froelich
      - name: Maarten van der Sande
      - name: Gert Jan C Veenstra
      - name: Huiqing Zhou
      - name: Simon J. van Heeringen
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Tue Jun 01 21:28:42 +0000 2021
      id: 1399840351549075500
      id_str: "1399840351549075462"
      text: >-
        üî• bioRxiv Systems-biology preprint by Q. Xu et al:


        "ANANSE: An enhancer network-based computational approach for p‚Ä¶ https://t.co/ThM8jx6qKz
      truncated: true
      entities:
        urls:
          - url: https://t.co/ThM8jx6qKz
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 0
    id: "5404468009"
    createdAt: 2021-06-01T16:02:48
    author:
      username: justinlovern
      about: ""
      name: Justin Lovern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/justinlovern/
      url: ""
      location: ""
      id: "284782035"
    isApproved: true
    raw_message: The burden of proof is on the entity wanting to enforce mask
      mandates that mask mandates actually work. There is no burden to prove
      that masks don't work. This study (and many others) set out to determine
      if mask mandates work (reduce transmission rates) and was not able to
      establish any correlation between mandates and reduced transmission rates.
      Hence, the burden of proof is still on the maskers to prove that masks
      work - not on anti-maskers to prove they don't.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Tue Jun 01 21:31:58 +0000 2021
      id: 1399841174060515300
      id_str: "1399841174060515328"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "The burden of proof is on the entity wanting to enforce‚Ä¶ https://t.co/eC8lF2nYft
      truncated: true
      entities:
        urls:
          - url: https://t.co/eC8lF2nYft
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 21:31:58 +0000 2021
      id: 1399841175029309400
      id_str: "1399841175029309454"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1399841174060515300
      in_reply_to_status_id_str: "1399841174060515328"
- preprint:
    id: "141492"
    doi: 10.1101/2021.05.12.21256975
    first_posted: 2021-05-13
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.12.21256975v1
    url: https://api.rxivist.org/v1/papers/141492
    title: Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of
      seroprevalence study data and imprecise mortality data
    category: epidemiology
    abstract: Estimating the COVID-19 infection fatality rate (IFR) has proven to be
      particularly challenging --and rather controversial-- due to the fact that
      both the data on deaths and the data on the number of individuals infected
      are subject to many different biases. We consider a Bayesian evidence
      synthesis approach which, while simple enough for researchers to
      understand and use, accounts for many important sources of uncertainty
      inherent in both the seroprevalence and mortality data. We estimate the
      COVID-19 IFR to be 0.40% (95% credible interval of (0.20%, 0.63%)) for a
      typical population where the proportion of those aged over 65 years old is
      9% and where the GDP (at purchasing-power parity (ppp)) per capita is
      $17.8K (the approximate worldwide values). Our results suggest that, as
      one might expect, lower IFRs are associated with younger and with
      wealthier populations.
    authors:
      - name: Harlan Campbell
        orcid: http://orcid.org/0000-0002-0959-1594
      - name: Paul Gustafson
        orcid: http://orcid.org/0000-0002-2375-5006
  comment:
    dislikes: 0
    thread: "8519217784"
    numReports: 0
    likes: 0
    id: "5404391858"
    createdAt: 2021-06-01T14:57:57
    author:
      username: disqus_Tt0mr386bH
      about: ""
      name: happydog
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_Tt0mr386bH/
      url: ""
      location: ""
      id: "59198730"
    isApproved: true
    raw_message: In version 2 of the manuscript, the Brazil data is not included.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.12.21256975v1
  tweets:
    - created_at: Tue Jun 01 22:58:39 +0000 2021
      id: 1399862988513837000
      id_str: "1399862988513837059"
      text: >-
        üí¨ medRxiv comment on "Inferring the COVID-19 IFR wit..."


        "In version 2 of the manuscript, the Brazil data is not i‚Ä¶ https://t.co/rCfqbxRaOo
      truncated: true
      entities:
        urls:
          - url: https://t.co/rCfqbxRaOo
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Tue Jun 01 22:58:39 +0000 2021
      id: 1399862989495308300
      id_str: "1399862989495308290"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/QUuq9FzzpV
      truncated: false
      entities:
        urls:
          - url: https://t.co/QUuq9FzzpV
      in_reply_to_status_id: 1399862988513837000
      in_reply_to_status_id_str: "1399862988513837059"
- preprint:
    id: "134592"
    doi: 10.1101/2021.03.22.436484
    first_posted: 2021-03-23
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.03.22.436484v1
    url: https://api.rxivist.org/v1/papers/134592
    title: "scTenifoldKnk: a machine learning workflow performing virtual knockout
      experiments on single-cell gene regulatory networks"
    category: bioinformatics
    abstract: Gene knockout (KO) experiments are a proven approach for studying gene
      function. A typical KO experiment usually involves the phenotypic
      characterization of KO organisms. The recent advent of single-cell
      technology has greatly boosted the resolution of cellular phenotyping,
      providing unprecedented insights into cell-type-specific gene function.
      However, the use of single-cell technology in large-scale, systematic KO
      experiments is prohibitive due to the vast resources required. Here we
      present scTenifoldKnk, a machine learning workflow that performs virtual
      KO experiments using single-cell RNA sequencing (scRNA-seq) data.
      scTenifoldKnk first uses data from wild-type (WT) samples to construct a
      single-cell gene regulatory network (scGRN). Then, a gene is knocked out
      from the constructed scGRN by setting weights of the gene's outward edges
      to zeros. ScTenifoldKnk then compares this "pseudo-KO" scGRN with the
      original scGRN to identify differentially regulated (DR) genes. These DR
      genes, also called virtual-KO perturbed genes, are used to assess the
      impact of the gene KO and reveal the gene's function in analyzed cells.
      Using existing data sets, we demonstrate that the scTenifoldKnk analysis
      recapitulates the main findings of three real-animal KO experiments and
      confirms the functions of genes underlying three Mendelian diseases. We
      show the power of scTenifoldKnk as a predictive method to successfully
      predict the outcomes of two KO experiments that involve intestinal
      enterocytes in Ahr-/- mice and pancreatic islet cells in Malat1-/- mice,
      respectively. Finally, we demonstrate the use of scTenifoldKnk to perform
      systematic KO analyses, in which a large number of genes are virtually
      deleted, allowing gene functions to be revealed in a cell type-specific
      manner.
    authors:
      - name: Daniel Osorio
        orcid: http://orcid.org/0000-0003-4424-8422
      - name: Yan Zhong
        orcid: null
      - name: Guanxun Li
        orcid: null
      - name: Qian Xu
        orcid: http://orcid.org/0000-0002-9267-906X
      - name: Andrew E. Hillhouse
        orcid: null
      - name: Jingshu Chen
        orcid: null
      - name: Laurie A. Davidson
        orcid: null
      - name: Yanan Tian
        orcid: null
      - name: Robert S Chapkin
        orcid: null
      - name: Jianhua Z Huang
        orcid: null
      - name: James J. Cai
        orcid: http://orcid.org/0000-0002-8081-6725
  comment:
    dislikes: 0
    thread: "8449125883"
    numReports: 0
    likes: 0
    id: "5404831186"
    createdAt: 2021-06-01T21:20:00
    author:
      username: disqus_DD69BrY3Kn
      about: ""
      name: disqus_DD69BrY3Kn
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_DD69BrY3Kn/
      url: ""
      location: ""
      id: "370292693"
    isApproved: true
    raw_message: >-
      Dear Samuel,


      Thank you very much for your interest in our work, as well as for your thorough review and comments. We will try our best to solve your questions below:


      1.	We agree with your point of view about the effect of a gene knockout on cellular homeostasis. In fact, in metabolic models where this kind of analysis is usually done using optimization approaches, the propagation effect of the gene knockout across several parts of the metabolism is evident. Nevertheless, Santolini and Barabasi (DOI: 10.1073/pnas.1720589115) compared the performance of the topology to predict the perturbation patterns caused by a gene knockout against the result of the optimization methods. They found a good overlap in the prediction, and based on those findings; we decided to use the topological approach. We did not try multi-knockout experiments since, as you mention single-cell RNA-seq characterization for those experiments is not yet available. However, we did try a double knockout and found a good overlap with the findings reported by the paper describing the dataset (Figure 3, Panel C). We yet do not have any other evidence to support or reject your hypothesis about the decrease of the precision of the predictions with an increasing number of knocked-out genes at the same time. 


      2.	Since the regulatory link between two genes is assessed using principal components regression (PCR), the result after evaluating all the associations is a fully connected asymmetric weighted network. You may consider PCR as a partial correlation analysis (pcorr). When C1 and C2 are the same, pcorr(A,B|C1) equals pcorr(B,A|C2). However, in PCR, C1 is not equal to C2‚ÄîC1 is all genes excluding B, while C2 is all genes excluding A. This asymmetry makes the result of PCR an asymmetric matrix. To further set the directionality of the resultant matrix, first, we removed the weaker link between two genes, and then, we filtered the links below the 95th percentile to reduce the false-positive rate. We provided evidence supporting that the true directionality of the regulation is favored by the regression method with a larger weight value (Figure S1, Panel C) when the directionality is tested using the transcription factors and their target genes reported by the ENCODE database. We also provided evidence of the accuracy of principal components regression to detect the association between genes in single-cell RNA-seq without imputation compared with other methods during the benchmark of scTenifoldNet (Figure 2, Panel A in DOI:10.1016/j.patter.2020.100139).


      3.	We are afraid we have to disagree with you on this. We did our best to perform an unbiased comparison of the gene knockout phenotypic effect reported by the authors of the datasets and the results provided by scTenifoldKnk. In fact, the characterizations made for the authors are not only based on data-driven approaches using the generated single-cell RNA-seq datasets but also include other experimental techniques. We used several gene-set databases to evaluate the extent of the overlap that we can predict, as it is recognized that a single gene or pathway often cannot fully explain a particular cellular state. Instead, biological processes are better characterized by gene regulatory networks, whose structures are altered as the phenotype changes (DOI: 10.1038/s41540-018-0052-5). We thought about reporting the result of scTenifoldNet and compare them with the results predicted by scTenifoldKnk. Still, since we are the developers of both methods, we decided to better compare our findings with the results reported by the original authors of the datasets. Please note that the original authors did not report all the changes or perturbed gene sets found after the gene knockout. We believe your experimental design is correct and feasible. However, also have in mind that not all the regulatory changes induced by a gene are detectable as changes in the expression level since a given gene may be under the regulation of more of one gene at the same time.


      4.	To evaluate the stability and robustness of the results provided by scTenifoldKnk, we used two approaches. First, we compared the results obtained by running independently scTenifoldKnk over two biological replicates in the Mecp2 example (Figure S2, Panel D) and found that the overlapping results agree with what is known about the Rett Syndrome pathology that is caused by the malfunctioning of the Mecp2 gene. Second, we resampled the cells used as input for scTenifoldKnk 10 times and compared the rank of the perturbed genes in the predicted in-silico knockout for each one of them. Since single-cell RNA-seq allows to uncover hidden subpopulations of cells with specialized phenotypes, and for that reason, by random subsampling the cells, we expect each of the constructed gene regulatory networks to be unique and provide a unique result. Because the approach is the same and the expected biological effect is the same (randomly sampling cells), we only performed the analysis over the Trem2 dataset. We expect the results to be similar in the other datasets.  


      Please let us know if you have any other questions or concerns,


      Best wishes,


      Daniel and James
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.03.22.436484v1
  tweets:
    - created_at: Wed Jun 02 03:02:59 +0000 2021
      id: 1399924475894902800
      id_str: "1399924475894902785"
      text: |-
        üí¨ bioRxiv comment on "scTenifoldKnk: a machine learn..."

        "Dear Samuel,

        Thank you very much for your interest in o‚Ä¶ https://t.co/q9Dl9HfXxy
      truncated: true
      entities:
        urls:
          - url: https://t.co/q9Dl9HfXxy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 03:02:59 +0000 2021
      id: 1399924476603736000
      id_str: "1399924476603736064"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/vhC6P5scn7
      truncated: false
      entities:
        urls:
          - url: https://t.co/vhC6P5scn7
      in_reply_to_status_id: 1399924475894902800
      in_reply_to_status_id_str: "1399924475894902785"
- preprint:
    id: "144122"
    doi: 10.1101/2021.05.31.446345
    first_posted: 2021-05-31
    repo: biorxiv
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.31.446345v1
    url: https://api.rxivist.org/v1/papers/144122
    title: Balanced mitochondrial and cytosolic translatomes underlie the biogenesis
      of human respiratory complexes
    category: cell-biology
    abstract: Oxidative phosphorylation (OXPHOS) complexes consist of nuclear and
      mitochondrial DNA- encoded subunits. Their biogenesis requires
      cross-compartment gene regulation to mitigate the accumulation of
      disproportionate subunits. To determine how human cells coordinate
      mitochondrial and nuclear gene expression processes, we established an
      optimized ribosome profiling approach tailored for the unique features of
      the human mitoribosome. Analysis of ribosome footprints in five cell types
      revealed that average mitochondrial synthesis rates corresponded precisely
      to cytosolic rates across OXPHOS complexes. Balanced mitochondrial and
      cytosolic synthesis did not rely on rapid feedback between the two
      translation systems. Rather, LRPPRC, a gene associated with Leigh's
      syndrome, is required for the reciprocal translatomes and maintains
      cellular proteostasis. Based on our findings, we propose that human
      mitonuclear balance is enabled by matching OXPHOS subunit synthesis rates
      across cellular compartments, which may represent a vulnerability for
      cellular proteostasis.
    authors:
      - name: Iliana C Soto
        orcid: null
      - name: Mary Couvillion
        orcid: null
      - name: Erik McShane
        orcid: null
      - name: Katja G Hansen
        orcid: http://orcid.org/0000-0002-9006-984X
      - name: J. Conor Moran
        orcid: null
      - name: Antoni Barrientos
        orcid: http://orcid.org/0000-0001-9018-3231
      - name: L. Stirling Churchman
        orcid: http://orcid.org/0000-0003-3888-2574
  comment:
    dislikes: 0
    thread: "8565056594"
    numReports: 0
    likes: 0
    id: "5404696578"
    createdAt: 2021-06-01T19:17:24
    author:
      username: eleonoraleucci
      about: ""
      name: Eleonora Leucci
      isPowerContributor: false
      profileUrl: https://disqus.com/by/eleonoraleucci/
      url: ""
      location: ""
      id: "352095537"
    isApproved: true
    raw_message: >-
      Coordination between the two translational machineries and its role in
      proteostasis was already shown in mouse and human cells and their
      desynchronisation for therapeutic purposes proposed. Here a few readings
      in case you want to acknowledge the authors...

      -https://www.cell.com/cell-reports/pdf/S2211-1247(17)31875-2.pdf

      -Nature. 2016 Mar 24;531(7595):518-22. doi: 10.1038/nature17161.

      -Nat Struct Mol Biol. 2018 Nov;25(11):1035-1046. doi: 10.1038/s41594-018-0143-4. Epub 2018 Oct 29.

      -bioRxiv 2020.06.26.173492; doi: https://doi.org/10.1101/2020.06.26.173492
    forum: biorxivstage
    points: 0
    link: https://www.biorxiv.org/content/10.1101/2021.05.31.446345v1
  tweets:
    - created_at: Wed Jun 02 13:21:44 +0000 2021
      id: 1400080193046282200
      id_str: "1400080193046282241"
      text: >-
        üí¨ bioRxiv comment on "Balanced mitochondrial and cyt..."


        "Coordination between the two translational machineries a‚Ä¶ https://t.co/mInpd1iq3P
      truncated: true
      entities:
        urls:
          - url: https://t.co/mInpd1iq3P
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 13:21:45 +0000 2021
      id: 1400080194090659800
      id_str: "1400080194090659841"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/1MSxR76y5s
      truncated: false
      entities:
        urls:
          - url: https://t.co/1MSxR76y5s
      in_reply_to_status_id: 1400080193046282200
      in_reply_to_status_id_str: "1400080193046282241"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404243620"
    createdAt: 2021-06-01T12:34:57
    author:
      username: The_European1000
      about: ""
      name: The_European1000
      isPowerContributor: false
      profileUrl: https://disqus.com/by/The_European1000/
      url: ""
      location: ""
      id: "221279842"
    isApproved: true
    raw_message: >-
      This is not good information, and the research is not well done. 


      They used a two-tailed t test with Holm Sidak correction, as if that is suffient to compensate for the complex interplay of factors that produce the same result (infection/non infection). Hell, they even made a simple linear regression to add insult to injury. 


      Essentially, to explain it more simply, using those tests rests on the assumption that there are 2 categories that correlate to other to categories perfectly- mask/not mask and infected/not infected. 


      This is not the case. Masks wearers that social distance will have lesses infection rates than mask wearers who do not. Ventialtion of enclosed areas is also an issue. 


      These "researchers" did not account for the confounding variables that affect infection rates- everything from other measures to testing rate differences among states. 


      Overall, there are many flaws with this research. Not good.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 15:03:15 +0000 2021
      id: 1400105740099068000
      id_str: "1400105740099067913"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "This is not good information, and the research is not we‚Ä¶ https://t.co/L1Ep58NWej
      truncated: true
      entities:
        urls:
          - url: https://t.co/L1Ep58NWej
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 15:03:15 +0000 2021
      id: 1400105740858187800
      id_str: "1400105740858187776"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400105740099068000
      in_reply_to_status_id_str: "1400105740099067913"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404010397"
    createdAt: 2021-06-01T06:55:31
    author:
      username: disqus_JpMFCTX7AP
      about: ""
      name: Darren Zhao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JpMFCTX7AP/
      url: ""
      location: ""
      id: "370259886"
    isApproved: true
    raw_message: >-
      I think you do have a couple fair points and I myself am a bit critical of
      the paper and agree that concluding masks wearing is not helpful is rash
      on this paper alone. However, Some of the factors that you mention should
      be held constant are, practically, infeasible in my opinion. How do you
      measure amount of enforcement objectively and their effect on mask
      wearing?

      Mask use potentially causing breaches of social distancing, while maybe true, are out of scope of the paper. Even under the assumption that that's true, that event would technically be encouraged under mandated states due to increased mask wearing and I think is fair to say is an unintended effect of mask wearing mandates.


      More research definitely does need to be done on this because, as you point out, a lot of factors could be compounding to mitigate any effectiveness mandates by themselves would bring but discrediting the paper because they do not explore all possible factors is not helpful either. If all papers were to explore all possible factors every time, publications would be few and far between.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 18:20:57 +0000 2021
      id: 1400155491410624500
      id_str: "1400155491410624513"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I think you do have a couple fair points and I myself am‚Ä¶ https://t.co/388hTB7jGy
      truncated: true
      entities:
        urls:
          - url: https://t.co/388hTB7jGy
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 18:20:57 +0000 2021
      id: 1400155492165562400
      id_str: "1400155492165562377"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400155491410624500
      in_reply_to_status_id_str: "1400155491410624513"
- preprint:
    id: 143783
    metric: 236
    title: The SARS-CoV-2 variants associated with infections in India, B.1.617,
      show enhanced spike cleavage by furin
    url: https://api.rxivist.org/v1/papers/143783
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.05.28.446163v1
    doi: 10.1101/2021.05.28.446163
    category: microbiology
    first_posted: 2021-05-28
    abstract: The SARS-CoV-2 spike (S) glycoprotein contains a suboptimal furin
      cleavage site at the S1/S2 junction with the sequence 681PRRAR/S686. This
      cleavage site is required for efficient airway replication, transmission,
      and pathogenicity of the virus. The B.1.617 lineage has recently emerged
      in India, coinciding with substantial disease burden across the country.
      Early evidence suggests that B.1.617.2 (a sublineage of B.1.617) is more
      highly transmissible than contemporary lineages. B.1.617 and its
      sublineages contain a constellation of S mutations including the
      substitution P681R predicted to further optimise this furin cleavage site.
      In this short report we provide experimental evidence that virus of the
      B.1.617 lineage has enhanced S cleavage, that enhanced processing of an
      expressed B.1.617 S protein in cells is due to P681R, and that this
      mutation enables more efficient cleavage of a peptide mimetic of the
      B.1.617 S1/S2 cleavage site by recombinant furin. Together, these data
      demonstrate viruses in this emerging lineage have enhanced S cleavage by
      furin which we hypothesise could be enhancing transmissibility and
      pathogenicity.
    authors:
      - name: Thomas P. Peacock
      - name: Carol M. Sheppard
      - name: Jonathan C. Brown
      - name: Niluka Goonawardane
      - name: Jie Zhou
      - name: Max Whiteley
      - name: PHE Virology Consortium
      - name: Thushan de Silva
      - name: Wendy S. Barclay
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Wed Jun 02 21:25:48 +0000 2021
      id: 1400202011233165300
      id_str: "1400202011233165320"
      text: >-
        üî• bioRxiv Microbiology preprint by T. P. Peacock et al:


        "The SARS-CoV-2 variants associated with infections in Ind‚Ä¶ https://t.co/0zYRW0mqjm
      truncated: true
      entities:
        urls:
          - url: https://t.co/0zYRW0mqjm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404967191"
    createdAt: 2021-06-01T23:55:02
    author:
      username: justinlovern
      about: ""
      name: Justin Lovern
      isPowerContributor: false
      profileUrl: https://disqus.com/by/justinlovern/
      url: ""
      location: ""
      id: "284782035"
    isApproved: true
    raw_message: Could your refer to any good research purporting to show that
      masking reduces transmission rates? The burden of proof is on the maskers
      if they want to impose masking, not on those who don't want to wear masks
      to prove they don't work.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 21:28:30 +0000 2021
      id: 1400202688906866700
      id_str: "1400202688906866690"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Could your refer to any good research purporting to show‚Ä¶ https://t.co/nMhNTVx0r1
      truncated: true
      entities:
        urls:
          - url: https://t.co/nMhNTVx0r1
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 21:28:30 +0000 2021
      id: 1400202689653489700
      id_str: "1400202689653489671"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400202688906866700
      in_reply_to_status_id_str: "1400202688906866690"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5405653767"
    createdAt: 2021-06-02T15:17:27
    author:
      username: miglet32
      about: ""
      name: Miglet32
      isPowerContributor: false
      profileUrl: https://disqus.com/by/miglet32/
      url: ""
      location: Chicago, IL
      id: "95808427"
    isApproved: true
    raw_message: Something that could be accounted for by other measures such as
      distancing or increased handwashing protocols.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Wed Jun 02 22:54:55 +0000 2021
      id: 1400224438780633000
      id_str: "1400224438780633093"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Something that could be accounted for by other measures‚Ä¶ https://t.co/VmwRptsvfY
      truncated: true
      entities:
        urls:
          - url: https://t.co/VmwRptsvfY
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Wed Jun 02 22:54:55 +0000 2021
      id: 1400224439539802000
      id_str: "1400224439539802112"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400224438780633000
      in_reply_to_status_id_str: "1400224438780633093"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5405929190"
    createdAt: 2021-06-02T18:51:12
    author:
      username: georgerapko
      about: ""
      name: George Rapko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/georgerapko/
      url: ""
      location: ""
      id: "51917517"
    isApproved: true
    raw_message: What?  Sidak adjusts alpha to control type 1 error for multiple
      comparisons.  It has nothing to do with confounding factors. In their
      test, they tested early mandates vs late mandates and early mandates
      versus no mandates and therefore needed to use a correction.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 02:38:29 +0000 2021
      id: 1400280698792067000
      id_str: "1400280698792067075"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "What?  Sidak adjusts alpha to control type 1 error for m‚Ä¶ https://t.co/fGuT7uQxjk
      truncated: true
      entities:
        urls:
          - url: https://t.co/fGuT7uQxjk
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 02:38:29 +0000 2021
      id: 1400280699626741800
      id_str: "1400280699626741766"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400280698792067000
      in_reply_to_status_id_str: "1400280698792067075"
- preprint:
    id: "144132"
    doi: 10.1101/2021.05.28.21258012
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.28.21258012v1
    url: https://api.rxivist.org/v1/papers/144132
    title: Observational Study on 255 Mechanically Ventilated Covid Patients at the
      Beginning of the USA Pandemic
    category: pharmacology-and-therapeutics
    abstract: "Abstract Introduction: This observational study looked at 255 COVID19
      patients who required invasive mechanical ventilation (IMV) during the
      first two months of the US pandemic. Through comprehensive, longitudinal
      evaluation and new consideration of all the data, we were able to better
      describe and understand factors affecting outcome after intubation.
      Methods: All vital signs, laboratory values, and medication
      administrations (time, date, dose, and route) were collected and
      organized. Further, each patient's prior medical records, including PBM
      data and available ECG, were reviewed by a physician. These data were
      incorporated into time-series database for statistical analysis. Results:
      By discharge or Day 90, 78.2% of the cohort expired. The most common
      pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and
      obesity (50.4%). Age correlated with death. Comorbidities and clinical
      status on presentation were not predictive of outcome. Admission markers
      of inflammation were universally elevated (>96%). The cohort's weight
      range was nearly 7-fold. Causal modeling establishes that weight-adjusted
      HCQ and AZM therapy improves survival by over 100%. QTc prolongation did
      not correlate with cumulative HCQ dose or HCQ serum levels. Discussion:
      This detailed approach gives us better understanding of risk factors,
      prognostic indicators, and outcomes of Covid patients needing IMV. Few
      variables were related to outcome. By considering more factors and using
      new methods, we found that when increased doses of co-administered HCQ and
      AZM were associated with >100% increase in survival. Comparison of
      absolute with weight-adjusted cumulative doses proves administration
      [&ge;]80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring
      Covid patients by over 100%. According to our data, HCQ is not associated
      with prolongation. Studies, which reported QTc prolongation secondary to
      HCQ, need to be re-evaluated more stringently and with controls. The
      weight ranges of Covid patient cohorts are substantially greater than
      those of most antibiotic RCTs. Future clinical trials need to consider the
      weight variance of hospitalized Covid patients and need to study
      therapeutics more thoughtfully."
    authors:
      - name: Leon G Smith
        orcid: null
      - name: Nicolas Mendoza
        orcid: null
      - name: Stephen Smith
        orcid: http://orcid.org/0000-0002-9158-6136
      - name: David P Dobesh
        orcid: null
  comment:
    dislikes: 0
    thread: "8564791155"
    numReports: 0
    likes: 1
    id: "5405282971"
    createdAt: 2021-06-02T08:09:56
    author:
      username: disqus_z3JbLWlo5D
      about: ""
      name: Le Bon
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_z3JbLWlo5D/
      url: ""
      location: ""
      id: "54104695"
    isApproved: true
    raw_message: >-
      The idea of looking at patients who had at least a substantial cumulated
      dose is great, but there is an important immortal time bias, since the
      patients can't die the first 10 days in the HCQ group, as seen on the
      Kaplan-Me√Øer


      I suggest to calculate again the results with excluding the first 10 days death in the control group.


      Due to the small group size, you will probably loose significance, but it still will be usefull for pooled analysis.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
  tweets:
    - created_at: Thu Jun 03 12:57:57 +0000 2021
      id: 1400436595317166000
      id_str: "1400436595317166081"
      text: >-
        üí¨ medRxiv comment on "Observational Study on 255 Mec..."


        "The idea of looking at patients who had at least a subst‚Ä¶ https://t.co/ypthFQaWXC
      truncated: true
      entities:
        urls:
          - url: https://t.co/ypthFQaWXC
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 12:57:58 +0000 2021
      id: 1400436596256743400
      id_str: "1400436596256743424"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/B5DO7aAXhF
      truncated: false
      entities:
        urls:
          - url: https://t.co/B5DO7aAXhF
      in_reply_to_status_id: 1400436595317166000
      in_reply_to_status_id_str: "1400436595317166081"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 0
    thread: "8565279083"
    numReports: 0
    likes: 1
    id: "5404874525"
    createdAt: 2021-06-01T22:05:39
    author:
      username: st_publichealth
      about: ""
      name: st_publichealth
      isPowerContributor: false
      profileUrl: https://disqus.com/by/st_publichealth/
      url: ""
      location: ""
      id: "370294261"
    isApproved: true
    raw_message: >-
      The article is interesting. A few questions to the authors. Did you
      pre-specify the definition of negative PCR?

      Did you compare changes in viral loads from the baseline? Since the median viral load was higher in the placebo arm, this might have affected the likelihood of viral clearance at day 6 and it should be accounted for.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Thu Jun 03 14:40:25 +0000 2021
      id: 1400462378844627000
      id_str: "1400462378844626951"
      text: >-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."


        "The article is interesting. A few questions to the autho‚Ä¶ https://t.co/cGNZ7rtpoO
      truncated: true
      entities:
        urls:
          - url: https://t.co/cGNZ7rtpoO
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 14:40:25 +0000 2021
      id: 1400462379960336400
      id_str: "1400462379960336399"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfChaW
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfChaW
      in_reply_to_status_id: 1400462378844627000
      in_reply_to_status_id_str: "1400462378844626951"
- preprint:
    id: "144165"
    doi: 10.1101/2021.05.31.21258081
    first_posted: 2021-05-31
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.31.21258081v1
    url: https://api.rxivist.org/v1/papers/144165
    title: Favorable outcome on viral load and culture viability using Ivermectin in
      early treatment of non-hospitalized patients with mild COVID-19, A
      double-blind, randomized placebo-controlled trial.
    category: infectious-diseases
    abstract: "Background: Ivermectin, an antiparasitic agent, also has antiviral
      properties. Our aim was to assess whether ivermectin can shorten the viral
      shedding in patients at an early stage of COVID19 infection. Methods: The
      double blinded trial compared patients receiving ivermectin 0.2 mg/kg for
      3 days vs. placebo in non-hospitalized COVID19 patients. RT-PCR from a
      nasopharyngeal swab was obtained at recruitment and then every two days.
      Primary endpoint was reduction of viral-load on the 6th day (third day
      after termination of treatment) as reflected by Ct level>30
      (non-infectious level). The primary outcome was supported by determination
      of viral culture viability. Results: Eighty nine patients were eligible
      (47 in ivermectin and 42 in placebo arm). Their median age was 35 years.
      Females accounted for 21.6%, and 16.8% were asymptomatic at recruitment.
      Median time from symptom onset was 4 days. There were no statistical
      differences in these parameters between the two groups. On day 6, 34 out
      of 47 (72%) patients in the ivermectin arm reached the endpoint, compared
      to 21/ 42 (50%) in the placebo arm (OR 2.62; 95% CI: 1.09 to 6.31). In a
      multivariable logistic regression model, the odds of a negative test at
      day 6 was 2.62 time higher in the ivermectin group (95% CI: 1.06 to 6.45).
      Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin
      samples vs. 14/29 (48.2%) in the placebo group (p=0.008). Conclusions:
      There were significantly lower viral loads and viable cultures in the
      ivermectin group, which could lead to shortening isolation time in these
      patients."
    authors:
      - name: Asaf Biber
        orcid: http://orcid.org/0000-0001-6007-0383
      - name: Michal Mandelboim
        orcid: http://orcid.org/0000-0002-5997-7241
      - name: Geva Harmelin
        orcid: null
      - name: Dana Lev
        orcid: null
      - name: Li Ram
        orcid: null
      - name: Amit Shaham
        orcid: null
      - name: Ital Nemet
        orcid: null
      - name: Limor Kliker
        orcid: null
      - name: Oran Erster
        orcid: http://orcid.org/0000-0003-4839-8997
      - name: Eli Schwartz
        orcid: null
  comment:
    dislikes: 1
    thread: "8565279083"
    numReports: 0
    likes: 1
    id: "5404617686"
    createdAt: 2021-06-01T18:07:54
    author:
      username: japhetk
      about: ""
      name: japhetk
      isPowerContributor: false
      profileUrl: https://disqus.com/by/japhetk/
      url: ""
      location: ""
      id: "346900262"
    isApproved: true
    raw_message: >-
      This research is problematic. 

      First, this clinical trial's primary outcome measures were as attached below. And authors did not mention 2 out of 3 primary outcome measures. These are not good omissions apparently. 


      Second even the primary outcome measure they used was not specified before the study. Authors used ct cut value of 30, which was arbitrary. Authors explain why they did not use 40, but they must have used 40 if that leads to the good results. And that is not a clinical trial. 


      They did not correct for multiple comparisons across three primary endpoints, either, which they should have done as there are three primary endpoints. 




      Second as the figure 2 and the table shows the ct values of two groups before the intervention are close to statistically significant differences (p = 0.10).

      And as the figure 2 shows this group difference did not show even a hint of change at day 6! The two groups were almost statistically different from the beginning and that did not change visually at day 6 apparently. I can't see any hints of effects of IVM from this study. 




      Lay persons are watching this study, and they say they love IVM and hate vaccine and let's use IVM instead of vaccine based on this study's result. We hope authors do the proper research. They should provide three primary endpoints, correct the preexisting differences, and correct multiple comparisons, and should provide apparent conclusions. 






      Primary Outcome Measures  :
            


      Viral clearance at day 6 [ Time Frame: Outcome will be determined till 6 days post intervention ]



      The primary outcome will be the viral clearance at day 6 in the intervention group compared to placebo.


                  	


      Viral shedding duration [ Time Frame: Outcome will be determined till 14 days post intervention ]



      Secondary outcomes: viral shedding duration (time between first positive PCR to last of two consecutive negative tests)


                  	


      Symptoms clearance time [ Time Frame: Outcome will be determined till 14 days post intervention ]



      Time between drug treatment and symptoms resolution
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
  tweets:
    - created_at: Thu Jun 03 17:51:55 +0000 2021
      id: 1400510574094606300
      id_str: "1400510574094606338"
      text: |-
        üí¨ medRxiv comment on "Favorable outcome on viral loa..."

        "This research is problematic. 
        First, this clinical tria‚Ä¶ https://t.co/qgoP8cvgjZ
      truncated: true
      entities:
        urls:
          - url: https://t.co/qgoP8cvgjZ
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 17:51:55 +0000 2021
      id: 1400510575046692900
      id_str: "1400510575046692867"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/fIgXlfTSzw
      truncated: false
      entities:
        urls:
          - url: https://t.co/fIgXlfTSzw
      in_reply_to_status_id: 1400510574094606300
      in_reply_to_status_id_str: "1400510574094606338"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 2
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404241223"
    createdAt: 2021-06-01T12:32:06
    author:
      username: The_European1000
      about: ""
      name: The_European1000
      isPowerContributor: false
      profileUrl: https://disqus.com/by/The_European1000/
      url: ""
      location: ""
      id: "221279842"
    isApproved: true
    raw_message: >-
      That is not a good point. 


      Medical personel are more exposed to the virus than the general population. Errors in use of protective equipment will produce greater infections than the equivalent errors in the general population. 


      Also, the use of masks as source control (controlling the spread instead of just preventing infection) has been demonstrated as effective thorlugh research and practice for more than a 100 years.
    forum: medrxiv
    points: -1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 19:58:40 +0000 2021
      id: 1400542471789088800
      id_str: "1400542471789088781"
      text: |-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."

        "That is not a good point. 

        Medical personel are more ex‚Ä¶ https://t.co/5kvAV7kF5n
      truncated: true
      entities:
        urls:
          - url: https://t.co/5kvAV7kF5n
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 19:58:40 +0000 2021
      id: 1400542472686682000
      id_str: "1400542472686682116"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400542471789088800
      in_reply_to_status_id_str: "1400542471789088781"
- preprint:
    id: 138498
    metric: 9335
    title: Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural
      infection and mRNA Vaccination
    url: https://api.rxivist.org/v1/papers/138498
    biorxiv_url: https://biorxiv.org/content/10.1101/2021.04.15.440089v1
    doi: 10.1101/2021.04.15.440089
    category: immunology
    first_posted: 2021-04-19
    abstract: We analyzed data from two ongoing COVID-19 longitudinal serological
      surveys in Orange County, CA., between April 2020 and March 2021. A total
      of 8,476 finger stick blood specimens were collected before and after an
      aggressive mRNA vaccination campaign. IgG levels were determined using a
      multiplex antigen microarray containing 10 SARS-CoV-2 antigens, 4 SARS, 3
      MERS, 12 Common CoV, and 8 Influenza antigens. Twenty-six percent of 3,347
      specimens from unvaccinated Orange County residents in December 2020 were
      SARS-CoV-2 seropositive. The Ab response was predominantly against
      nucleocapsid (NP), full length spike and the spike S2 domain.
      Anti-receptor binding domain (RBD) reactivity was low and there was no
      cross-reactivity against SARS S1 or SARS RBD. An aggressive mRNA
      vaccination campaign at the UCI Medical Center started on December 16,
      2020 and 6,724 healthcare workers were vaccinated within 3 weeks.
      Seroprevalence increased from 13% in December to 79% in January, 93% in
      February and 99% in March. mRNA vaccination induced much higher Ab levels
      especially against the RBD domain and significant cross-reactivity against
      SARS RBD and S1 was also observed. Nucleocapsid protein Abs can be used to
      distinguish individuals in a population of vaccinees to classify those who
      have been previously infected and those who have not, because nucleocapsid
      is not in the vaccine. Previously infected individuals developed higher Ab
      titers to the vaccine than those who have not been previously exposed.
      These results indicate that mRNA vaccination rapidly induces a much
      stronger and broader Ab response than SARS-CoV-2 infection.
    authors:
      - name: Rafael Ramiro de Assis
      - name: Aarti Jain
      - name: Rie Nakajima
      - name: Algis Jasinskas
      - name: Saahir Khan
      - name: Anton Palma
      - name: Daniel M. Parker
      - name: Anthony Chau
      - name: Amanda Leung
      - name: Christina Grabar
      - name: Fjolla Muqolli
      - name: Ghali Khalil
      - name: Jessica Colin Escobar
      - name: Jenny Ventura
      - name: Huw Davies
      - name: Bruce Albala
      - name: Bernadette Boden-Albala
      - name: Sebastian Schubl
      - name: Philip L Felgner
    repo: biorxiv
  comment: null
  tweets:
    - created_at: Thu Jun 03 21:17:13 +0000 2021
      id: 1400562236565950500
      id_str: "1400562236565950469"
      text: >-
        üî• bioRxiv Immunology preprint by R. R. d. Assis et al:


        "Distinct SARS-CoV-2 antibody reactivity patterns elicited‚Ä¶ https://t.co/irMcCVOqLB
      truncated: true
      entities:
        urls:
          - url: https://t.co/irMcCVOqLB
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5403997539"
    createdAt: 2021-06-01T06:28:18
    author:
      username: disqus_JpMFCTX7AP
      about: ""
      name: Darren Zhao
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_JpMFCTX7AP/
      url: ""
      location: ""
      id: "370259886"
    isApproved: true
    raw_message: >-
      I've only attempted to fact check your second source, the Denmark one, and
      your quotes really show your bias here. I could not find the first one cuz
      your reference kinda sucks. I attempted to ctrl f both quotes, and the
      first one "The researchers found no statistically significant difference
      between mask wearers and bare-faced participants." does not exist. 


      The second one while partially true, is cut off from what is actually said. The real quote is:


      "The recommendation to wear surgical masks to supplement other public health measures did not reduce the SARS-CoV-2 infection rate among wearers by more than 50% in a community with modest infection rates, some degree of social distancing, and uncommon general mask use. The data were compatible with lesser degrees of self-protection". 


      Note here where they specify the limitations of their study. Their conclusion is less general than, "does not reduce infection rate", but rather that when everyone else does not where masks, mask wearing does not appear to help. Their study, if you did actually read it, is only relevant to the specific scenario in the quote and by the authors notes while responding to comments ‚Äúthe findings, however, should not be used to conclude that a recommendation for everyone to wear masks in the community would not be effective in reducing SARS-CoV-2 infections, because the trial did not test the role of masks in source control of SARS-CoV-2 infection.‚Äù


      If you are going to cite papers, please read them instead of skimming for anything that you believe.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Thu Jun 03 21:23:06 +0000 2021
      id: 1400563719009046500
      id_str: "1400563719009046529"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "I've only attempted to fact check your second source, th‚Ä¶ https://t.co/Wu09rotThb
      truncated: true
      entities:
        urls:
          - url: https://t.co/Wu09rotThb
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 21:23:06 +0000 2021
      id: 1400563720003096600
      id_str: "1400563720003096576"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU30MFJ
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU30MFJ
      in_reply_to_status_id: 1400563719009046500
      in_reply_to_status_id_str: "1400563719009046529"
- preprint:
    id: "132435"
    doi: 10.1101/2021.03.05.21252998
    first_posted: 2021-03-08
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.03.05.21252998v1
    url: https://api.rxivist.org/v1/papers/132435
    title: COVID-19 mRNA vaccine is not detected in human milk
    category: pediatrics
    abstract: Several countries have recently approved the use of mRNA vaccines
      against COVID-19 under an emergency use authorization. However, no
      pregnant or lactating individuals were included in the Phase 3 clinical
      trials of these vaccines despite belonging to a group at high risk for
      severe complications of COVID-19 infection. We show here that the mRNA
      from anti-COVID vaccines is not detected in human breast milk samples
      collected 4-48 hours post-vaccine. These results strengthen the
      recommendation of ABM and WHO that lactating individuals who receive the
      anti-COVID-19 mRNA-based vaccine should continue to breastfeed their
      infants uninterrupted.
    authors:
      - name: Yarden Golan
        orcid: http://orcid.org/0000-0002-3043-3638
      - name: Mary Prahl
        orcid: null
      - name: Arianna Cassidy
        orcid: null
      - name: Christine Y Lin
        orcid: null
      - name: Nadav Ahituv
        orcid: http://orcid.org/0000-0002-7434-8144
      - name: Valerie J Flaherman
        orcid: null
      - name: Stephanie L. Gaw
        orcid: null
  comment:
    dislikes: 0
    thread: "8428869045"
    numReports: 0
    likes: 1
    id: "5403771013"
    createdAt: 2021-06-01T00:21:43
    author:
      username: patfrank
      about: ""
      name: Pat Frank
      isPowerContributor: false
      profileUrl: https://disqus.com/by/patfrank/
      url: ""
      location: ""
      id: "39488002"
    isApproved: true
    raw_message: >-
      "<i>We show here that the mRNA from anti-COVID BNT162b2 (Pfizer) and 

      mRNA-1273 (Moderna) vaccines is not detected in human breast milk 

      samples collected 4-48 hours post-vaccine</i>"



      Nice, but irrelevant. The worry has been that the mRNA encoded <i><b>spike protein</b></i> gets into breast milk (and other tissues). 




      There does not appear to be any concern that the mRNA itself appears in breast milk. So the paper of Golan, et al., is irrelevant to the concern.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.03.05.21252998v1
  tweets:
    - created_at: Thu Jun 03 22:56:59 +0000 2021
      id: 1400587344634433500
      id_str: "1400587344634433536"
      text: >-
        üí¨ medRxiv comment on "COVID-19 mRNA vaccine is not d..."


        ""&lt;i&gt;We show here that the mRNA from anti-COVID BNT162b2‚Ä¶ https://t.co/aCVm0KXnwm
      truncated: true
      entities:
        urls:
          - url: https://t.co/aCVm0KXnwm
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Thu Jun 03 22:56:59 +0000 2021
      id: 1400587345456504800
      id_str: "1400587345456504836"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/Dml5mNFcAW
      truncated: false
      entities:
        urls:
          - url: https://t.co/Dml5mNFcAW
      in_reply_to_status_id: 1400587344634433500
      in_reply_to_status_id_str: "1400587344634433536"
- preprint:
    id: "144560"
    doi: 10.1101/2021.06.03.21258293
    first_posted: 2021-06-03
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.06.03.21258293v1
    url: https://api.rxivist.org/v1/papers/144560
    title: Interim estimates of increased transmissibility, growth rate, and
      reproduction number of the Covid-19 B.1.617.2 variant of concern in the
      United Kingdom
    category: infectious-diseases
    abstract: This paper relates to data from the Wellcome Sanger Institute, UK,
      regarding Covid-19 genomic surveillance. We use a simple model to give
      point estimates of the effective reproduction numbers of the B.1.617.2 and
      B.1.1.7 lineages in England, from sequenced data as at 15 May 2021.
      Comparison with the estimated reproduction number of B.1.1.7 enables an
      estimate of the increased transmissibility of B.1.617.2. We conclude that
      it is almost certain that there is increased transmissibility that will
      rapidly lead to B.1.617.2 becoming the prevailing variant in the UK. The
      derived estimates of increased transmissibility have uncertainty relating
      to the actual distribution of the generation interval, but they do point,
      under present conditions of vaccination coverage and NPIs, to exponential
      growth of positive cases.
    authors:
      - name: John S Dagpunar
        orcid: http://orcid.org/0000-0001-7197-8231
  comment:
    dislikes: 0
    thread: "8571083762"
    numReports: 0
    likes: 0
    id: "5407102395"
    createdAt: 2021-06-03T18:02:57
    author:
      username: disqus_wtPyWa2JzO
      about: Father. Scientist. Singer.
      name: Peter Ellis
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_wtPyWa2JzO/
      url: ""
      location: ""
      id: "52268877"
    isApproved: true
    raw_message: >-
      "We conclude that it is almost certain that there is increased
      transmissibility that will rapidly lead to B.1.617.2 becoming the
      prevailing variant in the UK."


      This was posted on the day Public Health England released a report showing that the Delta variant (B.1.617.2) is currently 73% of sequenced cases - i.e. it was 73% of new cases a couple of weeks ago. S gene proxy data is only a week out of date and has the prevalence of Delta at 85.4%


      Forget journals not being able to keep up, even preprints can't keep up with this.
    forum: medrxiv
    points: 0
    link: https://www.medrxiv.org/content/10.1101/2021.06.03.21258293v1
  tweets:
    - created_at: Fri Jun 04 02:01:41 +0000 2021
      id: 1400633825768755200
      id_str: "1400633825768755204"
      text: >-
        üí¨ medRxiv comment on "Interim estimates of increased..."


        ""We conclude that it is almost certain that there is inc‚Ä¶ https://t.co/o2hHrSkL8a
      truncated: true
      entities:
        urls:
          - url: https://t.co/o2hHrSkL8a
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 02:01:41 +0000 2021
      id: 1400633826674622500
      id_str: "1400633826674622465"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/PfElOztpGA
      truncated: false
      entities:
        urls:
          - url: https://t.co/PfElOztpGA
      in_reply_to_status_id: 1400633825768755200
      in_reply_to_status_id_str: "1400633825768755204"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5406165268"
    createdAt: 2021-06-02T22:17:50
    author:
      username: georgerapko
      about: ""
      name: George Rapko
      isPowerContributor: false
      profileUrl: https://disqus.com/by/georgerapko/
      url: ""
      location: ""
      id: "51917517"
    isApproved: true
    raw_message: What's really interesting is the people that believe masks work now
      point to the reduction in recorded flu cases.  It doesn't come mind that
      the travel restrictions are a likely culprit in the reduction of seasonal
      flu.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 13:09:06 +0000 2021
      id: 1400801786290708500
      id_str: "1400801786290708481"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "What's really interesting is the people that believe mas‚Ä¶ https://t.co/wTGl51VE2U
      truncated: true
      entities:
        urls:
          - url: https://t.co/wTGl51VE2U
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 13:09:06 +0000 2021
      id: 1400801787062464500
      id_str: "1400801787062464518"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400801786290708500
      in_reply_to_status_id_str: "1400801786290708481"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5406160873"
    createdAt: 2021-06-02T22:13:03
    author:
      username: karl_elshoff
      about: ""
      name: Karl Elshoff
      isPowerContributor: false
      profileUrl: https://disqus.com/by/karl_elshoff/
      url: ""
      location: ""
      id: "327040158"
    isApproved: true
    raw_message: Lol.  Blaylock was using researched material.  You didn't even read
      his article.
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 14:54:11 +0000 2021
      id: 1400828234695053300
      id_str: "1400828234695053317"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Lol.  Blaylock was using researched material.  You didn'‚Ä¶ https://t.co/u4QrkO4hs0
      truncated: true
      entities:
        urls:
          - url: https://t.co/u4QrkO4hs0
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 14:54:12 +0000 2021
      id: 1400828235324272600
      id_str: "1400828235324272643"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400828234695053300
      in_reply_to_status_id_str: "1400828234695053317"
- preprint:
    id: "143204"
    doi: 10.1101/2021.05.18.21257385
    first_posted: 2021-05-25
    repo: medrxiv
    biorxiv_url: https://medrxiv.org/content/10.1101/2021.05.18.21257385v1
    url: https://api.rxivist.org/v1/papers/143204
    title: Mask mandate and use efficacy in state-level COVID-19 containment
    category: epidemiology
    abstract: "Background: Containment of the COVID-19 pandemic requires
      evidence-based strategies to reduce transmission. Because COVID-19 can
      spread via respired droplets, many states have mandated mask use in public
      settings. Randomized control trials have not clearly demonstrated mask
      efficacy against respiratory viruses, but observational studies suggest
      greater mask compliance may be associated with lower infection rates. We
      hypothesized that statewide mask mandates and mask use are associated with
      lower COVID-19 case growth rates in the United States. Methods: We
      calculated total COVID-19 case growth and mask use for the continental
      United States with data from the Centers for Disease Control and
      Prevention and Institute for Health Metrics and Evaluation. We estimated
      post-mask mandate case growth in non-mandate states using median issuance
      dates of neighboring states with mandates. Results: Case growth was not
      significantly different between mandate and non-mandate states at low or
      high transmission rates, and surges were equivocal. Mask use predicted
      lower case growth at low, but not high transmission rates. Growth rates
      were comparable between states in the top and bottom mask use quintiles
      adjusted for normalized total cases early in the pandemic and unadjusted
      after peak Fall-Winter infections. Mask use did not predict Summer 2020
      case growth for non-Northeast states or Fall-Winter 2020 growth for all
      states. Conclusions: Mask mandates and use are not associated with slower
      state-level COVID-19 spread during COVID-19 growth surges. COVID-19
      containment requires future research and implementation of existing
      efficacious strategies."
    authors:
      - name: Damian Guerra
        orcid: http://orcid.org/0000-0002-6621-4656
      - name: Daniel J Guerra
        orcid: null
  comment:
    dislikes: 0
    thread: "8550177462"
    numReports: 0
    likes: 1
    id: "5404294629"
    createdAt: 2021-06-01T13:28:56
    author:
      username: disqus_suDe0WWfKq
      about: ""
      name: Publius
      isPowerContributor: false
      profileUrl: https://disqus.com/by/disqus_suDe0WWfKq/
      url: ""
      location: ""
      id: "75251292"
    isApproved: true
    raw_message: Then how do you explain Sweden which had one of the lowest excess
      death rates with no mask mandates and no lockdowns?
    forum: medrxiv
    points: 1
    link: https://www.medrxiv.org/content/10.1101/2021.05.18.21257385v1
  tweets:
    - created_at: Fri Jun 04 17:48:17 +0000 2021
      id: 1400872047417434000
      id_str: "1400872047417434119"
      text: >-
        üí¨ medRxiv comment on "Mask mandate and use efficacy ..."


        "Then how do you explain Sweden which had one of the lowe‚Ä¶ https://t.co/MbPlqZ6cxS
      truncated: true
      entities:
        urls:
          - url: https://t.co/MbPlqZ6cxS
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 17:48:17 +0000 2021
      id: 1400872048054915000
      id_str: "1400872048054915078"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the medRxiv landscape:

        https://t.co/652MU3io4j
      truncated: false
      entities:
        urls:
          - url: https://t.co/652MU3io4j
      in_reply_to_status_id: 1400872047417434000
      in_reply_to_status_id_str: "1400872047417434119"
- preprint:
    id: "68453"
    doi: 10.1101/871194
    first_posted: 2019-12-11
    repo: biorxiv
    biorxiv_url: https://www.biorxiv.org/content/10.1101/871194v1
    url: https://api.rxivist.org/v1/papers/68453
    title: Insights into the ligand-free structure of cyclic diguanosine
      monophosphate I riboswitch of Vibrio cholerae using molecular dynamics
      simulation
    category: bioinformatics
    abstract: Riboswitches are key cis regulatory elements present at 5' UTRs of
      mRNAs. They play a critical role in gene expression regulation at
      transcriptional and translational level by binding selectively to specific
      ligands followed by conformational changes. Ligands bind to the aptamer of
      riboswitches and their complex structures have been solved, but
      ligand-free riboswitches structures are not available which is important
      to understand specific ligand binding mechanism. In this paper, an all
      atom 150 nano-second (ns) molecular dynamics (MD) simulations of cyclic
      diguanosine monophosphate (c-di-GMP I) riboswitch aptamer domain from
      Vibrio cholerae were carried out to study ligand-free c-di-GMP I
      riboswitch aptamer structure and the binding mechanism. The Principle
      component analysis, cross correlation dynamics analysis and trajectory
      analyses revealed that the ligand-free structure has stable conformation
      with folded P2, P3 and an open P1 helix which opens the ligand binding
      helix-join-helix while the ligand-bound structure shows less deviation and
      remains as closed structure compared to the ligand-free structure. The
      junction residues significantly showed anti-correlated motions with each
      other elucidating the open conformation of the ligand-free aptamer of
      riboswitch. The identified key residues involved in binding are A18, G20,
      C46, A47 and C92.
    authors:
      - name: Priyanka Kumari
        orcid: null
      - name: Anup Som
        orcid: http://orcid.org/0000-0003-1857-2368
  comment:
    dislikes: 0
    thread: "7758680208"
    numReports: 0
    likes: 1
    id: "5406484599"
    createdAt: 2021-06-03T05:36:41
    author:
      username: dranupsom
      about: ""
      name: Dr. Anup Som
      isPowerContributor: false
      profileUrl: https://disqus.com/by/dranupsom/
      url: ""
      location: ""
      id: "370362590"
    isApproved: true
    raw_message: >-
      This preprint has been published in Indian Journal of Biochemistry and
      Biophysics.  

      <b>Paper Link:</b>

      http://op.niscair.res.in/index.php/IJBB/article/view/37679
    forum: biorxivstage
    points: 1
    link: https://www.biorxiv.org/content/10.1101/871194v1
  tweets:
    - created_at: Fri Jun 04 19:48:29 +0000 2021
      id: 1400902294380630000
      id_str: "1400902294380630019"
      text: >-
        üí¨ bioRxiv comment on "Insights into the ligand-free ..."


        "This preprint has been published in Indian Journal of Bi‚Ä¶ https://t.co/4eUtpiI7nP
      truncated: true
      entities:
        urls:
          - url: https://t.co/4eUtpiI7nP
      in_reply_to_status_id: null
      in_reply_to_status_id_str: null
    - created_at: Fri Jun 04 19:48:29 +0000 2021
      id: 1400902295185985500
      id_str: "1400902295185985543"
      text: |-
        @PreprintBot

        üó∫Ô∏è See similar papers on the bioRxiv landscape:

        https://t.co/D1nwcPMwOs
      truncated: false
      entities:
        urls:
          - url: https://t.co/D1nwcPMwOs
      in_reply_to_status_id: 1400902294380630000
      in_reply_to_status_id_str: "1400902294380630019"
